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Summary
The integrin family of cell surface glycoproteins function as both adhesion and signal 
transduction molecules mediating cell-cell interactions, adherence to components of 
the extracellular matrix and providing an essential link between cells and their 
environment. Expression of specific integrin heterodimers, particularly those of the 
(33 integrin family (av(33 or allbp3) has been closely associated with proliferation, 
invasion, metastatasis and angiogenesis of many tumour types, particularly malignant 
melanoma.
Initial studies were aimed at cloning the murine p3 (and to a lesser extent allb) 
integrin subunits from the amelanotic murine melanoma cell line, B16a with the aim 
of using these in subsequent gene therapy procedures. RT PCR of B 16a cDNA was 
used to obtain two DNA fragments (of 709bp for the aDb subunit and 657bp for the 
p3 subunit), identified as belonging to the correct murine integrins. Screening of a 
XZAP II cDNA libraries with these fragments (labelled with 32P) isolated two library 
clones, although no homology to integrin subunits was seen. Further studies 
concentrated upon the gene therapy of the p3 integrin subunit using a human p3 
cDNA and an inactive mutant P3 cDNA (obtained from Dr J.C. Loftus, Scripps 
Research Institute).
Three antisense constructs of the human p3 cDNA (of varying size, from 0.5- 
3.9kb) were cloned into the expression vector pcDNA3. These vectors were 
transfected by electroporation into B16a cells and the human melanoma cell line 
A375. No significant reduction of integrin expression was noted in either cell line
over a period of transient gene expression (24-72 hours). Further studies of G418 
antibiotic stable polyclonal populations of B 16a cells demonstrated that surface levels 
of (33 could be reduced as detected by fluorescence assisted cell sorting (FACS). The 
size of transfected antisense fragments was potentially significant to the degree of this 
antisense effect, although total amounts of (33 integrin in these cells appear unchanged 
when examined by Western blotting. Treatment of B16a cells by FACS or by 
transfection of antisense integrin constructs had dramatic effects upon tumour cell 
proliferation, with a greater inhibition of growth arising from transfection of larger 
antisense fragments.
Other studies examined the potential of using transfected mutant human (33 
cDNA to competitively inhibit expression of active (33 heterodimers in B 16a cells. No 
inhibition of (33 was visible due to problems associated with efficiency of expression 




In the memory of Mr Richard W. Farr, 
who I know would have 
loved to have seen this work, 
and to Mr Paul Lawrence who still can.
4
Acknowledgements
Much thanks must go to Dr. Colin W. Pouton for his continued optimism and 
input, even in the roughest periods of the last 3 and a lot years. Additional praise must 
also go to Dr. Steve Moss for his realistic, level headed influence upon this work.
I am particularly grateful for the considerable advice and aid that has been 
supplied by both Dr. Stuart Watts and Dr David Hayes of Wellcome pic. Other 
invaluable people in the progression of this work have been Dr. John Marshall of the 
ICRF for many enlightening and informative chats, Helen Cox of Sheffield University 
for advice on plaque screening and Dr. Graham Smith for invaluable FACS help. My 
thanks also go out to Dr. Anthony Smith, Dr. Adrian Lowe and Dr. Iian Lamont for 
rapidly expanding my knowledge of molecular biology and making it all seem a little 
bit more possible. Thanks also go to Dr. Melanie Whelham and Ms Heather Bone for 
helping with the immunoprecipitation.
Many thanks go to the EPSRC and Wellcome pic for funding this project, and 
to Prof. D. J. Davies for providing the research facilities.
This last bit has to go out to all the special people who have put up with me 
over the best and worst times. In no particular order I have to give mucho praise to 
Mum, Dad, Sarah and Scott, Bruvver (wherever he is at the moment), my Nan, Paddy, 
Luke, Nicky and Lucy, Ay Oop, The Fluffies, The Lush, Rustic, The Captain Bobs’ 
lot, Joss, Big E and Stan, Gween, Nigel the teaman (and Roy), Julia and Elsie, Pazza, 
both Gazzas, Max, The Stick, All the Lawrences, Boneo, Rod and The Lardy Boys. I 
have to save the biggest hand for the 2:29 crew who deserve a big pat on the back - 
especially Plopps, “Auntie” Rach, Paully, Big Boy, Heenous, Dave, Reeky and The 
Moose Man. Last laughs go to the wonderful Miss Thomas.















1.1.3. Mortality associated with malignant melanoma................... 18
1.2. The Integrin family of cell adhesion molecules............................20
1.2.1. Structure of integrin subunits.................................................21
1.2.2. Integrin ligands....................................................................... 25
1.2.3. Ligand binding to integrin heterodimers.............................. 26
1.3. Integrin mediated transmembrane signalling............................... 28
1.3.1. Modulation of integrin affinity: inside-out signalling......... 28
1.3.2. Signal transduction through integrins: outside-in 
signalling............................................................................................ 31
1.4. Role of integrin receptors in malignant melanoma......................35
1.4.1. Changes in integrin expression in transformed cells............35
1.4.2. Role of integrins in migration, invasion and metastasis
of malignant melanoma..........................................................36
1.4.3. Role of integrin av(33 in tumour cell angiogenesis
and apoptosis.......................................................................... 42
1.5. Integrins as targets for drug and gene therapy............................. 43
1.5.1. Inhibition of gene expression using antisense DNA
or catalytic RNA.....................................................................44
1.5.2. Gene therapy of integrin expression......................................49
1.5.3. Antiadhesive therapy of integrins..........................................51
1.5.4. integrins as targets for drug delivery......................................52
1.6. Aims and Objectives.......................................................................53
6
Chapter 2. Materials and Methods..............................................................56
2.1. Bacterial strains...............................................................................56
2.2. Plasmid vectors...............................................................................56
2.3. cDNA constructs............................................................................ 57
2.4. Preparation of electrocompetent E. coli host strains.................... 58
2.5. Transformation of E. coli cells using electroporation..................59
2.6. Small scale preparation of bacterial plasmids (minipreps) 60
2.7. Large scale preparation of bacterial plasmids (maxipreps) 60
2.8. Spectrophotomeric determination of nucleic
acid concentration......................................................................... 61
2.9. Digestion of DNA with restriction endonucleases....................... 61
2.10. Concentration of DNA by ethanol pecipitation......................... 61
2.11. Horizontal agarose gel electrophoresis.......................................62
2.12. Denaturing agarose electrophoresis............................................ 62
2.12.1. Maintenance of RNAse free conditions............................. 63
2.13. Purification of DNA using Geneclean........................................63
2.14. Ligation of DNA fragments into plasmid vectors......................64
2.15. Nucleotide sequencing..................................................................64
2.15.1. Preparation of double-stranded template DNA.................65
2.15.2. Sequencing reactions...........................................................65
2.16. Analysis of nucleotide sequences............................................... 65
2.17. Mammalian cell lines................................................................... 65
2.18. Tissue culture media and conditions........................................... 66
2.18.1. Cell line maintenance and subculture..................................66
2.18.2. Dispersion of B 16a cells from solid lung tumours............ 67
2.18.3. Cell storage and recovery.................................................... 67
2.19. Preparation of a cDNA library.................................................... 68
2.19.1. mRNA purification from B 16a cells..................................68
2.19.2. cDNA synthesis by reverse transcription.......................... 68
2.19.3. Ligation of EcoHI linkers................................................... 69
2.20. Preparation of AZAP II library.................................................... 69
2.20.1. Ligation into AZAPII arms................................................ 69
2.20.2. Packaging into AZAP II...................................................... 70
2.21. Screening AZAP II cDNA library............................................... 70
2.21.1. Titration of the cDNA library.............................................. 70
2.21.2. Plaque screening................................................................... 71
2.22. Preparation of oligonucleotides.................................................. 71
2.23. Polymerase Chain Reaction (PCR) of cDNA probes
7
for murine integrin allb  and p3 subunits....................................72
2.24. Preparation of 32P-labelled cDNA probes...................................72
2.25. Hybridisation of labelled cDNA probes to fixed
nylon membranes......................................................................... 73
2.26. Autoradiography.......................................................................... 74
2.27. In vivo excision of pBluescript from AZAP I I ........................... 74
2.28. MTT assay for determination of cell number............................ 74
2.28.1. Calibration of MTT assay................................................... 75
2.28.2. Optimisation of G418 treatment of cells using an
MTT viability assay..............................................................76
2.29. Transfection of mammalian cells with DNA using 
electroporation...............................................................................77
2.29.1. Determination of efficiency of electroporation using 
FITC labelled dextran...........................................................78
2.29.2. Determination of efficiency of electroporation using
p galactosidase activity.........................................................79
2.29.3. Selection of stable transfectants using geneticin (G418) ..79
2.30. Adhesion assay for cells to ECM proteins..................................80
2.30.1. Coating surfaces with ECM proteins..................................80
2.30.2. Static cell adhesion assay to coated 96-well plates............80
2.30.3. Cell spreading assay upon coated surfaces......................... 81
2.31. Fluorescence assisted cell sorting (FACS) of cells.................... 81
2.31.1. Antibodies............................................................................ 81
2.31.2. Labelling cells for FACS analysis.......................................82
2.31.3. FACS analysis of intracellular proteins...............................83
2.32. Western blotting of total cell proteins.........................................83
2.32.1. Preparation of cell extracts.................................................. 83
2.32.2. Sodium dodecyl sulphate-polyacrylamide
gel electrophoresis................................................................83
2.32.3. Immunoblotting.................................................................... 84
Chapter 3: Cloning and sequencing of murine allbp3 from
B 16a melanoma cells..............................................................86
3.1. Construction of a B 16a cDNA library in AZAP II ....................... 86
3.1.1. Calculation of average inset size using random
plaque excision....................................................................... 87
3.2. Generation of allb  and p3 specific probes by reverse 
transcription PCR (RT PCR) of B 16a cDNA..............................88
8
3.2.1. Generation of an allb  fragment from RT PCR....................88
3.2.2. Generation of a P3 fragment from RT PCR......................... 89
3.2.3. Verification of PCR fragments by nucleotide sequencing ..90
3.3. Screening of AZAPII plaques with cDNA probes.......................92
3.4. Examination of reactive AZAP II plaques.....................................92
3.4.1. Sequence analysis of reactive cDNA clones........................ 93
3.5. Discussion.......................................................................................95
Chapter 4: Characterisation of p3 integrin expression in murine
and human melanoma cell lines.............................................99
4.1. Characterisation of P3 integrin expression of B 16a cells
using FACS....................................................................................99
4.1.1. FACS analysis of B 16a cells using mAb Hmp3................ 100
4.1.2. FACS of B 16a cells using p3 expression as a selection 
marker................................................................................... 102
4.1.3. Stability of P3 expression from FACS isolated cells 103
4.1.4. Morphology of FACS isolated cells....................................105
4.2. Static adhesion assays using B 16a cell populations................... 106
4.2.1. Calibration of chromium-based cell detection protocol.... 106
4.2.2. Adhesion to surfaces coated with fibronectin.................... 107
4.2.3. Adhesion to surfaces coated with fibrinogen..................... 109
4.2.4. Spreading of B 16a cells upon surfaces
coated with fibronectin.........................................................112
4.3. Proliferation of FACS isolated B 16a cell populations...............114
4.4. Characterisation of p3 integrin expression of A375 cells
using FACS.................................................................................... 115
4.5. Discussion......................................................................................... 118
Chapter 5: Treatment of melanoma cells with antisense mRNA
against p3 integrins............................................................... 122
5.1. Cloning of antisense P3 constructs into pcDNA3...................... 122
5.1.1. Cloning of an entire antisense p3 insert..............................123
5.1.2. Cloning of pcDNA3 with partial antisense p3 inserts 125
5.2. Transient expression of antisense p3 constructs........................ 126
5.2.1. Transient expression using B 16a cells................................126
5.2.2. Transient expression using A375 cells................................128
5.3. Stable transformation of B 16a cells with antisense
p3 constructs.................................................................................130
9
5.3.1. FACS analysis of polyclonal stable transfectants.............. 130
5.3.2. Western blotting of total protein extracts from stable 
transfectants for integrin (33................................................ 131
5.3.3. Proliferation of stable transfectants..................................... 133
5.4. Discussion................................................................................... 134
Chapter 6: Competitive inhibition of p3 integrins by transfection
of cells with inactive P3 subunits......................................... 140
6.1. Optimisation of electroporation of mammalian cells................. 141
6.1.1. Determination of B 16a cell uptake and viability after 
electroporation using FACS................................................ 141
6.1.2. Determination of COS7 cell uptake and viability after 
electroporation using FACS................................................ 143
6.1.3. Determination of electroporation efficiency using
P galactosidase expression.................................................. 145
6.2. Verification of mutation of CD3A D119A by
nucleotide sequencing.................................................................147
6.3. Cloning of integrin subunits into pcDNA3.................................148
6.4. Transient expression of integrin subunits...................................149
6.4.1. Transient expression in COS7 cells....................................149
6.4.2. Transient expression in B 16a cells...................................... 151
6.5. Stable expression of integrin subunits using B 16a cells 155
6.5.1. Detection of intracellular integrins using FACS............... 155
6.6. Discussion.................................................................................... 157





Table 1.1. Effect of stage of malignant melanoma upon prognosis 18
Table 1.2. Effect of primary tumour depth upon type I malignant
melanoma prognosis..................................................................19
Table 1.3. The integrin receptor family and recognised ligands..............23
Table 1.4. Signal transduction pathways mediated through integrins ....32
10
Table 1.5. Range and hierarchy of cytoplasmic molecules interacting
with p integrin cytoplasmic domains......................................34
Table 1.6. Changes in integrin expression between untransformed
melanocytes and melanoma cells in vivo ............................... 37
Table 2.1. Composition of running gel and stacking gel for
SDS-PAGE............................................................................... 84
Figures
1.1. Typical structure of an integrin heterodimer....................................22
2.1. Plasmid map of mammalian expression vector pcDNA3................57
2.2. Map of the human p3 integrin subunit cDNA, CD3A..................... 58
2.3. MTT assay of B 16a cell number vs.
absorbance at 540-690nm..................................................................75
2.4. MTT assay of log B 16a cell number vs.
absorbance at 540-690nm..................................................................76
2.5. MTT assay for G418 treatment of B16a cells.................................. 77
3.1. Agarose gel of six random plaque excisions from
B 16a cDNA library............................................................................ 87
3.2. Agarose gel showing RT PCR of integrin specific probes............. 90
3.3. Sequence comparison of allb  RT PCR fragment............................ 91
3.4. Sequence comparison of p3 RT PCR fragment............................... 91
3.5. Agarose gel showing allb  and p3 cDNA library clones..................93
3.6. Sequence comparison of allb  cDNA library clone......................... 94
3.7. Sequence comparison of p3 cDNA library clone............................ 94
4.1. Effect of cell detachment method upon FACS detection
of p3 integrin using B 16a cells........................................................101
4.2. Effect of soluble ligand upon FACS detection of p3
integrin using B 16a cells.................................................................. 102
4.3. FACS of B 16a cells using p3 expression as a marker................... 103
4.4. FACS of B 16a cells after cell sorting............................................. 104
4.5. Morphology of sorted B 16a cell populations.................................105
4.6. Calibration of Cr51 labelling protocol using B 16a cells.................107
4.7. Static adhesion of B 16a cells to various fibronectin
coating concentrations..................................................................... 108
4.8. Timed static adhesion assay of sorted B 16a cells to fibronectin... 109
4.9. Static adhesion of sorted B 16a cells to various fibrinogen
11
coating concentrations......................................................................110
4.10. Timed static adhesion assay of sorted B 16a cells to fibrinogen... 111
4.11. Spreading assay of sorted B 16a cells to fibronectin..................... 113
4.13. MTT assay of sorted B 16a cell proliferation over time................114
4.14. FACS of avp3 expression in A375P and A375MM cells............117
5.1. Agarose gel of PC3A restriction digest analysis..............................123
5.2. Agarose gel of PCa3A restriction digest analysis............................124
5.3. Agarose gel of PCKpn3A and PCBam3A confirming
presence of antisensed p3 fragments...............................................126
5.4. FACS of B 16a cells 48 hours after transfection with
antisense p3 constructs.....................................................................127
5.5. FACS of A375MM cells 48 hours after transfection
with antisense p3 constructs............................................................ 129
5.6. FACS of B 16a stable antisense transfectants..................................131
5.7. Western blot of total B 16a cell proteins for expression of
p3 integrin using mAb HmP3.......................................................... 132
5.8. MTT assay of stable B 16a cell proliferation over tim e.................. 133
6.1. Fluorescence of B 16a cells after electroporation with
FITC conjugated dextran................................................................. 142
6.2. Viability of B 16a cells after electroporation with FITC 
conjugated dextran and staining with propidium iodide................ 143
6.3. Fluorescence of COS7 cells after electroporation with
FITC conjugated dextran................................................................. 144
6.4. Viability of B 16a cells after electroporation with FITC 
conjugated dextran and staining with propidium iodide................145
6.5. p galactosidase expression of B 16a cells after electroporation 146
6.6. p galactosidase expression of COS7 cells after electroporation.... 146
6.7. Nucleotide sequence of the ligand binding site of
CD3A and CD3A D119A plasmids.................................................147
6.8. FACS of COS7 cells 48 hours after transfection with
integrin constructs............................................................................. 150
6.9. FACS of B 16a cells 48 hours after transfection with
integrin constructs............................................................................. 152
6.10. FACS of B 16a stable integrin transfectants................................... 154
6.11. FACS of B 16a stable integrin transfectants permeabilised with 





BSA bovine serum albumin
Ci Curie










EDTA ethylene diamine tetra-acetic acid
ERK extracellular signal-regulated kinase
F Farad
FACS fluorescence activated cell sorting
FITC fluorescein isothiocyanate
FCS foetal calf serum
G418 geneticin
g gramme(s)




LI-CAM neural cell adhesion molecule
1 litre(s)
LB Luria broth
M mole(s) per litre
mAb monoclonal antibody
mol moles
MEM Eagles’ minimal essential media












PCR polymerase chain reaction
PE phycoerythrin
pfu plaque forming units
RNA ribonucleic acid
rpm revolutions per minute
RSV Rous sarcoma virus
RT PCR reverse transcription polymerase chain reaction
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
TEMED N,N,N,'N'-Tetramethylethylene diamine.
Tris tris (hydroxymethyl) aminomethane
UVR Ultraviolet radiation
VCAM-1 vascular cell adhesion molecule 1
V volt(s)
v/v volume by volume




Cell adhesion events are essential to any biological process involving 
communication between a cell and its environment. These events are mediated by a 
number of recently characterised groups of adhesion molecules, spanning the cell 
membrane. They act as both molecules for cell anchorage and as signal transducers, 
connecting an extracellular environment to structural cytoskeletal components and 
signalling pathways that allow cells to respond to both external and internal stimuli. 
Such events can be diverse, ranging from growth and differentiation of tissue to 
migratory pathways such as inflammation, haemostasis and wound repair (Hynes,
1992)
Specific events are mediated by a number of significantly different adhesion 
molecule families. They include the integrins, immunoglobulin (Ig) superfamily, 
cadherins, selectins, CD44-related molecules and transmembrane proteoglycans. Each 
family consists of several members and have a specific role in the maintenance or 
formation of cellular contacts between other cells or to connective proteins of the 
extracellular matrix (ECM).
The role of these adhesion molecules in tumour cells has been the source of 
much interest over the past ten years. Tumour invasion and metastasis is a complex 
multistep process involving proliferation of the primary tumour, invasion of a 
basement matrix and release of neoplastic cells from the primary tumour into either 
the lymphatics or blood vessels (Nicolson, 1988; Hart et al., 1989). Arrest of these 
cells in metastatic sites requires specific interactions with the endothelium and 
underlying subendothelial matrix before adhesion, invasion and subsequent
15
proliferation occurs. Most (if not all) of these steps involve cell-cell and cell-matrix 
interactions so it can be clearly seen that molecules controlling these interactions bear 
great significance.
Members of the integrin family of cell adhesion molecules consist of non- 
covalently associated glycoprotein heterodimers and appear to play a significant role 
in the mediation of the metastatic cascade (Hynes, 1992). As both adhesion molecules 
and signal transduction receptors, they have a significant impact upon substrate 
independent growth and proliferation of transformed cells, influencing oncogenesis, 
proliferation, invasion, metastasis and angiogenesis of secondary tumours (Juliano and 
Varner, 1993). This is of particular significance in malignant melanoma where 
invasion and metastatic spread of tumours have a large impact upon patient prognosis 
(Kramer ef al. 1991).
In this study we have concentrated on using members of the integrin family of 
adhesion molecules as a target for gene therapy, particularly those present on the 
surface of metastatic melanoma cells. A number of gene therapy techniques have been 
used here in an attempt to reduce expression of specific integrin molecules on the 
surface of both human and murine melanoma cells and subsequently change the 
metastatic phenotype of transformed cells.
1.1 Malignant Melanoma
Malignant melanoma is a particularly virulent form of skin cancer which arises 
from the transformation of normal skin melanocytes to a malignant phenotype. 
Epidermal melanocytes are neural-crest derived cells which migrate to the basal layer 
of the epidermis early in embryonic development. Their role in the epidermis is to
16
closely interact with surrounding keratinocytes, forming a functional structure defined 
as the epidermal-melanin unit (Weiss and Greep, 1977). Melanocytes transfer melanin 
pigment granules through dendritic processes to these keratinocytes and help to protect 
the skin from environmental ultraviolet light damage (Yaar and Gilcrest, 1991). 
Malignant transformation of these cells appears to reinstate neural-crest cell migratory 
behaviour and facilitates substrate independent growth leading to highly invasive cells 
with a well developed ability to migrate to secondary sites in the body (Jimbow et al. 
1991).
1.1.1. Aetiology
The likelihood of melanoma developing in an individual depends greatly upon 
skin type, age and exposure to environmental risk factors (Clark et al, 1969). 
Melanoma occurs predominantly in fair skinned people, with a reducing risk with 
increasing natural skin colour, although a dark complexion is not a total defence 
against development of melanoma. Other important predisposing factors in melanoma 
are the presence of large numbers of moles (melanocytic nevi), freckling and family 
history of melanoma (Holly et al., 1987; Greene et al., 1985). Melanocytic nevi 
represent markers of melanoma risk rather than true precursors as at least 70% of 
melanomas arise in normal skin (Clark et al., 1969).
The effect of age upon melanoma incidence is difficult to separate from factors 
arising from exposure to environmental factors. Older age is generally the time that 
clinically significant melanomas appear although evidence suggests that exposure to 
environmental risk factors at a young age significantly increases risk of development 
of melanoma in later years (Marks, 1988).
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The major environmental risk factor of melanoma (and all other skin cancers) 
is exposure to sunlight, predominantly in the UVR wavelengths (290-320nm). 
However, unlike other types of skin cancer, length of exposure does not seem to have 
a direct relationship to melanoma risk.
1.1.2. Incidence
Although malignant melanoma comprises only 5% of all skin cancers, more 
than 3/4 of all deaths from skin cancer are due to malignant melanoma (Rigel, 1992). 
Greater information exists for the incidence of malignant melanoma in the United 
States where there are approximately 32 000 new cases each year and approximately 
6500 Americans die each year from the disease. Incidence of malignant melanoma in 
the US has increased more than 12-fold over the last 50 years from 1 in 1500 in 1935 
to 1 in 250 in 1991. Projections of current figures predict that the lifetime risk for 
developing malignant melanoma by the year 2000 will be 1 in 75 (Balch et al., 1985b).
1.1.3. Mortality associated with malignant melanoma
Prognosis of melanoma depends on a number of factors, however the primary 
prognostic variable is the stage of disease, represented by the data shown in table 1.1.
Table 1.1 Effect of stage of malignant melanoma upon patient survival
Stage Description Survival
I localised primary cutaneous malignant 40%-100% over five years
melanomas
n Palpable regional lymph nodes and 30% over five years
histological evidence of tumour
m Distant metastases Survival 5-16 months
18
Data taken from Balch et a l ,(1985a).
Many factors have a prognostic significance, particularly in stage I of 
malignant melanoma. These include age, where older patients are possibly less able to 
mount an effective immune response to tumour cells (Thom et al, 1987; Cohen et al, 
1987). Sex of patients has a significance with survival greater amongst females (Shaw 
et al, 1980). Location of the primary tumour is also significant, as patients with 
tumours on the extremities (excluding hands and feet) tend to survive longer than 
other lesions (Thom et al, 1989) although this phenomenon is not always predictable.
Morphological and histological factors are very important in the prognosis of 
malignant melanoma. Bleeding, ulcerated and nodular tumours indicate a potentially 
worse prognosis. The single best determinant of tumour prognosis is its thickness, and 
thus essentially, degree of invasion (Clark et al, 1969, Breslow 1970). It can be 
measured as the maximal vertical dimension of the tumour from the top of the 
granular cell layer to the deepest invasive tumour cell with an ocular micrometer. 
Mortality associated with tumour thickness is represented by table 1.2.
Table 1.2 Effect of primary tumour depth upon type I malignant melanoma survival.






Data taken from Balch et al, (19 85b)
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Tumour thickness characterisation forms the basis of therapeutic decisions, 
which include surgical resection, lymph node dissection and use of adjuvant 
chemotherapy. Surgical excision is an effective curative treatment approach for thin 
(<0.8mm) but less effective for thick (>1.7mm) tumours (Goldman et al., 1986) due to 
its link with invasion and dissemination. In some cases, tumour depth does not 
represent an accurate prognostic tool although these cases are isolated to a few 
individuals.
1.2. The integrin family of cell adhesion molecules
Integrins are non-covalently linked heterodimers of transmembrane 
glycoproteins consisting of two fairly similar components, termed a  and p subunits 
(Hynes, 1992). Currently the family consists of 16 known a  units and 9 known p 
units which are distinct in terms of processing and surface expression (O’Toole et al., 
1989). The range of potential a  and p subunit pairs is controlled, however, with a  
units forming specific heterodimers with distinct p units. However, some integrin p 
subunits (pi p2 and p3) can form heterodimers with a range of a  units, giving a total 
of 20 currently identified integrin heterodimers, each with a different spectrum of 
ligand specificities (Hynes etal., 1992; table 1.3).
A range of integrin heterodimers are constitutively expressed on the surface of 
all mammalian cells (except mature erythrocytes; Hemler, 1990). They can mediate 
adhesion contacts to both proteins of the extracellular matrix (ECM, Giancotti et al., 
1985, Pytela et al., 1985; Ginsberg et al., 1983) and to other cells through members of 
the immunoglobulin superfamily (Marlin and Springer, 1987) or through bridging 
soluble ligands (in the case of platelet coagulation, Plow et al., 1986). Adhesive
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contacts are divalent cation dependent (Gailit and Ruoslahti, 1988), and affinity of 
these integrins can be modulated through conformational changes between “active” 
and “resting” states to alter ligand binding properties (Shattil et al, 1985). Ligand 
binding to integrin heterodimers will additionally result in rearrangement of the cell 
cytoskeleton through contacts with the cytoplasmic portion of the integrin and 
triggering of secondary signalling pathways (reviewed by Clark and Brugge, 1995). 
Therefore, integrins can more accurately be described as dynamic surface receptors 
rather than purely adhesion molecules.
1.2.1. Structure o f integrin subunits
Electron microscope images of integrin heterodimers have indicated the 
presence of a 10-15nm extracellular globular “head” comprising both a  and p subunits 
with two “stalks” extending into the phospholipid membrane bilayer. These terminate 
in short cytoplasmic domains of -40-70 amino acid residues (Carrell et al., 1985; 
Nermut eta l., 1988; Weisel etal., 1992).
Integrin p subunits are generally -1000 amino acid residues long (90-1 lOkd) 
with a similar basic morphology to the a  subunit. The N-terminal 40-50kd “head” 
portion of the subunit is tightly folded with internal disulphide bonds, while the 
transmembrane “stalk” of all p subunits consist of characteristic four-fold repeats of a 
cysteine rich segment, believed to be internally disulphide bonded (Calvete et al., 
1991). All P subunit cytoplasmic domains consist of relatively short sequences of 
-40-60 amino acids, with the exception of p4 which has a -1000 residue tail (Suzuki 
and Naitoh, 1990) and appears directly interact with cytoskeletal components directly. 
Primary sequences within this region generally carry great homology between both
21
species, and different (3-subunits. Cytoplasmic domains of (3 integrin subunits interact 
with components of the cytoskeleton and are essential for activity of many secondary 











Fig 1.1 Typical structure of an integrin heterodimer, as expressed on the cell membrane. The dark 
shaded area marks the relative position of sites important to ligand binding for each subunit. The light 
shaded area on the P subunit shows the position of the characteristic cysteine-rich repeats. Sites marked 
with an ‘S’ illustrate the presence of disulphide bonded areas in the p subunit globular head, while the 
disulphide bonded area in the a  subunit indicates the position of the posttranslational cleavage site (if 
present). Areas of the a subunit marked with M2+ indicate sites of interaction with divalent cations, or 
EF-hand-like loops. For clarity, the position of the -190 residue I-domain (N-terminal of the EF hand 
repeats) has been omitted, although, when present is significant to both ligand and divalent cation 
binding. This diagram is not shown to scale. (Illustration modified from that presented by Hynes, 
1992).
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Table 1.3 The integrin receptor family and recognised ligands
Integrin Subunits Ligands and Counter Receptors Recognition sequence or domain
01* a l Collagen I, IV, laminin DGEA (collagen)
a2 Collagen I, IV, laminin RGD (?)
a3* Collagen I, IV, laminin, fibronectin, 
epiligrin
Domain 1 & 4 (VCAM-i), EILDV 
RGD






av Vitronectin, fibronectin RGD (fibronectin)
p2 aL ICAM-1, ICAM-2, ICAM-3 Domain 1 (ICAM-1)
aM iC3b, ICAM-1, fibronectin, vWF, factor X Domain 3 (ICAM-1)
aX Fibronectin, iC3b GPRP (fibrinogen)
p3* allb Fibrinogen, fibronectin, vWF, 
thrombospondin
RGD, KQADGV (fibrinogen)
av Fibrinogen, fibronectin, vWF, vitronectin, 
Ll-CAM, CD31 (PECAM-1)
RGD, domains 1&2 (CD31)
p4 a6 ?




P7 a4 fibronectin, Vitronectin, MAdCAM-1, 
VCAM-1
RGD
p8 ocE Fibronectin (?) RGD
av VCAM-1, fibronectin, MAdCAM-1 EILDV (fibronectin)
p9 ?
* indicates the identification of alternatively spliced integrin subunits
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Integrin a  subunits are approximately 1000 residues long (120-180kd) and 
comprise a similar N-terminal extracellular globular “head” which is not internally 
bonded but contains a seven-fold repeat of a homologous segment, termed the EF- 
hand-like repeats. The last 3 or 4 of these repeats are believed to contribute to divalent 
cation binding (Gulino et al., 1992) (actual number of sites depends on specific 
subunits). Some a  subunits (aM, aL, aX, a l  and a2) have an additional -190 
residue amino acid sequence, inserted before the last five homologous repeats of the 
N-terminus, termed the I (insert) domain and are also closely implicated in ligand and 
divalent cation binding (Michishita et al, 1993). Divalent cations are essential to 
receptor function, and the nature of the cation has a significant impact upon both 
affinity and ligand specificity (Smith and Cheresh, 1991), particularly in integrins 
carrying an I domain (Lee et al., 1995a; Lee et al., 1995b) (see section 1.2.3). Some a  
subunits are posttranslationally cleaved to give a 25-30kd transmembrane and 
cytoplasmic domain disulphide-bonded to a larger extracellular chain. The 
cytoplasmic domain of a  subunits are of similar size to p subunits (15-77 residues) 
and bear significant homology between species. However, homology between 
different subunits is low (up to 60%). The role of a  cytoplasmic domains in cell 
signalling is less clear although they do have a well defined role in the regulation of 
ligand specificity (LaFlamme et al., 1994; Kassner et al., 1994).
An additional level of complexity is present in the structure of integrins in that 
many subunits are present in an alternatively spliced form (indicated on table 1.3). 
The activity of these alternatively spliced integrins is similar to their “parent” 
molecules. Reasons for the existence of these alternate forms is currently unknown
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but probably serves to add versatility to individual receptor function (discussed in 
Hynes, 1992).
1.2.2 Integrin ligands
Integrins have been identified as receptors for components of the extracellular 
matrix (ECM)(Ginsberg et al., 1983), cell surface Ig superfamily receptors including 
the intercellular adhesion molecules ICAM-1 and ICAM-2 and vascular adhesion 
molecules VCAM-1 (Marlin and Springer, 1987), micro-organisms such as the 
adenovirus (Wickham et al., 1993), certain gram positive bacteria (mediating 
endocytosis, Vannhieu et al., 1996) and the spirochete responsible for lymes disease 
Borrelia burgdorferi (Cobum et al, 1993), certain plasma proteins (deposited at sites 
of injury in haemostasis e.g. fibrinogen), complement activation (iC3b) and integral 
membrane proteins, such as MAdcCAM-1 (Berlin etal. 1993).
Integrins mediate interactions with components of the insoluble extracellular 
matrix or surface proteins on other cells to form links with intracellular elements 
involved in bidirectional signalling events. The extracellular matrix consists of a 
complex multiplicity of proteins and glycoproteins including fibronectin Mosher,
1993), fibrinogen (which in soluble form can also mediate cell-cell aggregation), von 
Willebrands’ factor (vWF) (Ruggeri,1993), laminin, vitronectin, collagens and 
thrombospondin. These molecules form specialised matrices on the surfaces of cells, 
with composition depending on cell-type and location. Matrices can either be derived 
from cells or by deposition from soluble, plasma derived molecules.
Examination of receptor recognition sites of ligands or counterreceptors almost 
always identifies the presence of an acidic residue as a key component. Ligands may 
often have multiple integrin receptors and conversely, an integrin may bind many
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different ligands (Reviewed by Hynes, 1992). This redundancy is illustrated in Table 
1.3 which additionally indicates active residues involved in ligand binding function. 
In some ECM proteins, such as fibronectin and vitronectin, these active residues can 
be assigned to short linear sequences such as Arg-Gly-Asp (RGD; Pierschbacher and 
Ruoslahti 1984) and can be recognised by integrins containing cleaved a-subunits 
without I-domains. Other active residues include Lys-Gln-Ala-Gly-Asp-Val 
(KQAGDV; D’Souza et a l 1991) in fibrinogen, Asp-Gly-Glu-Ala (DGEA) in type I 
collagen (Staatz et al., 1991) and Tyr-He-Gly-Ser-Arg (YIGSR) in laminin (Graf et al., 
1987). Strong evidence exists to suggest that other ligand domains also contribute to 
integrin binding: Analysis of tertiary structures in a variety of RGD containing ligands 
has shown that active peptides are located in highly flexible loop structures containing 
p turns (Leahy et al, 1992, Main et al, 1992) and that this may allow protein ligands 
to contribute secondary sites (Obara et al, 1988).
1.2.3. Ligand binding to integrin heterodimers
Studies using ligand binding to fragments of N-terminal integrin subunits, 
generated through proteolysis (Lam, 1992) or recombinant truncations (Wippler et al,
1994) have identified that both a  and p subunits are capable of binding ligand. 
However, high affinity ligand recognition requires a heterodimer of both a  and P 
subunits (Fitzgerald and Phillips, 1985) and therefore elements of both subunits.
Binding studies using ligand-mimetic peptides (O’Toole et al., 1989), chemical 
cross-linking (D’Souza et al., 1988), site-directed mutagenesis (Loftus et al., 1990) 
and monoclonal antibodies (D’Souza et al., 1994) have revealed potential ligand 
binding and recognition sites in the N-terminal extracellular domains of both integrin 
subunits. Ligand binding function of p integrin subunits has been mapped to a highly
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conserved -62 residue region of the subunit such as D109-E171 in human integrin p3 
subunits (Smith and Cheresh, 1988; D’Souza et al., 1988). Substitution of key, 
conserved residues within this region (at D119 of p i, p2, p3 and p6) result in a total 
loss of ligand binding (Loftus et al, 1990). A second site within this same conserved 
region has also been identified as important for ligand binding (Bajt et al., 1992; 
Lanza e ta l, 1992).
Positions of critical ligand recognition sites with a  subunits are less easy to 
classify and depend on the presence of an I-domain. The I-domain of a  integrin 
subunits is closely implicated with ligand recognition and is structurally related in 
secondary structure to the conserved region of p subunits (Bajt and Loftus, 1994; Lee 
et al., 1995a). Mutation of the I-domain results in a similar blockage of ligand binding 
function (Michishita et al., 1993). Identification of recognition sites in a  subunits 
without I-domains (such as allb and av) has only recently become more clear, and 
requires a combination of two regions, an N-terminal region and the first two EF hand 
divalent cation repeats (Loftus et al, 1996).
It must be noted that the ligand specificity of many integrins is variable 
between cell lines (Kirchofer et al., 1990) and even within the same cell lineage 
(Elices and Hemler, 1989). Additionally, level of expression of integrins does not 
necessarily equate with ligand binding or functional activity, as this may depend on 
activity status (Masumoto and Hemler, 1993).
27
1.3. Integrin mediated transmembrane signalling
Large amounts of information has recently been gathered concerning the role 
that integrins take in mediation of a number of biological phenomena. Integrin ligand 
recognition and receptor occupancy can not only influence a number of signalling 
pathways, termed “outside in” signalling, but affinity of integrins for ligand can be 
rapidly changed through interaction with cytoplasmic cell elements, termed “inside 
out” signalling (as termed by Hynes, 1992).
1.3.1. Modulation o f integrin affinity: inside out signalling
Modulation of integrin affinity is an important phenomenon in many integrin 
mediated biological systems. Platelet aggregation and inflammatory cells such as 
leukocytes and neutrophils require rapid, reversible “activation” of cell adhesion in 
order for the transition from suspension to adhesion to occur (Peerschke et al., 1980; 
Dustin and Springer, 1989). Many (if not all) integrins can exist in different 
conformational states which influence ligand affinity and recognition. The platelet 
integrin, allbp3 for example, can exist in two affinity conformations: “unstimulated”, 
where resting platelets will attach to surface-bound fibrinogen and a “stimulated” 
conformation allowing affinity for soluble fibrinogen in the vasculature. This change 
in ligand affinity arises from conformational changes in the extracellular domain of the 
integrin heterodimer (Sims et al., 1991).
Ligand binding to integrins and changes in integrin affinity are closely 
associated with the displacement of divalent cations, such as calcium. These divalent 
cations bind to specific active sites present on both a  and P subunits (Smith et al., 
1994; D’Souza, 1994). The actual location of these domains is unclear as they appear 
to be coordinated from domains aligned through complex tertiary structural
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relationships which also link ligand binding domains. Recent crystal structure 
elucidation has however closely linked a  integrin I domains and structurally related 
domains in the ligand binding region of p integrin subunits (Lee et al, 1995a).
Specific divalent cations (such as Mn2+) have been shown to enhance the 
adhesive property of many integrins (Smith et al., 1994; Crowe et al, 1994). It has 
been suggested that occupancy of cation binding sites with calcium stabilises the 
“resting” (or low affinity) conformation of the ligand binding site and that increases in 
ligand affinity caused by Mn2+ is thought to be due to antagonism of calcium binding 
to specific domains (Lee et al, 1995b; Pelletier et al, 1996). An “active” 
conformation of integrins can be induced by binding of ligands or ligand mimetics 
(such as RGD for allbp3) and subsequent displacement of divalent cations (Du et al,
1991).
Both a  and p integrin cytoplasmic domains play a crucial role in this 
modulation of affinity, with deletion or mutation within this region affecting ligand 
affinity (Loftus et al, 1990; Michishita et al, 1993). However, their role in integrin 
affinity modulation remains difficult to characterise due to apparent variation of 
integrin activity in different cell types as a result of active cellular signals (Kirchofer et 
al, 1990; Masumoto and Hemler, 1993; Elices and Hemler, 1989). A conserved 
GFFKR motif, present within a  integrin cytoplasmic domain, proximal to the cell 
membrane has been found to closely control the low affinity state of integrins. 
Deletion studies of this motif result in a constitutively high affinity integrin, 
independent of cell type or metabolic inhibitors (O’Toole, 1994). It has been 
suggested that this domain acts as an activating “hinge”, inducing long range 
conformational changes of the ligand binding site. Homology of the remaining
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cytoplasmic portion of a  integrin subunits is low, indicating the potential for a wide 
divergence in the variety of interacting cellular elements (reviewed by Sastry and 
Horwitz, 1993).
The p cytoplasmic domain also has a critical role in affecting ligand affinity. 
Mutation within the cytoplasmic domain of the [33 integrin subunit Ser752 to Pro 
results in an apparent activation defect (Chen et al, 1992a) of allb(33 indicating that (3 
integrin subunits are necessary for maintenance of a high affinity state. Furthermore, 
introduction of isolated (3 subunit cytoplasmic domains into cells lowers ligand 
binding affinity (Chen et al., 1994b), suggesting that affinity modulation by (3 integrin 
cytoplasmic domains is dependent upon beta subunit contacts with cytoplasmic 
signaling pathways.
Phosphorylation events at integrin cytoplasmic domains have been extensively 
studied as a source for this activation stimulus (particularly in platelets - reviewed by 
Shattil and Brugge, 1991). However, the link between phosphorylation and integrin 
activation seems unclear. For example, phosphorylation of neutrophil p2 has been 
documented, but many agonists can activate aMp2 in neutrophils without 
phosphorylation (Merill et al, 1990; Buyon et al, 1990) and mutation of the 
phosphorylation site does not block activation (Hibbs et al, 1991). Therefore, no 
general cytoplasmic pathway can be isolated as specific for increases in integrin 
affinity. Recent important evidence however has implicated the GTP-binding protein, 
R-ras (in its activated form), as a potential cytoplasmic modulator of integrin 
activation (Zhang et al, 1996). The exact mechanism for this activation remains to be 
elucidated.
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1.3.2. Signal transduction through integrins: Outside In Signalling
As transmembrane receptors, integrins represent a primary link between the 
extracellular environment, cytoskeletal organisation and secondary signalling 
pathways. The molecules involved in these pathways, and their links with signal 
transduction through integrins have only recently begun to be identified and the role of 
integrins in many signalling pathways has yet to be deduced.
Integrins will bind to extracellular matrix proteins and other ligands to form 
clusters of receptors at sites of close cell-substratum contact. These are termed “focal 
contacts” and are commonly defined as a tight (10-15nm) clustering of specialised 
structures to a surface providing a link between the extracellular environment, actin 
cytoskeleton and signalling pathways (Chen and Singer, 1982). In vivo these classic 
contacts can rarely be seen, due to the irregular nature of the ECM and exist more as 
“ECM contacts” clustering around streaks or fibrils of the ECM. Integrin clustering 
and ligand ligation result in the accumulation of receptor bound kinases and the 
tyrosine phosphorylation of a variety of proteins resulting in the initiation of signal 
transduction cascades in a distinct hierarchy of interactions (Miyamoto et al., 1995a; 
Miyamoto et a l, 1995b), as displayed in table 1.5. These studies have shown that 
many of the molecules identified as associating with integrin cytoplasmic domains are 
only weakly bound. Additionally, the actual stimulus initiating signalling is still 
unclear.
Table 1.4 represents a current snapshot of identified integrin mediated 
pathways, many of which link up with classic transduction pathways such as growth 
factors and cytokines.
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Phosphorylation of proteins resulting from integrin occupancy/clustering 
occurs predominantly in the size range 110-130kDa (Komberg et al, 1991) and 
involves the integrin p subunit. One of the primary proteins phosphorylated by many 
P integrins is focal adhesion kinase (ppl25FAK or FAK) which can autophosphorylate 
in response to clustering of intact integrins or even chimeras of p i, p3 and P5 (but not
alternatively spliced P3) integrin cytoplasmic domains (Lukashev et a l, 1994; 
Akiyama er a/., 1994).
Table 1.4. Signal transduction pathways mediated through integrins
Signal transduction Comments Reference
Calcium influx / mobilisation through certain av  integrins, linked to 
IAP
Schwartz et al., 1993
Hydrogen influx Schwartz & Lechene 
1992
FAK tyrosine phosphorylation Induced by a variety of ECM ligands Schaller et al., 1992
ILK tyrosine phosphorylation Hannigan et al., 1996
Insulin induced proliferation Association of phosphorylated IRS-1 
to avP3
Vouri & Ruoslahti 1994
Activation of Src and related 
tyrosine kinases
Schlaepfer et a l ,  1994
Growth regulation via P6 cytoplasmic domain Agrez etal . ,  1994
Enhanced gene expression Of integrins, and ECM proteins in Delcommenne & Streuli
response to substrate composition 1995
Of P-casein Roskelley et al., 1994
Of collagenase Tremble et al., 1995
Apoptosis Prevented by ligation to a number of Ruoslahti and Reed,
ECM ligands (section 1.4.4) 1994
Protein kinase C and arachidonic Woods and Couchman,
acid 1992
Accumulation of signal Association of growth factor receptor- Schlaepfer et a l ,  1994
transduction adapters and enzymes bound protein 2 (Grb2) to FAK and 
activators of the Ras pathway (mSosl)
ERK activation Chen etal . ,  1994a
JNK activation Miyamoto et a l ,  1995b
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FAK, unlike other tyrosine kinases lacks both Src homology domains (SH2 
and SH3 domains-responsible for intermolecular interactions that couple signalling 
proteins), but phosphorylation of tyrosine-397 of FAK appears to act as a gateway for 
activation of a large number of other protein kinases and recruitment of cytoskeletal 
proteins in a controlled hierarchy of interactions, dependent on clustering and 
activation state of integrins (Clark and Brugge, 1995; Miyamoto et al., 1995b) as 
shown in table 1.5, overleaf. Studies using swaps or truncations of integrin subunits 
indicate that the initiation of many specific signal transduction pathways is integrin- 
specific, resulting in changes in cell adhesion, migration and focal adhesion formation 
(Pasqualini and Hemler, 1994). Additionally, specific integrin subunits are 
responsible for initiation of a growing number of individual pathways (Vuori and 
Ruoslahti, 1994; Agrez etal., 1994).
a  integrin cytoplasmic domains have also been found to associate with 
cytoplasmic proteins, particularly a 60kDa calreticulin homologue at the conserved 
GFFKR motif (Rojiani et al., 1991). Calreticulin is a nuclear inhibitor of receptor 
mediated transcription and will only associate to a  integrin domains in a high affinity 
conformation. It has been suggested that this association with integrins not only 
stabilises a high affinity state but sequesters calreticulin away from the nucleus 
enhancing gene transcription (Dedhar et al, 1994).
Very recent studies have shown that the membrane proximal sequences
significant for long range inside out “activation” of integrins (or the integrin “hinge”, 
as discussed above) are additionally significant for outside in signal transduction 
(Hughes et al., 1996). Disruption of a potential salt bridge between conserved 
membrane proximal sequences KvGFFKR (a  subunit) and KLLitihD (p subunit, 
lower case symbols represent less conserved residues) by point mutation constitutively 
activates signalling pathways mediated by integrins, such as FAK phosphorylation.
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This recent discovery will have tremendous implications upon the elucidation of 
further integrin mediated signalling pathways, through the examination of cells 
transfected with integrins mediating this constitutive activation.
Table 1.5. Range and hierarchy of cytoplasmic molecules interacting with p integrin 
cytoplasmic domains, and their relationship to integrin clustering and ligation.
State of receptor
Cytoplasmic molecules integrin integrin integrin aggregation
aggregation aggregation aggregation tyrosine
+ + phosphorylation
ligand tyrosine ligand occupancy
occupancy phosphorylation







Src substrates FAK FAK FAK FAK
Tensin Tensin Tensin Tensin
Cortactin Cortactin
ppl20 ppl20



















Table reproduced from Miyamoto et al. (1995b)
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1.4. Role of integrin receptors in malignant melanoma
Integrins have a critical role to play in mediating the malignant phenotype of 
melanoma. This process requires complex changes in the degree of normal cell-cell 
and cell-substratum interactions which can manifest as increases or decreases in 
integrin expression or changes in receptor activation and affinity (Juliano, 1987). An 
active malignant melanoma will be able to undergo substrate independent growth and 
survival and be able to complete the metastatic cascade of detachment from the 
primary tumour, invasion of basement membranes of the surrounding stroma, passage 
within the lymphatic system or vasculature and migration to remote sites of the body 
before secondary substrate attachment, invasion of endothelia and metastatic growth 
(Clark et al, 1984; Clark et al, 1986). Control of this cascade of events cannot be 
assigned to a single integrin heterodimer or to the influence of a single oncogenic 
signalling pathway. Here we shall examine the changes in integrin and ECM 
expression that occur in transformed melanocytes and examine the role of key 
integrins in the migratory phenotype of malignant melanoma.
1.4.1 Changes in integrin expression in transformed cells
Oncogenic transformation of any cell type results in altered expression of 
integrin receptors in comparison to untransformed cells (Plantefaber and Hynes,
1989). Changes in integrin expression profiles appear to be both tumour specific and 
integrin specific, and this is very much the case in transformed melanocytes. Table 
1.6, overleaf, gives an indication of the range of changes that have been reported in the 
expression profile of transformed melanocytes.
Distinct differences are hard to elucidate as integrins expressed upon 
melanocytes are difficult to detect in situ due to their isolated nature and close
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association with keratinocytes. Comparisons with cultured cell lines is additionally 
difficult since expression of many surface proteins are changed in a tissue culture 
system (Herlyn et al., 1987). A more significant indicator of the importance of 
integrins on tumour progression can be found from comparisons of integrin expression 
at different stages of tumour progression in vivo (Albelda et al., 1990; see section 
1.4.2). It must be noted that it is not clear whether changes in integrin expression 
patterns in melanoma are a contributor to the malignant state or a consequence of it.
Oncogenic transformation of cells will have a significant impact upon integrin 
mediated signalling pathways. Constitutive activation of intracellular signalling 
proteins such as oncogenes Src and p21Ras will uncouple the requirement of integrin 
ligation and clustering for substrate dependent intracellular signalling and survival (as 
described above). Constitutive activation of integrin associated signalling pathways 
will also have an impact upon the subsequent expression of specific genes, including 
integrins and ECM proteins.
Transformed cells express altered levels of ECM components (such as fibronectin) 
and changes in ECM composition can play an active part in changes in adhesiveness, 
motility and morphology of transformed cells (Yamada, 1983).
1.4.2. Role o f integrins in migration, invasion and metastasis o f malignant melanoma
Functional studies have shown that integrins play an active role in the motility 
of melanoma. Synthetic peptides containing the ligand mimetic RGD motif inhibit the 
invasion of human melanoma cells through amniotic basement membrane models in 
vitro (Gehlsen et al., 1988). RGD peptides also reduce the number of metastatic lung 
nodules in vivo when co-injected into C57 mice with B16F10 melanoma cells 
(Humphries et al., 1986; Saiki etal., 1989; Humphries et al., 1988).
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Table 1.6. Changes in integrin expression between untransformed melanocytes and melanoma cells in vivo
a l p l cx2pl a3 p i a4 p l a5 p l oc6pl a6p4 a7 p l allbp3 avp3 avp5 References
T T TT T TT
TT
Albelda et al., 1990 








Schadendorf et al., 1993 
Van Duinen et al., 1994 
Si and Hersey, 1994 
Kramer etal. ,  1991 
Natali etal. ,  1993 
Natali et al., 1991




Danen etal . ,  1994 
Danen etal . ,  1995 
Chang etal. ,  19921
1. It must be noted that identification of allb|33 has only been identified in vitro in murine cultures of B 16a cells. A double arrow represents a large change 
(or de novo expression, in the instance of av(33 expression by Albelda et al,1990) in the marked integrin heterodimer. A single arrow represents a small, but 
reproducibe change in expression. No arrow denotes either no change or that the integrin subunit was not studied.
As described in section 1.4.1, in situ monoclonal antibody detection of 
integrins on sections of human melanoma from benign naevi, non-invasive radial 
growth phase (RGP) primary melanotic lesions, vertical growth phase (VGP) lesions 
and metastatic melanoma have revealed significant alterations in integrin profiles 
(McGregor et a l, 1989; Albelda ef al, 1990). Most striking amongst these differences 
is that VGP and metastatic melanoma express P3 integrins whereas non-invasive 
melanoma lesions (and native melanocytes) do not. There are two identified p3 
integrins, aEbp3, the major platelet integrin (Phillips et al, 1988) and avp3, the 
classical vitronectin receptor (Cheresh and Spiro, 1987). Integrin avp3 has become 
closely implicated with an invasive tumour phenotype.
Further evidence for avp3 integrin involvement in melanoma metastasis has 
been obtained through a number of studies: Antibody treatment of human melanoma 
cell lines with an anti avp3 antibody inhibits subcutaneous growth of human 
melanoma xenografts (Boukerche et al, 1989). Ligand binding to avp3 integrin with 
soluble vitronectin or antibodies is associated with an increased in vitro invasive 
potential of A375M human melanoma cells (Seftor et al., 1992). It has been 
postulated that this ligand binding results in induction of signal transduction pathways, 
increasing expression of type IV collagenase enzymes (Seftor et al., 1992). Further 
studies have shown that avp3 can also recognise a cryptic ligand binding site exposed 
upon denaturation of collagen I matrix (Davis, 1992), exposed by collagenase 
digestion of the basement membrane by invading tumour cells (Montgomery et al,
1994) and allowing invasion of collagen matrices. Further important evidence of a co­
ordination between proteolytic enzymes and oivp3 has recently been published by
Brooks et a l (1996) who provide evidence for a co-localisation and interaction 
between avp3 and activated receptor bound matrix metaloproteinase (MMP-2).
A similar pattern of p3 integrin expression has also been elucidated in a 
murine melanoma cell model B16a, except the functionally active integrin is the 
classic platelet integrin allbp3 (Chen et al, 1992b). Similar to expression of avp3 in 
human melanoma, allbp3 expression in B 16a cells has been implicated with increased 
metastatic capacity (Chang et al., 1992), which is reduced (but interestingly, not 
totally prevented) by treatment with specific anti allbp3 monoclonal antibodies.
The ability of tumour cells to migrate to distant sites of the body has been 
closely linked to their association with platelets in several studies (reviewed by Honn 
et al, 1992). During this process, many tumour cells can induce platelet aggregation 
and subsequently form co-aggregated thrombi in the bloodstream. This is followed by 
arrest at distant sites in the vasculature, and tumour cell invasion. The mechanisms 
behind this process have long been thought to be due to the passive entrapment of 
tumour/platelet thrombi in narrow capillary vessels. However, the site specific nature 
of many tumour types and increased shear conditions at sites of capillary occlusion 
have lead to the discovery of the importance of P3 integrins in this process.
Induction of platelet aggregation by tumour cells can be mediated by a number 
of factors including ADP release (Grignani and Jamieson, 1988; Longenecker et al,
1989), generation of tissue factors (Bastida et al, 1984) or thrombin release by tumour 
cells (Tohgo et al, 1985). These interactions can “activate” the platelet integrin, 
allbp3 into a high affinity state, resulting in the aggregation of platelets using soluble 
plasma proteins (such as fibrinogen, von Willebrand factor, fibronectin or
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thrombospondin) as bridging ligands (Peerschke et al, 1980). Recent studies 
(Felding-Habermann et al., 1996) have shown that tumour cell arrest under flow is 
influenced by adhesion events mediated by this platelet activation. Tumour cells 
expressing either p3 integrin (allbp3 or avp3) can use activated platelet arrest to 
vessel walls as an primary anchor for their arrest via the soluble bridging ligands 
described.
Vitronectin expression in the ECM is vital for melanoma progression mediated 
by avP3 (Sanders et al, 1992). Vitronectin is produced in the liver and accumulates 
in the serum from where it deposits into the ECM at the lungs, striated skeletal 
muscle, lymph nodes, skin and kidneys. Vitronectin deposits in the skin have been 
shown to increase with age and exposure to sunlight (Dahlback et al, 1989) - both are 
in part factors in the development of melanoma. Co-injection of vitronectin with M21 
human melanoma cells into nude mice results in an increase in tumour proliferation 
(Sanders et al, 1992). Adhesion to lymph nodes, a primary target for melanoma 
metastasis is mediated through avp3 mediated attachment to ECM vitronectin, and is 
blocked by specific antibodies to avp3 or vitronectin (Nip et al, 1992).
Integrin signaling events following ligand binding are vital to avp3 mediated 
invasion and metastasis, as deletions or changes in integrin cytoplasmic domains 
prevents cell spreading, focal adhesion formation and migration (La Flamme et al, 
1994; Ylanne et al, 1993). Deletion of a highly conserved NPXY sequence in the 
cytoplasmic domain of the p3 subunit (residues 744-747) results in the loss of the 
metastatic phenotype of melanoma cells (Filardo et al, 1995). The NPXY sequence is 
closely linked with recruitment of secondary signalling molecules and cytoskeletal
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contacts, although deleted p3 subunits can still attach to soluble ligand (Filardo et al, 
1995).
Post-ligand binding signalling pathways have been implicated in the urokinase- 
type plasminogen activator system of basement membrane proteolysis which is closely 
linked to cell invasion (Seftor et al, 1992). Lowering the expression of av  integrin 
subunits (using antisense av phosphorothioate oligonucleotides) lowers expression of 
urokinase plasminogen activator receptor (uPAR), mAb ligation of av|33 also causes a 
transcriptional increase in uPAR (Nip et al, 1995).
Although avp3 integrin has been closely linked to invasive and metastatic 
capacity of human melanoma cells, several important contradictions and 
complications have been elucidated which complicate understanding of the specific 
role of p3 integrin mediated melanoma progression (discussed below). Due to the 
complex nature of the metastatic cascade, a spectrum of other integrins (with different 
ligand affinities) are also closely linked with melanoma migration, invasion and 
metastasis as suggested by the range of integrins highlighted by table 1.6. Many 
isolated metastatic melanomas (up to 25%) do not express the avp3 heterodimer 
(Albelda et al, 1990; McGregor et al, 1989; Boukerche et al, 1994) and it is most 
likely that metastatic activity is compensated by altered expression of other integrins. 
Additionally, Seftor et a l (1993) have reported that reduction of avp3 surface 
expression using fluorescence activated cell sorting (FACS) of A375M human 
melanoma cells causes an increase in ability of cells to invade in vitro. This appears to 
contradict avp3 mediated increases in invasion in vitro seen by Seftor et a l (1992).
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1.4.3. Role o f integrin ccvp3 in tumour cell Angiogenesis and apoptosis
Recent evidence has closely implicated integrin avp3 with angiogenesis (the 
growth of new blood vessels) during many processes such as wound repair, 
inflammation, development and pathological conditions such as diabetic retinopathy, 
rheumatoid arthritis and tumour cell development (Brooks et al 1994a; Brooks et al,
1995).
Angiogenesis is vital for both blood supply to primary tumours and to aid 
passage of invading metastatic cells into the vasculature. In many tumour types (for 
instance prostatic and breast cancer) the degree of blood vessel infiltration of primary 
tumours provides a prognostic indication of disease status (Weidner et al., 1992, 1993) 
as this has direct impact upon metastasis. Angiogenesis requires invasion, migration 
and proliferation of smooth muscle and endothelial cells of the vasculature (Clark et 
al., 1982). Examination of this phenomenon in in vivo models of chick chorioallantoic 
membranes (CAM) challenged with cytokine impregnated discs or fragments of solid 
human melanoma (not expressing avp3) has revealed that infiltration of blood vessels 
involves av(33 integrin (Brooks et al., 1994a). Treatment of these models with cyclic 
RGD peptides or mAb’s against avp3 dramatically decreases blood vessel infiltration 
and directly affects primary tumour cell growth (Brooks et al., 1994b). Similar avP3 
dependent tumour cell angiogenesis has also been seen in human mammary tumours 
(also not expressing avp3) grown upon human foreskin tissue grafted onto 
immunocompromised mice (Brooks et al., 1995).
One interesting observation of anti-avp3 monoclonal antibody treatment of 
angiogenesis is that antibodies have no effect upon preformed tumour vascularisation.
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However, treatment of forming angiogenic vessels at the peak of ccv|33 expression (12- 
24 hours) results in programmed cell death, or apoptosis of forming blood vessels 
detected with antibodies to DNA fragmentation (Brooks et al., 1994b). Therefore, 
avp3 ECM interactions appears vital for survival and maturation of newly forming 
blood vessels.
Other integrin influenced apoptotic events have also been noted in the aberrant 
survival of human melanoma cells in a three dimensional dermal collagen I matrix. 
Human M21-L melanoma cells, selected (from wild type M21 cells) for lack of avp3 
expression will initially spread through dermal collagen (type I, mediated by a2 p l) 
but will rapidly lose their spread dendritic morphology after 24 hours. They 
subsequently undergo apoptosis after a two day period unless supplemented with 
growth factors or insulin to supplement inactive signaling pathways (Montgomery et 
al., 1994). Wild type M21 cells (avp3 positive) in this system do not undergo 
apoptosis due to ligation of avp3 integrins with cryptic RGD binding sites revealed by 
melanoma cell proteolysis of collagen I (through integrin mediated collagenase 
synthesis, section 1.4.2.). This has been proposed as a major factor in tumour 
progression (Marx, 1993). It has therefore been suggested that avp3 ligation is vital 
to melanoma survival and growth before angiogenesis or in poorly vascularised areas 
of the tumour.
1.5. Integrins as targets for drug and gene therapy
It has been shown that integrin molecules are vital mediators in the regulation 
of many pathogenic and non pathogenic cell functions (Juliano and Varner, 1993;
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Clark and Brugge, 1995). Their nature as a contact between the extracellular 
environment, and intracellular signalling pathways makes them a very interesting 
target for drug or gene therapy of any condition involving aberrant cell aggregation, 
migration, growth or differentiation. Potential target conditions could be as diverse as 
control of haemostasis, treatment of primary tumour spread or metastasis, or 
inflammatory conditions such as arthritis. This may be tackled using downregulation 
or inactivation of integrins involved in a pathogenic process, or stimulation of integrin 
expression or integrin conformation mediating a non-pathogenic phenotype.
They potentially pose an additionally interesting role as sites for drug (or gene) 
targeting to specific cell types, or even specific cell types in a certain stage of 
development. These topics are discussed in the following few chapters, with special 
consideration for studies that have already taken place.
1.5.1. Inhibition o f gene expression using antisense DNA or catalytic RNA
Inhibition of protein translation through the use of single stranded DNA or 
RNA that hybridises in a sequence specific manner to target mRNA sequences in the 
cell have been extensively studied since its discovery and suggestion that it may have 
a clinical potential (Zamecnik and Stephenson, 1978). Several gene inhibition 
techniques, based on this approach have been suggested over the last 15 years 
including triplex DNA formation, catalytic RNA (ribozymes) and antisense 
RNA/DNA. All techniques utilise base pair hybridisation to DNA or mRNA to 
disrupt transcription and translation of proteins and are briefly reviewed here.
(a) Triplex DNA:
This technique of gene therapy is different to others in that it involves colinear 
association of specific DNA oligonucleotides (short lengths of linear single stranded
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DNA) to double stranded genomic DNA in the nucleus. Complimentary 
oligonucleotides will form a triplex with purine rich double stranded DNA by forming 
non-Watson-Crick hydrogen bonds to the major groove of the double helix and 
causing a shift in the helix structure in a cation dependent manner. Consequences of 
this triplex formation are believed to be both a steric and conformational hindrance of 
mRNA transcription (Maher et al., 1989). Conjugation of triplex forming DNA 
oligonucleotides with a number of modifying groups such as EDTA-Fe (Moser and 
Dervan, 1987) has also shown that triplex DNA conjugates can cause sequence 
specific double strand breaks. Triplex formation has also been shown to occur when 
using all-purine methylphosphonate oligonucleotides (see antisense oligonucleotides, 
below) complementary to all-pyrimidine mRNA targets (Reynolds et al., 1994). 
Triplex DNA therapy has applications in both gene mapping and gene therapy 
although specific examples of effective use in vivo and in vitro are limited. Specific 
limitations of triplex therapy include the requirement of purine rich target DNA sites 
and reluctance of DNA to form triplexes due to charge repulsions between DNA 
phosphate backbones (Maher et al., 1989).
(b) Ribozymes
Ribozyme therapy utilises the discovery that RNA can have catalytic cleavage 
activity upon endogenous mRNA (Cech and Bass, 1986) without the association of 
proteins, in a divalent cation and pH dependent manner. Several ribozymes have been 
discovered which selectively cleave mRNA, primarily the “hairpin” and 
“hammerhead” ribozymes, named due to their two-dimensional structural appearance. 
From their discovery, sequence specific ribozymes have been engineered, using two 
target mRNA specific antisense flanking sites (12-13 base pairs), connected together
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with a short unpaired catalytic core. Modification of the structure to DNA/RNA 
chimeras has additionally reduced ribozyme susceptibility to ribonuclease attack 
(Bratty e ta l,  1993).
One problem with ribozyme therapy is their inability to cross the Plasma 
membrane into cells due to their size and anionic charge. As a consequence, ribozyme 
therapy is either mediated through transfection methods such as liposomes or by 
endogenous cellular production after transfection of mammalian expression vectors 
coding for specific ribozymes with expression driven by viral or bacterial promoters.
Few studies have examined the potential role of ribozymes against malignant 
melanoma, with the majority of ribozyme studies focusing on their use against 
oncogenes, such as H-ras (Ohta et al, 1994). Studies using ribozymes against 
integrins, or even other adhesion molecules are limited.
(c) Antisense RNA/DNA oligonucleotides
Antisense technology uses single stranded RNA or DNA to hybridise to and 
cause the intermediary metabolism of mRNA, interrupting the translation pathway 
between gene and protein. This alteration relies on sequence specific hybridisation of 
the single stranded RNA or DNA to a target mRNA and therefore in theory can affect 
target genes without altering expression of any other genes, although this is dependent 
upon non-specific sequence homology.
Antisense DNA or RNA is known to inhibit mRNA processing by a number of 
mechanisms. Primary amongst these is the physical inhibition provided by 
oligonucleotide binding to mRNA. This can occur in many forms, from nuclear 
inhibition of mRNA splicing, polyadenylation and transport from the nucleus, to 
cytoplasmic effects such as ribosomal translation and elongation (Helene and Toulme,
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1990). Some workers have suggested that targeting the 5’ translation initiation site 
(AUG) of mRNA will afford additional inhibition of translation initiation factors 
(Leonetti et al., 1993). An unexpected inhibition can also occur from the action of 
ribonucleases such as RNase H on mRNA/DNA duplexes (Walder and Walder, 1988) 
and RNase L on mRNA/RNA duplexes (Maitra et al, 1995). These ribonucleases will 
hydolyse the mRNA strand and lead to degradation of the target strand. It is thought 
that unmodified phosphodiester oligonucleotides function primarily through the 
cleavage of RNase H (Walder and Walder, 1988)
Many problems occur with antisense treatment of cells. Synthetic single 
stranded phosphodiester oligomers are very sensitive to 3’ exonucleases in 
extracellular fluids and have a half life of 5-60 minutes (usually around 20 minutes) 
(Akhtar et al., 1991). Synthetic modification of DNA oligonucleotides by substitution 
of the non-bridging oxygen atom in the phosphate backbone can lead to nuclease 
resistant oligomers. For example, phosphorothioate oligonucleotides have the oxygen 
substituted for a sulphur atom (Matsukura et al, 1987), increasing half life to over 1 
hour, or methylphosphonate oligonucleotides with substituted methyl residues (Smith 
et al., 1986). Modification of oligonucleotides can lead to inherent problems 
associated with degraded modified oligonucleotides entering the nucleotide pool and 
potential mutagenic effects (Stein and Cheng, 1993).
A second common problem associated with oligonucleotide delivery is their 
inefficient uptake into cells, particularly the nucleus. Untreated phosphodiester or 
phosphorothioate oligonucleotides are taken up into the cell by both receptor mediated 
endocytosis and passive absorbtive pinocytosis and tend to accumulate in endosomes 
and lysosomes with little transport to the nucleus (Wagner, 1994). Cell
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permeabilisation techniques such as liposomes or microinjection greatly increase 
delivery to the nucleus and in some studies are found to be absolutely necessary for 
antisense activity (Bennett et al, 1992).
Another technique to combat this delivery problem is by transfection of cells 
with mammalian expression vectors containing DNA encoding target specific 
antisense sequences with expression driven by a viral promoter (such as the 
Cytomegalovirus, CMV, or Rous Saracoma virus, RSV promoter). By the use of 
specific vectors and promoters, expression can be engineered to allow either episomal 
expression of constructs (using vectors based on the Epstein-Barr Virus) or an 
integration of DNA into the nucleus. Antibiotic markers such as geneticin or 
purimicin, encoded within the expression vector, allow for the in vitro selection of 
stable transfected cells. This technique ensures constant transcription of antisense 
mRNA and no subsequent need for cell permeabilisation to achieve adequate 
oligonucleotide targeting. Drawbacks of this method are that these RNA 
oligonucleotides are exonuclease sensitive, tend to be of longer length and therefore 
less specific and can give a gradual loss of antisense affect over time in some systems, 
possibly due to pathway redundancy.
As suggested above, other potential problems associated with antisense 
treatment are non-specific effects, particularly with longer oligonucleotides. This can 
include steric hindrance of non-target mRNA but is most likely a result of non-specific 
ribonuclease activity, for instance Woolf et al. (1992) have shown that RNase H 
activity can be seen if 6-10 base pairs of a 20-24mer oligonucleotide hybridise to non­
target mRNA. Non-specific inhibition can also potentially arise from polyanionic
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phosphodiester or phosphorothioate oligonucleotide binding to various proteins in the 
cell (Stein and Cheng, 1993).
1.5.2. Gene therapy o f integrin expression.
Most studies with the techniques described above have been in the field of 
cancer therapy, with the most intensive body of work concentrating on the use of 
modified oligonucleotide delivery to cells in culture and in vivo studies. In the field of 
integrin targeting, most work has been in the field of non-therapeutic characterisation 
of integrin depletion through the use of antisense DNA or RNA oligonucleotides. 
Phosphorothioate DNA oligonucleotides have been used to great apparent effect in 
quail neural crest cells, using 18-21 mers coding for antisense a l  or (31 subunits 
(Lallier and Bonner-Fraser, 1993). Treatment of cells in culture with 0.02-50jiM 
oligonucleotides gave a dose dependent reduction in both adhesion to laminin and 
fibronectin (up to 70%) and of protein levels (detected using immunoprecipitation of 
biotinylated surface integrins), up to 90% after a 4-6 hour incubation of cells with 
phosphorothioate oligonucleotides. Cells regained the ability to bind to substrata 8 to 
16 hours after treatment.
Many other studies have been carried out using antisense RNA, particularly 
against the a2 subunit (Keely et al., 1995; Riikonen et al, 1995a; Riikonen et al., 
1995b). These studies all used partial or total (1.1 kb to the entire 4.5kb) antisense 
cDNA constructs coding for the 5’ end of the cDNA ligated into either integrating or 
episomal mammalian expression vectors in an antisense orientation. Keely et al. 
(1995) demonstrated a decrease (30-70%) in surface expression (and apparently 
protein levels using Western blots although data is not shown) of the a2 subunit via 
flow cytometry in isolated antisense treated human melanoma clones, although a2
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mRNA levels in these clones appeared similar to wild type expression. Riikonen et al. 
(1995a, 1995b) used a total antisense RNA against human osteosarcoma cell lines and 
produced reductions in both a2 protein (data yet again not shown) and mRNA levels, 
where a decrease in expression of up to 50% was observed in selected clones. This 
study however fails to produce a clear link between antisense RNA expression and a2 
downregulation. Other studies have also shown conflicting data on antisense effects 
upon mRNA levels, which can possibly be explained by the varied nature of any 
potential antisense effect and that it may exert an antisense effect which does not lead 
to the degradation of its target mRNA.
Antisense RNA studies of pi integrin subunit downregulation (Koivisto et al., 
1994) have used a 1.1 kb cDNA fragment of the 3’ end of human pi (1227-2357bp) 
ligated into the integrating expression vector pcDNAlneo. This study failed to 
produce any apparent decrease in surface expression of the pi subunit in human 
osteosarcoma cells, however it specifically decreased total pi protein and expression 
in intracellular p i precursor pools resulting in an increased maturation rate of the pi 
integrin subunit. Steady-state surface levels in this study were therefore not affected 
due to cellular reserves of receptor, although total levels of p i subunits were reduced.
None of these antisense RNA studies have examined the possibility of non 
specific effects occurring from the use of long antisense oligonucleotides. 
Additionally, most studies have described the effects of antisense cDNA vectors by 
selection of individual clones after antibiotic selection. Great care must be taken in 
this course of events that any downregulation of integrin expression is due to a 
specific antisense effect rather than simply natural variation in expression.
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1.5.3. Antiadhesive therapy o f integrins
As explained in section 1.2.2, proteins of the extracellular matrix act as ligands 
for integrins by the presentation of specific amino acid sequences, such as arginine- 
glycine-aspartic acid (RGD) (Summarised in table 1.3). Synthetic peptides of RGD or 
peptide fragments from ECM proteins can compete with natural ECM ligands and will 
inhibit adhesion and spreading of many cell types to substrates coated with adhesion 
proteins containing an RGD motif (Pierschbacher and Ruoslahti 1984). Additionally, 
soluble RGD containing peptides have been found to inhibit human melanoma cell 
invasion through amniotic basement membrane in vitro (Gehlsen et al., 1988) and in 
murine models of experimental metastasis in vivo (Humphries et al., 1986). YIGSR 
peptides against laminin have also shown this ability in similar models (Iwamoto et 
al., 1987). The inhibitory effect of these peptides can be additionally increased by the 
use of polymeric peptides containing repeating units of the active sequence (Saiki et 
al., 1989).
Although monomeric and polymeric soluble peptides will inhibit integrin 
functions, their stability, potency and affinity for integrins is low (Pierschbacher and 
Ruoslahti 1984). The discovery of the importance of focal adhesive contacts and 
flexible nature of ligand binding sites helps to explain that conformational elements 
play a significant part in ligand/receptor affinity. A family of small proteins isolated 
from the venom of Crotalidiae and Viperidae snake species and termed “disintegrins” 
(Gould et al., 1990) have been shown to contain RGD or KGD sequences and have 
high affinity (1000-2000 times linear RGD; Williams, 1992) for integrins. These 
proteins have shown to be potent inhibitors of platelet aggregation (Huang et al., 
1987), thrombotic disease (Gould et al., 1990) and experimental metastasis models of
51
melanoma cells (Trikha et al, 1994). Their lack of specificity for integrins and 
potential for antigenicity however have limited the potential use of disintegrins to 
experimental aids.
Recent studies have used natural forms of ECM proteins with very high 
integrin affinity and low toxicity which could potentially be used in anti-melanoma 
therapy (Morla et al., 1994). Multimers of fibronectin, created by induction of 
spontaneous disulphide crosslinking using a fragment type-in repeat of the ECM 
protein produces a high molecular weight “superfibronectin” resembling in vivo 
matrix fibrils and having greatly enhanced adhesive properties although solubility is 
poor.
1.5.4. Integrins as targets for drug therapy
Studies of pathways for adenovirus endocytosis into host cells have shown that 
attachment and intemalistaion of the virus is mediated by interactions with integrins. 
Adenovirus have been found to express five RGD motifs upon a penton base of the 
virus fibre protein (Wickham et al., 1993). Antibodies against ocvp3 and ocvp5 block 
internalisation of this virus but not attachment. Further studies have shown that 
interactions between this RGD motif and avp5 (and to a lesser extent avp3) are 
necessary for virus internalisation in a receptor mediated manner (Wickham et al., 
1994). This novel biological role for integrins has interesting implications for delivery 
of not only engineered adenovirus-mediated gene transfer but also for the targeting of 
drugs. RGD motifs of the adenovirus penton base have been replaced by the peptide 
motif EILDVPST which mediates binding to a4p i (Wickham et al., 1995). Further 
studies should indicate the potential of this active motif replacement upon adenovirus 
targeting to specific integrins (and therefore delivery to specific cells).
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An integrin-specific targeting technique has been used by Smith et al. (1995), 
who have grafted the complementary determining region of a (33 specific antibody into 
the epidermal growth factor module of human tissue type plasminogen activator (t- 
PA). The resulting molecule binds to platelet integrin ocIIb(33 with nanomolar affinity 
and retains full enzymatic activity and may be highly useful as its thrombolytic activity 
is more actively targeted to platelet rich arterial thrombi that lead to acute myocardial 
infarction.
1.6. Aims and Objectives
It is clear that integrin av(33 plays a unique role in the progression of human 
malignant melanoma. Although many other integrins undoubtedly play a vital role in 
melanoma dynamics, ocv(33 is a particularly attractive target for integrin therapy due to 
its de-novo expression upon vertically migrating primary melanomas (Albelda et al.,
1990) and host of recently discovered actions upon invading melanoma such as 
angiogenesis and control of apoptosis.
As a parallel model to the involvement of (33 integrins in human melanoma, 
the role of integrin allb|33 has been carefully examined in the B 16a murine melanoma 
system (Chen et al., 1992b). There is no evidence for the existence of integrin allb|33 
expression on the surface of human melanoma cells, however, expression seems to 
parallel the relationship between av|33 levels and metastatic potential (Chang et al.,
1992). A murine model for melanoma metastasis is an attractive prospect due to this 
laboratory groups’ experience with the B16 murine cell line and its use in vivo with 
C57 mice.
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Neither murine integrin subunit has been fully cloned and characterised at 
cDNA level. Chen et al. (1992b) have generated allb  and p3 integrin sequence 
fragments (423bp and 711bp respectively) through reverse transcription polymerase 
chain reaction (RT PCR) with degenerate PCR primers to potentially homologous 
human sequences. Further characterisation has been carried out by Cieutat et al. 
(1993) who have cloned further portions of the murine p3 integrin subunit from 
murine kidney cells using RT PCR.
The initial aim of this project is to fully characterise these integrin subunits by 
cloning cDNA sequences for both allb and P3 subunits from B16a cells. This will be 
accomplished by screening a AZAPII (Stratagene) phage-based cDNA library of B 16a 
cells with integrin-specific probes generated from RT PCR of B 16a mRNA. Clones 
obtained using this method will be useful in the characterisation of integrin homology 
between species and identification of active homologous residues within integrin 
subunits.
They will be additionally useful in two separate studies to examine the 
possibility of using the integrin p3 subunit as a target for melanoma gene therapy. 
Firstly, antisensed (reversed) portions of the p3 integrin cDNA will be cloned into the 
mammalian expression vector pcDNA3 - a potent mammalian expression system 
driven by the cytomegalovirus (CMV) promoter. This non-viral vector based 
expression system is simple to purify and transfect and allows analysis of cell 
transfection in both transient and stable systems (see below).
A number of different sized antisense fragments will be cloned to ascertain the 
effect of antisense fragment size upon integrin expression. These vectors will be
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transfected into B16a cells using electroporation and effects upon (33 surface 
expression will be examined using fluorescence activated cell sorting (FACS) analysis 
with a specific (33 monoclonal antibody.
Studies will be carried out, both in transient expression systems (24 to 96 
hours after transfection) and in selected cell populations transfected with antisense 
vectors and selected for stable antisense expression using the geneticin (G418) 
antibiotic marker expressed by pcDNA3. Effects of antisense therapy will also be 
examined using a range of in vitro assays designed to give an indication of metastatic 
potential such as static adhesion, spreading, and invasion on a variety of ECM 
proteins.
A second approach will be the competitive inhibition of active av(33 
heterodimers present on the surface of human melanoma cell-lines such as A375 cells 
using murine p3 subunits carrying inactivating point mutations. Mutation of 
functional cloned murine (33 cDNA, such as at position D119 or equivalent in the 
murine sequence (discussed in section 1.2.3) will enable the integrin subunit to form 
heterodimer complexes with specific a  subunits but render the complex incapable of 
binding ligand and activating secondary signalling pathways. Mutated murine p3 
integrin cDNA will then be ligated into mammalian expression vector pcDNA3 and 
transfected into A375 human melanoma cells using electroporation. The degree of 
competitive integrin inhibition will be examined using a range of in vitro 
tumorigenicity assays.
Human melanoma cells will be useful in these assays as expression of mutated 
murine (33 subunit will be distinct from that of endogenous (33 using specific murine 
monoclonal antibodies which do not cross react with human p3 using FACS analysis.
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Chapter Two: Materials and Methods
2.1. Bacterial strains
General cloning procedures using pBluescript, and XZap II plaque screening 
were performed using the host strain E. coli XLl-Blue MRF (Stratagene). Excision 
of pBluescript from ^Zap II plaques was carried out with the E. coli strain SOLR 
(Stratagene). Cloning procedures using the mammalian expression vector pcDNA3 
(Invitrogen) were performed using the host strain E. coli TOPI OF (Invitrogen). 
Cloning procedures using the expression vector CDM8 (Invitrogen, obtained from Dr 
J. C. Loftus section 2.3) were carried out with the E. coli host strain MC1061/P3 
(Invitrogen). The host strain used for pRSV/acZ was E. coli XLl-Blue MRF’. 
Bacterial growth media and other solutions are defined in appendix C. Growth media 
plates were produced by adding 15% Bacto Agar (Difco) to the media of choice before 
autoclaving, allowing the solution to cool to 55°C before addition of antibiotics (see 
section 2.5) and pouring into 90mm polystyrene petri dishes.
2.2. Plasmid vectors
General cloning procedures were carried out using the plasmid vector 
pBluescript pSK(-) (Strategene). Mammalian expression experiments were all carried 
out using the mammalian expression vector pcDNA3 (Invitrogen), derived from the 
human cytomegalovirus (CMV) major intermediate early promoter/enhancer region 
(illustrated by figure 2.1, below). Selection of stable transformants was carried out 
using the neomycin resistance marker as described in section 2.28.3. Control
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expression studies were carried out using the mammalian expression vector pRSV/acZ  
obtained with thanks from Dr D. Ogllvie (Zeneca Pharmaceuticals, Alderley Edge, 
Cheshire, U.K.). This is a 7.8kb reporter plasmid based on the Rous Sarcoma Virus 
long terminal repeat (RSV LTR) promoter and driving expression of a 3.1kb cDN A  

















5.45 Kb u II 1.29
SV40 ori
Pvu
SV40 pA -u II 2.39
Neomycin
Fig 2.1 Plasmid map of mammalian expression vector pcDNA3. Abbreviations, P CMV CMV 
promoter, BGH pA bovine growth hormone polyadenylation signal, SV40 ori SV40 promoter and 
origin for transient episomal replication in cells expressing SV40 large T antigen. The boxed region 
represents endonuclease restriction sites within the multicloning site (in order).
2.3. cDNA constructs
The cDNA for a wild-type human integrin subunit 03, CD3A, and a mutant 03 
clone CD3A D119A were obtained with thanks from Dr Joseph C. Loftus, Dept of 
Vascular Biology, Scripps Research Institute, La Jolla, CA, USA. Both inserts were 
cloned into the mammalian expression vector CDM8 (Invitrogen) at a BstX I
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endonuclease restriction site. The entire 3.9kb insert using either clone could be 
removed as an Xba I restriction fragment (Fig 2.2 below). The cDNA clone for wild- 
type human integrin subunit av , VnRa, was obtained from Dr. J. C. Loftus as a ~4kb 
insert cloned into the EcoR I site o f pBluescript pSK-.
ATG Kpnl BamH! EcoRI TGA
21 505 1500 2274 2372
Fig 2.2 Diagram showing the human (33 integrin subunit cDNA clone obtained from Dr. J. C. Loftus. 
Endonuclease restriction sites of interest are marked with corresponding nucleotide positions. The 
shaded area at the 5’ end of the cDNA (position 327-513) shows the position of the ligand binding site. 
The ATG site at position 21 indicates the start codon while the TGA site at position 2372 indicates the 
stop codon. The shaded area at the 3’ end of the cDNA (3170-3900) indicates an untranslated region of 
unknown nucleotide sequence. The map of this cDNA was obtained using the MAP software as 
detailed in section 2.16 and is based on that described by Fitzgerald et al. (1986).
2.4. Preparation of electrocompetent E. coli host strains.
An overnight starter culture o f E. coli XL-1 Blue, E. coli TOPI OF or E. coli 
M C1061/P3 cells was diluted 1:100 and grown to an OD600 of 0.5-1.0 in 500ml LB 
medium. The cells were chilled briefly on ice and centrifuged at 4000g for 15 minutes 
at 4°C using a Beckman J2-MC centrifuge. The ionic strength of the suspension was 
reduced by washing the cells in 500 ml ice cold sterile water, followed by 250 ml of 
sterile water, then 10 ml of sterile ice cold 10% glycerol, and finally resuspending in 
0.5-1 ml o f 10% glycerol. The ice-cold cell suspension was dispensed into 40pl 
aliquots in sterile microfuge tubes and snap-frozen in cardice/methanol. The 
electrocompetent cells were stored at -70°C until required.
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2.5. Transformation of E. coli cells using electroporation.
Electroporation of all bacterial cells was carried out using a modified protocol to 
that described by Dower et. al (1988). Concentrated electrocompetent cells were 
thawed slowly on ice. Chilled recombinant plasmid DNA (up to lpg in water) was 
added, and the cell mix was pipetted into a sterile pre-chilled 0 .2cm electroporation 
cuvette (Bio-Rad Laboratories, Richmond, CA). The cuvette was placed in the pre­
chilled cuvette carrier of a Gene Pulser and Pulse Controller (Bio-Rad) and subjected 
to a single 2.5kV pulse, capacitance and resistance of the power supply having been 
set to 25pFarads and 200Q, respectively, to produce a nominal time constant for the 
capacitor discharge of ~5ms. Following electroporation, cells were allowed to recover 
in 1 ml SOC medium at 37°C with shaking for 1 hour (to allow expression of plasmid- 
coded antibiotic resistance). Transformed cells were selected by spreading onto L- 
agar plates containing ampicillin (50pg/ml or 30pg/ml for MC1061/P3 cells) and 
tetracycline (12.5 fig/ml or 7.5pg/ml for MC1061/P3 cells).
Transformations using E. coli XL1 Blue with pBluescript were plated onto L- 
agar plates surface coated with 40 pi X-gal (Melford Laboratories, 20 mg/ml in DMF) 
and 4 pi 0.84M IPTG. After growing for 18 hours at 37°C, cells containing 
recircularised pBluescript plasmids appeared as blue colonies, recombinants grew as 
white colonies. From each transformation, several white colonies (or several random 
colonies for pcDNA3 and MC1061/P3 transformations) were picked with a sterile 
wire and grown overnight in LB broth containing ampicillin (50pg/ml) and 
tetracycline (12.5pg/ml). Plasmid DNA was recovered by miniprep (see section 2.6.) 
and analysed by restriction endonuclease digestion.
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2.6. Small scale preparation of bacterial plasmids (minipreps).
Small scale preparation of plasmids was carried out using an alkali lysis method 
based upon the methods of Bimboim and Doly (1979) and Ish-Horowicz and Burke 
(1981) as described in Molecular Cloning (Sambrook, J., Frisch, E.F. and Maniatis, T. 
Cold Spring Harbor Laboratory Press, 1989). Briefly, 1.5ml of an overnight culture of 
bacterial host was centrifuged at 10,000g for 1 minute. Pellets of cells were 
resuspended into lOOpl solution I (for this and other solutions see appendix C). Cells 
were lysed by addition of 200 j l i 1 solution n, mixed gently by inversion and incubated 
on ice for 10 minutes. 150pl solution ID was added and mixed by vortexing before 
incubation on ice for 5 minutes. The reaction was centrifuged at 12,000g for 5 
minutes at 4°C and the supernatant transferred to a clean tube.
Extraction of DNA from the supernatant was carried out using an equal volume 
of phenol.chloroform (Amresco Ltd) to precipitate polluting proteins. The upper 
aqueous layer was transferred to a clean tube and contaminating phenol removed using 
an equal volume of chloroform/isoamyl alcohol (24/1, Amresco Ltd). DNA was then 
precipitated using ethanol as described in section 2.10 and resuspended in 50pl TE 
buffer supplemented with 20jj,g/ml RNase.
2.7. Large scale preparation of bacterial plasmids (maxipreps).
Large scale plasmid preparation was carried out with a Qiagen Maxiprep Kit 
(Qiagen, Hilden, Germany) in accordance with manufacturers' protocols. This 
modified alkaline lysis method plus an anion exchange resin column purification step 
routinely produced approximately 500|ig of ultrapure pcDNA3 plasmid from 300ml L 
Broth cultures of E. coli. TOPI OF.
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2.8. Spectrophotomeric determination of nucleic acid concentration.
For quantification of aqueous solutions of DNA or RNA, spectrophotomeric 
readings were taken at 260nm and 280nm using 1ml matched quartz cuvettes in a 
Specronic 601 spectrophotometer (Milton Roy). An OD of 1 at 260nm corresponds to 
a solution at 50pg/ml for double stranded DNA and 39pg/ml for single stranded DNA 
and RNA. Contaminating phenol and protein absorbs at 280nm. Nucleic acid 
solutions with a 260nm:280nm absorbency ratio of less than 1.8 were considered too 
impure for routine use.
2.9. Digestion of DNA with restriction endonucleases.
DNA restrictions were performed using New England Biolab (NEB) restriction 
enzymes and buffers, in accordance with manufacturer's instructions. For complete 
plasmid digestion, reaction mixtures were allowed to incubate at 37°C for 1 hour. For 
digestion with Pvu 7, mixtures were allowed to incubate at 37°C overnight in the 
presence of 50mM KC1. Standard endonuclease restrictions, used in size analysis and 
cloning, were carried out using lpg DNA in a lOpl total reaction mix volume. Large- 
scale endonuclease restriction of plasmids for mammalian cell transfection was carried 
out using 20(ig plasmid DNA and subsequently purified by phenol/chloroform 
extraction (section 2 .6) before use.
2.10. Concentration of DNA by ethanol precipitation
DNA was precipitated from aqueous solutions by the addition of 3M sodium 
acetate pH 5.2 to a final concentration of 0.3M, followed by two volumes of ethanol at 
-20°C. The solution was vortexed well and allowed to precipitate at -70°C for 15
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minutes. A pellet of DNA was recovered by centrifugation at 12,000g using a Jouan 
A14 centrifuge at 4°C for 30 minutes. Ethanol was aspirated off and the pellet washed 
with 70% ethanol at 4°C before drying the pellet at 37°C for 20 minutes. DNA was 
finally resuspended in TE buffer.
2.11, Horizontal agarose gel electrophoresis
Agarose gels were cast and run in Bio-Rad DNA sub-cells. Ultrapure agarose 
(Bethesda Research Laboratories) was dissolved in 0.5x TBE buffer at 100°C. The 
solution was allowed to cool to approximately 60°C, and 1 mg/ml ethidium bromide 
(Sigma) was added to a final concentration of 0.5pg/ml. The gel was poured and 
allowed to set at room temperature for 45 minutes. Once set, gels were submersed in 
0.5x TBE. DNA samples were mixed with 0.2 vol 5x DNA loading buffer (appendix 
C) and electrophoresis was carried out at 70-200V until the tracking dye reached the 
end of the gel. DNA bands were visualised on a UV light box (Mighty Bright, 
Hoefer). Photographs were taken using Polaroid 655 film in a Polaroid MP4 camera.
2.12. Denaturing agarose electrophoresis
In order to maintain denaturing conditions during electrophoresis of RNA 
samples, denaturing formaldehyde/agarose gels were used. All procedures involving 
formaldehyde and formamide were carried out in a chemical hood, in RNase free 
conditions (see below). To 30 ml of a molten 1.28% agarose solution (DEPC treated),
9.4 ml of 5x formaldehyde gel-running buffer was added (appendix C) with 8.6 ml of 
12.3M formaldehyde. Gels were quickly cast, and allowed to set for at least 30 
minutes at room temperature.
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RNA samples for electrophoresis were prepared as follows. Five to ten 
micrograms of RNA in 4.5pl water were added to 2pl 5x formaldehyde running 
buffer, 3.5pl formaldehyde and lOpl formamide and heated to 65°C for 15 minutes 
then chilled on ice. Two microlitres of formaldehyde gel-loading buffer (50% glycerol, 
ImM EDTA, 0.25% bromophenol blue), and lpl of ethidium bromide lmg/ml was 
added, and the samples electrophoresed at 100V. Gels were viewed on a UV light box 
and photographed if required.
2.12.1 Maintenance o f RNase free conditions
In order to protect RNA samples from degradation by contaminating RNase 
enzymes, all RNA manipulation techniques were carried out in RNase-free conditions. 
All water, glassware and salt solutions were treated with diethyl pyrocarbonate 
(DEPC) to inactivate RNase’s. Briefly, solutions (except Tris solutions which DEPC 
reacts with) were treated with 0.1% DEPC overnight at 37°C before autoclaving 
(appendix C). Tris solutions were made with sterile DEPC treated water Glassware 
was soaked in DEPC treated water overnight before autoclaving. Laboratory 
plasticware (such as electrophoresis kit) was rinsed in chloroform before use.
2.13. Purification of DNA using Geneclean
DNA was purified from agarose gels by adsorption of DNA to silica matrix 
using the Geneclean II DNA purification system (Bio-101, La Jolla, CA, USA). 
Following agarose gel electrophoresis, the section(s) of the gel containing restriction 
fragment(s) of interest were excised and purified into TE buffer or water as detailed in 
the manufacturers’ protocol.
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2.14. Ligation of DNA fragments into plasmid vectors
Plasmid vectors (pBluescript pSK-, pcDNA3 or pcDM8) were linearised by 
restriction at one or two sites within the vector polylinker as described in section 2.5. 
Vectors linearised with a single enzyme were subsequently dephosphorylated with calf 
intestinal alkaline phosphatase (CIAP, New England Biolabs) in accordance with 
manufacturers’ protocol to prevent re-ligation of linearised vector. Enzymes used 
were subsequently denatured (as specified in the protocols) and ljig vector run on a 
horizontal TBE agarose gel and recovered using Geneclean. Fragments to be 
subcloned were similarly recovered to ensure purity. The DNA samples were mixed 
together, with a five fold molar excess of insert DNA over vector and ligated with T4 
DNA ligase (NEB) in accordance with the manufacturers' protocol. Mixtures were 
incubated at 16°C for four hours in the case of sticky end ligations, or at 16°C 
overnight for blunt end ligations. Reaction mixtures were purified using Geneclean 
before transformation of host cells by electroporation.
2.15. Nucleotide sequencing
Nucleotide sequencing was performed by the dideoxy mediated chain 
termination method of Sanger et al, (1977). Sequencing reactions were performed 
using the Sequenase II system (United States Biochemical), using double-stranded 
template DNA. Subsequent electrophoresis was performed using the Bio-Rad Sequi- 
Gen system (21cm x 40cm x 0.04cm), and Severn Biotech acrylamide/bis acrylamide 
sequencing solution (6% w/v acrylamide ratio 19:1, 7M urea, lx TBE) in accordance 
with manufacturers' protocols.
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2.15.1. Preparation o f double-stranded template DNA
Double-stranded plasmid DNA (l|Lig) was denatured in 0.2M NaOH, 0.2mM 
EDTA at 37°C for 30 minutes, then precipitated with ethanol as described in section 
2.10 before resuspending in 7pl sterile water.
2.15.2. Sequencing reactions
Using double-stranded templates, approximately 5jig of DNA was used per 
sequencing reaction with 0.5pmol of sequence specific primer. Template DNA was 
sequenced using the Sequenase (version 2.0) kit according to the manufacturers' 
instructions, incorporating [35S dATP] 1000-1500Ci/mmol, 12.5mCi/ml (NEN). 
Sequencing gels were subsequently soaked in 10% acetic acid/15% methanol for 15 
minutes follow by drying for 2 hours at 80°C using a Bio Rad 583 gel dryer in 
accordance with manufacturers instructions.
2.16. Analysis of Nucleotide sequence.
DNA sequence analysis was performed using the GCG (University of Wisconsin 
Genetics Computer Group) package at the SERC Seqnet computing facility at 
Daresbury, UK. Genbank database searching was performed using the SEQED, 
FAST A and TFASTA software. Restriction mapping of sequences was carried out 
using MAP software.
2.17. Mammalian Cells lines
The B16a murine melanoma cell line were a kind gift of Dr K. V. Honn, Dept 
of Radiation Oncology, Wayne State University, Detroit, and were obtained as solid
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lung tumours from C57 black mice (obtained from Dr David Hayes, Wellcome PLC, 
Beckenham, Kent). Parental human melanoma cell-lines A375P (passage 182) and a 
more metastatic sub-population, A375MM (passage 21) were obtained with thanks 
from Dr A. Fabra, Cancer Research Institute, Hospital Duran I Reynals, Barcelona, 
Spain. The SV40 transformed monkey kidney cell line, COS7 was obtained from the 
European Collection of Animal Cell Cultures (ECACC, Porton Down, Salisbury, UK)
2.18. Tissue culture media and conditions
All cell lines were cultured in Eagles' Minimal Essential Medium (MEM) with 
Earles' salts, supplemented with 10% foetal calf serum, 200|iM L-glutamine, 5IU/ml 
penicillin and 5IU/ml streptomycin and lx non essential amino acids. All reagents 
were purchased from Gibco Life Sciences. Cells were maintained in an LEEC
anhydric incubator at 37°C in an atmosphere of 95% air/ 5% CO2 and a humidified
atmosphere. Cells were grown in Falcon polystyrene flasks (Beckton and Dickinson) 
or 6-, 24- and 96-well plates (Nunc). Adhesion assays were carried out using 96-well 
flexible assay plates (Falcon Microtest III, N° 3912, Beckton Dickinson)
2.18.1. Cell line maintenance and subculture
All cell lines were routinely subcultured from adherent semi-confluent 
monolayers of cells every 2-3 days, except COS7 cells which were subcultured every 4 
days. Subculture was carried out by washing twice with calcium and magnesium free 
phosphate buffered saline (PBS, Oxoid), and adding a sufficient volume of 
trypsin/EDTA (Gibco) to cover the cells. Flasks were incubated at 37°C for 5 minutes 
or until total detachment had taken place MEM (~20ml) was added to detached cells 
which were transferred to a 50ml centrifuge tube (Falcon) and pelleted at 200g for 10
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minutes using a Jouan B 3.ll centrifuge. The pellet was resuspended into 5ml media 
and 0.5ml was re-seeded into a fresh flask.
Where necessary, viable cell numbers were evaluated using a grid 
haemocytometer, visualising cells on an M40 inverted biological microscope (Wiold 
Heerbrugg Ltd) after staining with 0.1% w/v trypan blue (Sigma) in PBS as described 
in the Sigma biochemicals catalogue (1996, p i702-3).
2.18.2. Dispersion o f B 16a cells from solid lung tumours
Tumours of approximately 2g size were minced with a sterile razor blade and 
pieces transferred to a sterile 50ml centrifuge tube (Coming). 25 ml of tumour 
dispersion solution (appendix C) was added to this tube and incubated with shaking at 
37°C for 15 minutes after which it was strained through two sterile pieces of 
cheesecloth and discarded. A further 25ml of dispersion solution was added to the
tube and incubated shaking at 37°C for 45 minutes. This fraction was collected after 
straining through cheesecloth, and pooled with a second fraction collected after a third, 
60 minute incubation with a further 25ml dispersion solution. The pooled fraction 
was centrifuged at 200g for 7 minutes, and washed twice with 20ml MEM before 
resuspending the final cell pellet in 2ml MEM. This was then used to seed a 75cm2 
Falcon flask.
2.18.3. Cell storage and recovery
Cells were stored in 2ml cryogenic ampoules (Falcon) in the vapour phase of a 
Union Carbide LR-40 liquid nitrogen refrigerator at approximately -148°C. Cells were 
prepared for storage by trypsinising semi-confluent flasks of cells (as described in 
section 2.10.1.), washing once with MEM and resuspending cells in 1ml MEM with 
10% DMSO (Aldrich, spectophotometric grade) as a cryoprotectant. Cells were
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slowly frozen in a BF6 biological freezer unit plug (Union Carbide) inserted into a 
Union Carbide LR-33 liquid nitrogen refrigerator.
Recovery of cells was carried out by rapidly defrosting cryotubes at 37°C, 
followed by washing cells twice in 20ml MEM and seeding a 175cm2 tissue culture 
flask.
2.19. Preparation of a cDNA library
2.19.1. mRNA purification from B16a cells
Polyadenylated RNA (or messenger RNA, mRNA) was obtained from B16a 
cells using a "Quickprep" mRNA Purification Kit (Pharmacia) in accordance with 
manufacturers’ protocol. All preparations were carried out in RNase-free conditions 
as described in section 2.12.1. Each isolation was carried out with lxlO7 cells, 
trypsinised from a semi-confluent 175cm2 tissue culture flask and centrifuged at 200g 
for 10 minutes before extraction. To ensure greater purity of mRNA, eluate from the 
first purification step was applied to a second oligo (dT)-cellulose column as 
described in the manufacturers’ protocol. Purity (from polluting ribosomal RNA 
bands), and size distribution of mRNA was ascertained by visualisation of sample 
using denaturing agarose electrophoresis as described in section 2 .12.
2.19.2. cDNA synthesis by reverse transcription
2pg of polyadenylated RNA was reverse transcribed using a cDNA synthesis kit 
(Pharmacia) in accordance with manufacturers' protocols. Briefly, 20|nl of denatured 
mRNA was added to a first-strand reaction mix containing 5|Xg oligo(dT)i2-i8 primer 
and 60 units of Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase. 
The mix was incubated at 37°C for 1 hour. This was then added to a second-strand
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reaction mix containing 1 unit RNase H and 25 units DNA polymerase I and incubated 
at 12°C for 1 hour then 22°C for 1 hour. Finally, 5 units of Klenow fragment were 
added to blunt end any double stranded cDNA from the reaction.
2.19.3. Ligation o f EcoRI linkers
Linker ligation to newly synthesised cDNA was carried out using EcoR I linkers 
supplied with the cDNA synthesis kit (Pharmacia).
AATTCGCGGCCGC
GCGCCGGCGp
The “p” designates a dephosphorlyated blunt end, while the other end of the 
linker is a non-dephosphorylated Eco RI overhang. The linker also contains an 
internal Not I restriction site. Briefly, cDNA from the procedure described above was 
column purified and the eluate (lOOpl) was added to 2ng EcoR I linkers, ljul lOOmM 
ATP and 3 pi DNA ligase (3 units/pl). The mixture was incubated at 12°C overnight.
2.20. Preparation of A.ZAP II library
For cloning purposes the Stratagene system, Lambda Zap II was used. This 
system has a standard lambda phage library construction plus the pBluescript 
phagemid cloning vector, to allow rapid in vivo excision of plasmid with cloned insert.
2.20.1. Ligation o f cDNA into XZAPII arms
To approximately lOOng cDNA (calculated from initial mRNA in reaction), lpl 
(lpg) 7CZAP II EcoR I/CIAP arms, lpl lOx ligase buffer, lpl lOOmM ATP, lp l T4 
DNA ligase (5 units/pl) and sterile water to lOpl was added. The mixture was 
incubated at 12°C overnight. Parallel reactions with 0.5x and 2x cDNA in the reaction 
mix were also carried out to maximise efficiency of ligation.
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2.20.2. Packaging into XZAPII
Packaging was carried out according to manufacturer's instructions, using Gigapack II 
packaging extracts (Stratagene). Following ligation, 4pl of DNA was added to one 
melting 'freeze-thaw' extract. Sonic extract (15pl) was added and the tube contents 
and mixed by pipetting. Packaging was allowed to continue for 2 hours at 22°C then 
stopped with 500pl of SM and 20pl chloroform. The library was stored at 4°C.
2.21. Screening XZapII cDNA library
Lambda Zap II libraries were screened from plaque lifts of 90mm petri dishes 
using 82mm Hybond N+ Nylon membrane discs (Amersham) as described below.
2.21.1. Titration o f the cDNA the library
This was carried out as detailed in the Lambda Zap II Cloning Kit protocol 
(Stratagene). Briefly, the E. coli strain XLl-Blue MRF' was grown overnight (30°C 
shaking) in LB/lOmM MgS(V0.2% maltose. Cells were spun down at 2,000g for 10 
minutes, resuspended in lOmM MgSC>4 to an OD600 ° f  0.5 and divided into aliquots 
of 200pl. To each aliquot, lpl packaged phage suspension (of a 1:1, 1:10, 1:100 or 
1:1000 dilution in SM buffer) was added, and incubated for 15 min at 37°C to allow 
phage to attach to cells. Each mixture was then added to 3ml of molten top NZY agar 
(with 0.7% agarose) at 48°C and poured onto the surface of a pre-warmed and dried
NZY plate. Plates were incubated overnight at 37°C. Number of plaque forming units 




DNA screening was carried out using a slightly modified protocol from that 
described in the Lambda Zap II Cloning Kit. Briefly, 99mm plates were plated with 
approximately 15,000 pfu as described in section 2.22.1 and incubated at 37°C for 8 
hours. Plates were chilled at 4°C for two hours before transferring DNA. An 82mm 
Hybond N+ nylon membrane (Amersham) was placed over the surface of the plate, 
orientated by pricking through the filter using a syringe needle and allowed to transfer 
for 2 minutes. Membranes were then removed and placed colony side up onto three 
layers of 3MM paper soaked in denaturing solution for 7 minutes. This was then 
transferred to a pad of 3MM paper soaked in neutralising solution for 5 minutes. 
Finally, the filter was rinsed for 30 seconds in 2 x SSC buffer. A duplicate plate was 
produced by placing onto the plate for 5 minutes, marking for orientation using a 
syringe needle. Membranes were fixed by rinsing in 0.4M NaOH solution for 20 
minutes. All membranes were stored at 4°C wrapped in clingfilm.
2.22. Preparation of oligonucleotides
Oligonucleotides used for PCR amplification of cDNA were synthesised by Dr. A. 
Wolstenholme (School of Biochemistry, University of Bath, U.K.). They were eluted 
from their synthesis columns using 1ml concentrated ammonia solution, drawn 
through the column using a 5ml syringe in 0.2ml aliquots every 20min. The resulting 
solution was transferred to a 1.5ml screw-capped microcentrifuge tube and placed into 
a glass universal bottle containing 0.5ml concentrated ammonia solution. This was 
incubated overnight in a water bath at 55°C, to remove the amino-protecting groups. 
The concentrated ammonia solution was removed by vacuum drying in a DNA
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Speedvac (Savant) and the oligonucleotide pellet resuspended in 1 OOjllI sterile ddH20 . 
Oligonucleotides were precipitated using ethanol as detailed in section 2.8 and the 
dried pellet resuspended in 1ml ddH20. Yield of oligonucleotide was calculated as 
described in section 2.2 and diluted accordingly. Typical yield was between l-2mg.
2.23. Polymerase Chain Reaction (PCR) of cDNA probes for murine integrin 
allb  and (33 subunits
cDNA, generated as explained in section 2.19 was used as a template for PCR 
using the GeneAmp PCR Core Reagent Kit (Perkin Elmer Cetus, Norwalk, CT) with 
settings and reagent concentrations as detailed in the manufacturers protocol. Briefly, 
lOx Buffer, lOmM dNTP's, lfiM oligonucleotide primers (described in section 2.22) 
and 2.5 units Amplitaq were combined into a "master mix" to which l-4mM 
magnesium chloride and approximately l-100ng template cDNA was added. The 
reaction was exposed to standard temperature cycling parameters of 94°C for 1 
minute, 55°C for 1 minute and 72°C for 1 minute, repeated for 30 cycles using a 
Crocodile II temperature cycler (Appligene). This Taq DNA polymerase based 
protocol is based upon a method described by Saiki et a l (1985) and Mullis and 
Falonna (1987). Any bands obtained from this process were gel purified using 
Geneclean before ligation into cloning vectors.
2.24. Preparation of 32P-labelled cDNA probes
PCR fragments of allb and (33 obtained as described in section 2.23 were 
recovered from a horizontal agarose gel using Geneclean. This DNA was used as a 
template for generation of an [a-32P]dATP labelled probe using DNA polymerase
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primed by random hexanucleotides. Approximately 25ng of purified DNA in 9pl 
water was added to 2pl random hexanucleotide mixture (Boehringer Mannheim), 3pl 
of a mixture of dTTP, dCTP and dGTP, all at 20 mM (Pharmacia), 5pl [a-32P]dATP 
(3000 Ci/mmol, lOpCi/pl) (NEN) and lpl (10 units) Klenow fragment of DNA 
polymerase (NEB). The reaction mixture was incubated at 37°C for 30 minutes and 
stopped by heating to 65°C for 5 minutes. Unincorporated nucleotides were removed 
by passing the final mixture through a Nuc-Trap column (Stratagene) in accordance 
with manufacturers’ protocols. This method generates probes of very high specific 
activity 108-109 cpm/pg. Such high activity probes were used within a week of 
synthesis, as high energy a -32P emissions can cause destruction of the molecular 
structure of the nucleotide sequence.
2.25. Hybridisation of labelled DNA probes to fixed nylon membranes
Hybond N+ Membranes (Amersham) for screening were hybridised and washed 
in accordance with manufacturers protocols. Briefly, fixed membranes were 
prehybridised in 25ml of 5x Denhardts’ solution, supplemented with 0.5% SDS, 5x 
SSC and 0.5mg denatured sonicated salmon sperm DNA (Strategene) at 65°C for at 
least 1 hour. Labelled probe was prepared as described in section 2.24 and denatured 
at 100°C for 5 minutes. An aliquot of the labelling mix (5-20pl, dependant on age of 
the isotope) was then added to the membranes and allowed to hybridise at 65°C for 12 
hours. After hybridisation, membranes were washed once with 50ml 2x SSC at 65°C 
for 15 minutes, once with 50ml 2x SSC, 0.1% SDS at 65°C for 30 minutes and once 
with 50ml O.lx SSC, 0.1% SDS at 65°C for 10 minutes. Membranes were wrapped in 
clingfilm and developed as described in section 2.26.
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2.26. Autoradiography
Hybridised nylon membranes from library screens were exposed to Kodak X- 
omat film for 12-24 hours in a light proof cassette with intensifying screens 
(Amersham) at -70°C. Dried sequencing gels were exposed to Kodak X-omat AR film 
for 24-48 hours at room temperature in a light-proof cassette. Hybridised 
nitrocellulose membranes from western blots were exposed to Kodak X-omat film for 
1-30 minutes at room temperature. After exposure, film was developed using a Fuji 
RG II X-ray film processor in accordance with the manufacturers’ protocol.
2.27. In vivo excision of pBluescript from A,ZAP II
Plaques of interest were isolated from plates using a fine pasteur pipette to core 
an agar plug. Phage from this plug was resuspended by adding 500pl SM buffer (see 
appendix C) and 20jxl chloroform and incubated for 2 hours at 4°C. In vivo excision 
of pBluescript SK(-), containing clones of interest from phage suspensions was carried 
out using the ExAssist/SOLR excision system as described in the Lambda Zap II 
Cloning Kit protocol.
2.28. MTT assay for determination of cell number
Cell number determination, for use in growth, and survival assays was carried 
out using a modified MTT assay as described by Mosmann, (1983) and Amould et al. 
(1990). Briefly, cells were seeded into 96-well plates at a desired density. After 
treatment or at regular time points for growth assays, media was removed by inversion 
and the cells washed twice with serum free MEM. 200|il of 1 mg/ml solution of 1-
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[4,5-dimethylthiazol-2-yl]-3,5-diphenylformazan (MTT formazan, Sigma) in complete 
MEM was added to each well and the plate was incubated at 37°C for 3 hours. MTT 
solution was carefully removed from the plates by gentle inversion and resultant 
crystals of formazan blue were solubilised with 200|il DMSO and agitation on an 
orbital mixer for 5 minutes. Cell number was calculated by reading optical density of 
wells (on a Titretek plate reader) at 540nm with a reference wavelength of 690nm.
2.28.1. Calibration o f MTT assay
Calibration of this assay was carried out by seeding 96-well plates with a 
known number of cells, ranging from lxlO3 to 5x10s. Cells were allowed to adhere 
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Y = A + B * X
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log cell concentration x10'
Fig 2.3 MTT assay showing the effect of B 16a cell number upon mean absorbance of treated cells at 
lower absorbance values. Each point represents a mean absorbance value ± standard deviation of 











log cell concentration xIO3
Fig 2.4 Effect of B 16a cell number upon mean absorbance of treated cells over the whole range of cell 
concentrations tested (represented as a logarithmic scale). Each point represents a mean absorbance 
value ± standard deviation of samples (n=8). This experiment is representative of two experiments
Figure 2.3 indicates that a linear relationship between the number of cells and 
absorbance is obtainable up to ~4xl 04 B16a cells per well (or up to an absorbance of 
-1.5). Figure 2.4 illustrates the limitations of the MTT assay at higher, saturating cell 
concentrations. Subsequent growth and viability assays were carried out upon tissue 
culture grade plastic with no added ECM substrate.
2.28.2. Optimisation ofG418 treatment o f cells using an MTT viablity assay
B16a cells were seeded at a density of 5xl03 cells per 96-well plate and 
allowed to adhere in full media for 4 hours before addition of 0-2 mg/ml of the 
antibiotic Geneticin (G418, Gibco). Cells were cultured under standard conditions for 
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Fig 2.5 MTT assay showing the effect of G418 concentration upon growth of 5xl03 B16a cells after 3 
days of treatment. Each point represents a mean absorbance value ± standard deviation of samples 
(n=8).
Figure 2.5 illustrates that the optimal G418 concentration for treatment of 
B16a cells is approximately 1.5 mg/ml or higher as this results in the greatest 
suppression of cell growth, as represented by the lowest MTT absorbance after three 
days incubation with G418.
2.29. Transfection of mammalian cells with DNA using electroporation
Transfection of B16a, A375 and COS7 cells with plasmid DNA was carried 
out using electroporation and protocols based on procedures described by Neumann et 
al. (1982) and Wong and Neumann (1982). Electroporation was additionally modified 
using lower voltage and higher capacitance settings as described by Chu et al. (1987). 
Cells were electroporated in a Bio Rad Gene Pulser connected to a Bio Rad 
Capacitance Extender using 4mm electroporation cuvettes (Bio Rad). Briefly, semi­
confluent cells from 175cm2 tissue culture flasks were trypsinised and washed three
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times with 20ml ice cold PBS. The contents of one 175cm2 flask (approximately 5- 
10xl06 cells/ml) was resuspended into 500|ll1 ice cold PBS. Twenty micrograms of 
plasmid for transfection, generated by Qiagen maxi-preps (section 2.7) was added to 
this suspension as an aqueous solution (lpg/p.1) and incubated on ice for 5 minutes. 
The mixture was transferred to a 4mm electroporation cuvette (Bio-Rad, pre-chilled) 
and electroporated at optimal transfection settings for the cell line used. After 
transfection, cuvettes were incubated at 4°C on ice for 20 minutes before transferral to 
tissue culture flasks. Plasmids used for stable transfection of cells were linearised and 
purified before electroporation as described in section 2.9.
2.29.1. Determination o f efficiency o f electroporation using FITC labelled dextran
Optimisation of electroporation settings was carried out by measuring cellular 
uptake of FITC labelled dextran (Sigma, average MW 71,200) in a protocol based on 
that described by Andreason and Evans (1989) and Graziadel (1991). Briefly, 50|il (of 
a lOmg/ml stock) FITC dextran was added to lxlO6 cells in 500j l l 1 ice cold PBS and 
transfected using a standard electroporation protocol. Cells were seeded into 99cm2 
tissue culture dishes and incubated at 37°C for 4 hours. After this period, all cells 
(including non-adherent and dead cells) were removed by trypsination, washed, and 
resuspended into 50|il PBS and analysed for FITC fluorescence by FACS. Cell death 
was measured by labelling cells with lOOng/ml propidium iodide and measuring 
fluorescence of the same population of cells in the FL-2 region of fluorescence 
emission in a protocol based on that described by Sasaki et al. (1987). Refer to 
section 2.30 for details of FACS.
2.29.2. Determination o f efficiency of electroporation using P galactosidase activity
A secondary method utilised to ascertain the efficiency of electroporation
settings was transfection of a reporter vector, pRSV/acZ expressing the P~ 
galactosidase enzyme (section 2.2). Efficiency of transfection was visualised by light 
microscopy following incubation with chromogenic substrate 5-bromo-4-chloro-3- 
indolyl-p-galactosidase (X-Gal) in a protocol based on that detailed by MacGregor et 
al. (1991). Briefly, 20pg of pRSV/acZ was transfected into lxlO7 cells by 
electroporation using optimised electroporation settings. Aliquots of transfected cells 
were seeded into 99cm2 tissue culture dishes and incubated at 37°C for 24-96 hours 
before being washed twice with PBS and fixed with 1% glutaraldehyde in PBS at 4°C 
for 5 minutes. Fixed cells were washed twice with PBS and overlaid with 10ml X-Gal 
solution (see appendix C) and incubated at 37°C overnight. After this period X-Gal 
solution was removed and cells washed twice with PBS before visualisation under an 
M40 inverted light microscope.
2.29.3. Selection o f stable transfectants using geneticin (G418)
Selection of stable transfected cells was carried out with the antibiotic 
selection marker geneticin (G418, Gibco), in accordance with manufacturers' 
protocols. Briefly, cells were transfected with recombinant pcDNA3 vectors (section 
2.2). Two days post-transfection, media was removed from cells and replaced with
1.5 mg/ml G418 in complete MEM (optimised in section 2.28.2). G418 media was 
replaced every 48 hours (or as necessary on initial treatment) and colonies were 
trypsinised once they had attained a sufficient size.
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2.30. Adhesion assays of cells to ECM proteins
2.30.1. Coating surfaces with ECM proteins
Extracellular matrix proteins, fibronectin (1 mg/ml solution, Sigma) and 
fibrinogen (Sigma) were used to coat tissue culture plasticware. Proteins for coating 
were diluted in PBS to 2-50|ig/ml and 50jil of solutions added to 96-well plates, and 
incubated at 4°C overnight. Fibrinogen is insoluble at low temperatures, so solutions 
were made up with pre-warmed PBS and surfaces coated at 37°C for 90 minutes. 
Plates were subsequently washed twice by immersion in PBS and then treated with 
200|H.l 0 . 1% w / v  Bovine serum albumin (BSA, Sigma) solution in PBS and incubated 
at 37°C for 1 hour to prevent non-specific binding. Coated wells were washed twice 
with PBS before use.
2.30.2. Static cell adhesion assay to coated 96-well plates
Adhesion assays were carried using ECM protein coated Falcon MicroTest El 
flexible assay plates. Cells for testing were trypsinised from flasks and washed once 
with 20ml complete MEM before resuspended into 300 j l l 1 complete MEM. Sodium 
chromate [51Cr] (Amersham, CJS1) was used to label cells in a modified protocol to 
that described by Holden et al. (1973).
To 1ml stock 51Cr, 1 10|il lOx Hanks buffered salt solution (HBSS, Gibco) was 
added to make isotonic. lOOjil of this solution was added to cells and incubated at 
37°C for 45 minutes, agitating every 10 minutes. Cells were washed 3 times in 1ml 
serum free MEM and a IOOjllI aliquot removed to determine cell number and viability. 
Cells were resuspended in serum free MEM at 2xl05 cells/ml and 50|il aliquots added 
to protein treated wells (8 repeats per point). Cells were incubated at 37°C for 30-120 
minutes and non-adherent cells removed by slowly immersing titre plates in PBS
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supplemented with cations (ImM Ca2+/0.5mM Mg2+) and gently tapping the 
underside of the plate. This was repeated and counts in each well taken by cutting up 
plates, placing wells into scintillation tubes and taking counts in a Gammamaster 1277 
(Wallac). y-Counts from coated wells were then compared to counts obtained by a 
parallel adhesion assay carried out in BSA treated wells, and a percent adhesion 
generated by comparison of adherent cell counts to counts obtained from 50jil initial 
labelled cell suspension.
2.30.3. Cell spreading assay upon coated surfaces
Six well-plates (Falcon) were coated with 200pl of 2pg/ml fibronectin as 
described. Cells were trypsinised from 175cm tissue culture flasks and resuspended 
at lxlO4 cells/ml in MEM. 1ml aliquots were transferred to wells and at regular time 
intervals from 0-120 minutes, medium was carefully removed, cells were washed once 
with PBS at 37°C and fixed with 1% formaldehyde (Sigma) in PBS. Morphology of 
cells was recorded by taking pictures of cells using an M40 inverted biological 
microscope.
2.31. Fluorescence activated cell sorting (FACS) of cells
2.31.1. Antibodies
Purified hamster anti-mouse IgG monoclonal antibody (mAb), Hmp3, against 
the murine P3 integrin subunit was obtained from Pharmingen (Sorrento Valley Road, 
San Diego U.S.A.). Monoclonal mouse anti-human IgGl antibody, Y2/51, against the 
human P3 integrin subunit was obtained from Dako (Glostrup, Denmark). 
Monoclonal mouse anti-human IgGl antibody, P2W7, against the human av integrin 
subunit was obtained as a kind gift of Dr. Ian Hart (ICRF, London). Fluorescein
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isothiocyanate (FITC) conjugated mouse anti-hamster IgG monoclonal antibody 
cocktail (clones G70-204 and G94-56), specific for Hmp3 was obtained from 
Pharmingen. R-phycoerythrin (RPE) conjugated f(ab')2 fragment of goat anti-mouse 
immunoglobulins, specific for Y2/51 and P2W7 was obtained from Dako. Mouse 
IgGl negative control was obtained from Dako.
2.31.2. Labelling cells fo r FACS analysis
Cells for analysis were detached by trypsinisation and allowed to recover in 
20ml fresh MEM for 30 minutes at 37°C. Cells were counted as described and 
approximately 5xl05 cells used for each analysis. Cells were washed in cold PBS at 
4°C and resuspended into 50pl PBS with a sufficient excess of primary antibody 
(generally between 1:50 and 1:500). Tubes were incubated at 4°C for 30 minutes, 
washed once with 1ml PBS and resuspended into 50|il of PBS plus 0.1% BSA and 
incubated for 10 minutes at 4°C. Cells were subsequently washed with 1ml PBS and 
resuspended into 50p,l with a sufficient excess of fluorescently labelled secondary 
antibody (in accordance with manufacturers’ protocols) and incubated at 4°C for 30 
minutes. Excess antibody was removed by washing three times with 1ml PBS before 
analysis on a FACS Vantage analyser (Beckton Dickinson). For FACS samples 
measured in the FL-1 emission spectrum (530 ± 15nm), viability was estimated by the 
addition of lOOng/ml propidium iodide as described in section 2.29.1. If necessary, 
cells were fixed with 1% formaldehyde in PBS before analysis. Prior to FACS 
analysis, formaldehyde was washed off with 1ml PBS.
Where cell sorting was desired, the procedure above was carried out in a sterile 
environment, and approximately 5xl06 cells were sorted into sterile 6ml sample tubes 
(Falcon) containing 500pi MEM.
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2.31.3. FACS analysis o f intracellular proteins
Comparisons of the amount of surface protein to intracellular protein were 
carried out using a cell permeabilisation assay based on a protocol suggested by 
Pollice et al. (1992). Briefly, three samples of cells were treated by either: (1) FACS 
labelling cells with mAb as described. (2) Fixing the cells with 0.25% 
paraformaldehyde at room temperature for 15 minutes before washing once with PBS 
and carrying out a standard FACS analysis. (3) Fixing cells as described, washing 
once with PBS and treating cells with 1ml cold (4°C) 70% methanol for 60 minutes to 
make both the cell and nuclear membranes permeable before FACS analysis. Control 
scans (1) and (2) give an indication of the degree of background fluorescence.
2.32. Western blotting of total cell proteins
2.32.1. Preparation o f cell extracts
Cell protein extracts were obtained from semi-confluent 75cm2 tissue culture 
flasks which were washed twice with PBS before aspiration of washings and addition 
of 1ml solubilisation buffer (appendix C). Cells were solubilised through scraping 
with a sterile cell scraper (Costar) and transferred to a sterile microfuge tube. Samples 
were centrifuged at 12000g for 2 minutes in a Jouan A 14 centrifuge at 4°C. The 
supernatant was transferred to a clean tube and stored at -20°C before use.
2.32.2. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of B16a proteins was carried out by electrophoresis in the Bio-Rad
Protean and Mini Protean system, using an 8% denaturing polyacrylamide gel 
(formula shown below) in a protocol based on that described by Lugtenberg et al., 
(1975), under reducing conditions.
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Constituent Running Gel (8%) Stacking Gel
h 2o 4.6ml 1.4ml
30% acrylamide mix* 2.7ml 0.33ml
1.5M Tris pH 8.8 2.5ml -
0.5M Tris pH 6.8 - 0.25ml
SDS 10% w/v 0.1ml 0.02ml
AMPS 10% w/v 0.1ml 0.02pl
TEMED 0.006ml 0.002ml
*29.2% w/v acrylamide and 0.8% w/v N,N'-methylene-bis-acrylamide (Bis) (Bio-Rad)
Table 2.1. Composition of running gel and stacking gel for SDS-PAGE.
Briefly, lOjxl protein samples were boiled with 2|l l 1 5x  SDS sample loading 
buffer (appendix C) for 5 minutes. These were spun briefly and loaded onto the gel. 
Electrophoresis was carried out at 200V in lx SDS-PAGE running buffer (appendix 
C) until the tracking dye reached the bottom of the gel. After electrophoresis, the gel 
was removed from the glass plates, and proteins either stained directly (to ascertain 
loading) or transferred to nitrocellulose for subsequent probing with antibodies (see 
Immunoblotting).
Directly stained gels were soaked with gentle agitation in 0.1%w/v Coomassie 
Brilliant Blue R-250 in 50% methanol/10% acetic acid for 30-60 mins. Gels were then 
destained in 10% methanol/20% acetic acid until background stain was removed. Gels 
could then be dried onto filter paper.
2.32.3 Immunoblotting
Following separation by SDS-PAGE, cell components were transferred onto 
nitrocellulose membranes (0.45 pm pore size, Bio-Rad) according to the western 
blotting method modified from Towbin et al., (1979). Semi-dry transfer of proteins 
was carried out using a Multiphor II transfer block (Pharmacia) in accordance with
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manufacturers’ protocols. Briefly, the gel was transferred onto a cut piece of 
nitrocellulose placed onto a stack of 4 sheets of 3MM paper, soaked in transfer buffer. 
This stack was covered in another 4 sheets of soaked 3MM paper and proteins 
transferred for 60 minutes at 0.8mA/cm2. Transferred nitrocellulose was then rinsed 
in ddH20 and stained with diluted Ponceau S (Sigma) to ascertain transfer efficiency, 
protein loading and positions of markers (which were marked by pencil).
Transferred proteins were immunodetected using monoclonal antibody Hm(33 
specific for murine (33 integrin subunit. Blots were first blocked overnight with gentle 
agitation in 10ml TBS containing 1% ovalbumin and 0.05% sodium azide. This 
blocked unbound sites on the nitrocellulose. Membranes were then rinsed with lx 
TBS followed by hybridisation with primary antibody diluted in 5ml blocking buffer 
(dilution sufficient to give minimal background hybridisation) for 4 hours. Blots were 
then washed once with 10ml TBS then three times with 10ml TBSN and finally, once 
with 10ml TBS (~10min per wash) and incubated for 2 hours with a 1/10,000 dilution 
of horseradish peroxidase (HRP) conjugated mouse immunoglobulins (Dako) in 10ml 
TBSN. A second round of TBS/TBSN washes was then followed by developing blots 
using ECL (Amersham) for 1 minute in accordance with manufacturers’ protocol. 
Membranes were blotted briefly on 3MM paper then developed as described in section
2.26.
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Chapter 3: Cloning and sequencing of murine allb(33 from 
B16a melanoma cells
Expression studies involving the transfection of complete, functional genes 
into mammalian cells require an entire cDNA, free from sequence errors. For this 
purpose, screening of complete cDNA libraries packaged into X phage with 
homologous probes remains one of the most reliable methods for retrieving full length 
target genes. The information detailed below describes work carried out on this 
cloning procedure in an attempt to obtain complete murine ocllb and p3 cDNA 
sequences. This includes generation of library probes specific to the integrins of 
interest using RT-PCR, generation of a B16a cDNA library and its packaging into 
^Zapn and subsequent screening of recombinant lambda phage.
3.1. Construction of a B16a cDNA library in XZAPII
Messenger RNA was extracted from B16a cells in culture as described in 
section 2.19.1 and approximately 2 pg (quantified by spectrophotomeric 
determination) was used as a template for the generation of double stranded DNA 
(section 2.19.2). A parallel control reverse transcription, labeled with 20p,Ci 
[a-32P]dCTP revealed a good size distribution of synthesised cDNA of between 
approximately 0.5 and 10 kbases after analysis in a 1% denaturing alkaline agarose 
gel. Analysis of the subsequently packaged phage library on IPTG/X-Gal plates 
showed that it contained 6.89xl06 phage of which 99% were recombinants (did not 
stain blue).
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3.1.1. Calculation of average insert size using random excision of plaques
An additional step to ascertain packaging efficiency was carried out using 
random excision of six plaques as described in section 2.27. Six host E. coli XL1- 
Blue M RF’ recombinants were generated, all of which grew in LB under ampicillin 
and tetracycline selection. pBluescript plasmid was recovered by miniprep and the 
average cDNA insert size observed by endonuclease restriction with Not I to cut 
plasmids at Not I sites within the cDNA insert linkers, releasing any packaged murine 
cDNA.




Fig 3.1 1% horizontal agarose gel stained with 0.5pg/ml ethidium bromide showing restriction digest of 
six randomly excised pBluescript SK(-) plasmids from a A.ZAPII B16a cDNA library. Counting lanes 
left to right, Lanes 1 & 8 show X Hind III/Eco RI DNA markers. Lanes 2-7 show Not I restriction of 
lpg  of randomly excised recombinant pBluescript SK(-) (See text for explanation).
Fig 3.1 shows restriction o f the six pBluescript plasmids, revealing a single 
band at ~3kb of linearised pBluescript and second, lighter bands of cDNA inserts. 
Half o f the isolated plasmids showed no visible insert, probably indicating insertion of 
insignificant inserts too small to visualise. Other plasmids contained 50 (lane 2, insert
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not visible above), 400 (lane 3), and two -2000 base pair fragments (lanes 5 & 7). 
Therefore although 99% of phages were apparently recombinant under IPTG/X-Gal 
visualisation, approximately 50% contain insignificant inserts. The clones of interest 
are approximately 3300bp (|33) and 2370bp (aDb). Although no inserts of this size 
were observed, the sample size was very low and the presence of 2000 base pair 
inserts indicated packaging of inserts in the kilobase range.
3.2. Generation of allb and p3 specific probes by reverse transcription PCR of 
B16a cDNA
Two pairs of PCR oligonucleotide primers were generated as described in 
section 2.22 using primers specific for portions of human allb  and p3 with known 
homology between different species. Specific primers described below were used 
with a standard PCR protocol (section 2.23) and cDNA template generated using the 
cDNA synthesis kit as described.
3.2.1. Generation o f an a llb  fragment from RT PCR o f B 16a cDNA
allb  oligonucleotide primers were synthesised using sequences based on 
primers described by Chen et al. (1992b) and homologous for a 709bp fragment in the 
region of 2370-3079 of both human and rat platelet integrin allb. Primer as was 
designed to incorporate three nonsense bases plus an endonuclease restriction site for 
Eco RI (underlined). Primer aas was similarly synthesised, but with a Hind HI 
endonuclease site to allow directional cloning into pBluescript (underlined).
as 5’ - CCCGAATTC TGGTGGTGGCAGCAGAA - 3’
aas 5’ - CCCAAGCTT GTTCCGCTTGAAGAAGCC - 3’
PCR of approximately lng cDNA using reaction conditions as detailed and 
2mM magnesium chloride gave rise to a single ~700bp DNA fragment (Fig 3.2B). 
Approximately l|ig  of this PCR fragment was removed from a 1.5% horizontal TBE 
gel using Geneclean and dual-restricted with both Hind IH and Eco RI and ligated into 
Hind W E co  RI dual-restricted pBluescript SK for sequence analysis.
3.2.2. Generation o f a f$3 fragment from RT PCR
Integrin p3 oligonucleotide primers were synthesised using sequences based on 
primers described by Cieutat et al. (1993) and are homologous to a 657bp fragment in 
the region of 1684-2358bp of human integrin p3 cDNA.
Ds 5’ - TCCGCTACAAAGGGGAGAT - 3’
Alh 5’ - TACGTGATATTGGTGAAGGT - 3’
PCR using these primers with ~lng cDNA template and 2mM magnesium 
chloride generated a single band of around 650bp (fig 3.2A). No incorporation of 
restriction site was carried out with the PCR primers described above. Therefore, lpg 
PCR fragment was removed from a 1.5% horizontal TBE agarose gel using Geneclean 
and cloned into pBluescript by dual-restriction with both Eco RV and Pvu II to release 
a 322bp fragment which was removed from a TBE gel using Geneclean. Prior to
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ligation, ljig pBluescript was restricted with Eco RV and dephosphorlyated with
alkaline phosphatase before a standard blunt-end ligation.
(A) (B)
500
1 2  3 1 2
Fig 3.2 1.5% TBE agarose gel stained with 0.5pg/ml ethidium bromide showing RT PCR fragments 
generated using B16a cDNA template and integrin specific oligonucleotide primers. (A) From left, 
lanes 1&3: A. Hind III/Eco RI markers, lane 2: RT-PCR fragment generated using integrin [53 specific 
primers Ds and Alh,. (B) From left, lane 1: Promega low MW markers, lane 2: RT-PCR fragment 
generated using integrin a llb  specific primers as and aas.
3.2.3. Verification o f PCR fragments by nucleotide sequencing
Sequencing of both pBluescript PCR fragment clones was carried out using 
denatured double stranded vector and the Sequenase II protocol as described in section 
2.15. PCR clones were sequenced using a Sequenase II -40 kit primer, specific to a 
pBluescript sequence upstream (5’) of the multicloning site. After sequencing, 
nucleotide sequences were entered into the Daresbury database using the GCG 
SEQED software, as described in section 2.16. Comparison o f sequenced portions of 
PCR products was carried out against human a llb  and p3 cDN A using GCG FASTA  
software. This sequence comparison identified each PCR fragment as having 
significant homology to a corresponding region of published human allbp3 sequences.
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Degree of homology using FASTA was 82.7% for allb  PCR fragment and 85.7% for
the (33 PCR fragment (fig 3.3 and fig 3.4).
90  1 0 0  1 1 0
m a l l b  GTGGTGGCAGCAGAAGAAGGTGACAGGGAG
1 1 1 1 1 1 1 I I 1 1 1 1 I I 1 1 !  1 1 1 1  1 1 1 1 1 1
h allb CTGCGAGGGAACTCCTTTCCAGCCTCCCTGGTGGTGGCAGCAGAAGAAGGTGAGAGGGAG 
2 3 5 0  2 3 6 0  2 3 7 0  2 3 8 0  2 3 9 0  2 4 0 0
1 2 0  1 3 0  1 4 0  1 5 0  1 6 0  1 7 0
m a l l b  CAGGAAGACTTGGACAGATGGGTCTCCAGGCTGGAGCACAACCTATGAGCTCCACAACAT
I I I  I M I N I M  I N I  I I I  M I N I M  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
h  a l l b  CAGAACAGCTTGGACAGCTGGGGACCCAAAGTGGAGCAC- ACCTATGAGCTCCACAACAA 
2 4 1 0  2 4 2 0  2 4 3 0  2 4 4 0  2 4 5 0  2 4 6 0
1 8 0  1 9 0  2 0 0  2 1 0  2 2 0  2 3 0
m a l l b  TGGCCCTGGCACTGTGAATGGCCTCAGACTTCTCATCCACATTCCTGGCCAGTCCCAGCC
I I I I I I I I I I I I I I I I I I I I II II I I I I I I I 1111 II I I I I I I I I I I I
h  a l l b  TGGCCCTGGGACTGTGAATGGTCTTCACCTCAGCATCCACCTTCCGGGACAGTCCCAGCC 
2 4 7 0  2 4 8 0  2 4 9 0  2 5 0 0  2 5 1 0  2 5 2 0
2 4 0  2 5 0  2 6 0  2 7 0
m a l l b  CTCGGATCTGCTCTACAT-CTGGATGTGCAGCCGCAGGAGGTT
I I I  I I  1 1 1 1 1 1 1 1 1 1 1  M i l l  I M i l l  1 1 1 1  I I
h  a l l b  CTCCGACCTGCTCTACATCCTGGATATACAGCCCCAGGGGGGCCTTCAGTGCTTCCCACA 
2 5 3 0  2 5 4 0  2 5 5 0  2 5 6 0  2 5 7 0  2 5 8 0
Fig 3.3 Sequence alignment of murine allb  PCR fragment with human a llb  cDNA (accession J02764) 
using the Wisconsin gcg package and FASTA software
m u r in e  (33
100  110  120  
GATCTGTGTGTGCGTCCAGCCAGGCTCCTAT
hum (33 TGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT 
1 8 3 0  1 8 4 0  1 8 5 0  1 8 6 0  1 8 7 0  1 8 8 0
13 0  1 4 0  1 5 0  1 6 0  1 7 0  1 8 0
m ur (33 GGAGACACCTGTGAGAAGTG-CCCACCTGCCCAGATGCCTGCTCCTTTAAGAAGGAGTGT
I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I
hum (33 GGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT 
1 8 9 0  1 9 0 0  1 9 1 0  1 9 2 0  1 9 3 0  1 9 4 0
1 9 0  2 0 0  2 1 0  2 2 0  22 9
m ur (33 GTGGAGTGTAAGAAGTTCAACCGGGAACGCTCCATGA--AGAAACACCTG
I I I I I I I I I I I I I I I I I I I I I I I I I I I  M i l l  I I I  M i l l
hum (33 GTGGAGTGTAAGAAGTTTGACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTAC 
1 9 5 0  1 9 6 0  1 9 7 0  1 9 8 0  1 9 9 0  2 0 0 0
Fig 3.4 Sequence alignment of |33 PCR fragment with human (33 cDNA (accession J02703 using the 
Wisconsin gcg package and FASTA software
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3.3. Screening of AZAPII plaques with cDNA probes
Phage were plated at 15,000 pfu per 82mm plate, lifted onto Hybond N+ 
circles and screened with l-5pl of denatured [a-32P]dATP labeled PCR probe (see 
section 2.21-2.25). Screening of 25 plates for each integrin subunit revealed 12 allb 
reactive plaques and 16 p3 reactive plaques. These plaques were removed from each 
plate and eluted into 500|il SM buffer plus 15jll1 chloroform. Secondary screening 
with a titre of approximately 150 pfu per plate revealed only one allb  and one (33 
reactive clone under high stringency washes. Excision of single reactive plaques into 
E. coli SOLR (section 2.27) and extraction of plasmids from host cells by miniprep 
gave two clones which were examined by restriction with both EcoR I and Not I, both 
of which restrict at the cDNA linker of cloned plasmids, releasing a cDNA insert 
(section 2.19.3).
3.4. Examination of reactive AZAPII plaques
Size analysis of both reactive clones was carried out by restriction with either 
Eco RI or Not I endonuclease enzymes. Fig 3.5A indicates restrictional analysis of the 
allb  clone. Both Eco RI and Not I restriction released a single insert band of ~750bp 
and linearised pBluescript (~3kb). Fig 3.5B indicates restrictional analysis of the (33 
clone. Restriction with Not I released a single ~1.5kb cDNA insert while Eco RI 
restricted the insert twice internally to give two ~550bp bands and a single ~250bp 





1 2 3 4 1 2 3 4
Fig 3.5 1% horizontal TBE agarose gel stained with 0.5gg/ml ethidium bromide showing endonuclease 
restriction of a llb  and (33 cloned pBluescript plasmids. (A) Restriction of a llb  clone: from left, lanes 
1&4: A, Hind UUEco RI markers, lane 2: Eco RI, lane 3: Not I. (B) Restriction of (53 clone: from left, 
lanes 1&4 A, Hind III/Eco RI markers, lane 2 Eco RI, lane 3 Not I restriction.
3.4.1. Sequence analysis o f reactive cDNA clones
Sequence analysis of these two isolated clones was carried out using denatured 
double stranded plasmid templates with the Sequenase 13 protocol as described. 
Template was primed using kit -40 primers. Resulting sequences gave two -2 0 0  base 
pair nucleotide sequences which were compared using FASTA software against their 
human counterpart integrin cDNA sequences and to the entire Genbank database.
The murine a llb  clone nucleotide sequence has a reasonable homology to the 
3 ’ untranslated end of the human a llb  sequence (68.7%, fig 3.6), however large 
portions o f the sequence carry no homology, and further FASTA searches revealed 
poor hom ology to other a  integrin subunits within the Genbank database. Wider scale 
searches using the entire Genbank database showed little homology to any gene 
(murine or otherwise). Therefore, homology of this a llb  clone to sections of the PCR
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fragment used may have been sufficient to give hybridisation even at high stringency 
washes.
Searches using the sequenced section of the (33 clone showed virtually no 
homology to either human, rat, or known sections of mouse (33 (fig 3.7). FASTA 
searches against the entire Genbank database showed no significant homology to any 
relevant gene. It is possible that the sequenced portion of the clone detailed here 
represents a distant 3’ post-translational site of (33 and that the 5’ end of this sequence 
is specific to murine p3. Clones of human P3 as isolated by Fitzgerald et al. (1987) do 
contain -700 bases of 3’ information, so if the region sequenced is specific to murine 
p3, the majority of this fragment will be untranslated 3’ sequence. Otherwise, it is 
possible that regions of this clone (not sequenced here) are sufficiently homologous to 
the p3 PCR probe to result in a hybridisation.
1 1 9  1 0 9  99  89 79  69
a l p h a c  GTTTCAGCCAGTTGCCTTGCTCAGAACTCCATGGGGTC-TTCCCTTTCCAGCAGACCGG
I M l  I I I  I I  I I  I I I I  I N I  I I
j  0 2 7 6 4 CTTTGGGTTGGAGCTGTTCCATTGGGTCCTCTTGGTGTCGTTTCCCTCCCAACAGAGCTG 
3 2 1 0  3 2 2 0  3 2 3 0  3 2 4 0  3 2 5 0  3 2 6 0
59 49 39  29 19  9
a l p h a c  GTGCATCCCTTTTCCTAATACCTAATAAAGAGCTTGACAGTGAAAAAAAAAGCGGCCGGC
I I I I I  I N I  I M I N I M U M  I I I
j  0 2 7 6 4 GGCTACCCCCCCTCCTGCTGCCTAATAAAGAGACTGAGCCCTG 
3 2 7 0  3 2 8 0  3 2 9 0  3 3 0 0
Fig 3.6 Sequence alignment of allb  library clone fragment to the human allb  cDNA (accession
J02764)sequence
49  39 29  19 9
b e t a c l  GGTTTTCAGGTGAGCTCTGGGGTTACACTACAGTCCGCTGCCTAGCTGAGCGGCCGCG
I I  I M i l l  I I  1 1 1 1 1 1 1 1 1 1
j  0 2 7 0 3 TACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTGTGC — AGCGGCCGCGGC 
1 7 8 0  1 7 9 0  1 8 0 0  1 8 1 0  1 8 2 0  1 8 3 0
j  0 2 7 0 3 AAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTATGGGGACACCTGTGAG 
1 8 4 0  1 8 5 0  1 8 6 0  1 8 7 0  1 8 8 0  1 8 9 0




It is clear from the sequences described above that the PCR probes generated 
from RT-PCR of B 16a were highly homologous to the same fragment contained in 
human allb  and (33. The sequences described above are completely homologous to 
the published partial PCR sequence information obtained by Chen et al. (1992) and 
Cieutat et al. (1993) thus confirming the expression of integrin allb|33 by murine 
B 16a melanoma cells. Screening of a B16a cDNA library with these probes recovered 
only two small fragments with low homology to any human integrin, or integrin- 
related sequences (confirmed using the FASTA software contained in the Wisconsin 
GCG package). Hybridisation of these sequences to PCR probes was probably due to 
partially homologous sequences further downstream from those sequenced. The 
limited size of these fragments also precluded isolation of full length cDNA sequences 
for either integrin subunit.
Time became an important consideration and limited the screening of further 
library plaques. Due to inexperience with the process of library screening within the 
lab, significant time was required to set up the necessary equipment and optimal 
conditions for efficient hybridisation. High levels of background counts were 
encountered in early experiments, so that a number of probe labeling protocols, 
hybridisation conditions and blocking solutions were used before the eventual protocol 
described was chosen. Further library screening could have been carried out, but the 
length of time that this screening takes, and the low number of recombinant phages 
recovered from a high number of plaque screens indicated that the library generated 
from reverse transcription of B 16a mRNA was unlikely to yield full length clones of 
a llb  or (33.
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In retrospect, it would have been constructive to attempt to determine the 
abundance of allb and p3 mRNA amongst total cellular mRNA (using methods such 
as immunoprecipitation of integrin markers and comparison to other cellular proteins 
such as actin). This would have given an indication of the number of clones necessary 
to screen. The modal size within a mammalian mRNA population is usually around 
1.8kb. Both integrin subunits of interest are larger than this (allb is 3300bp while P3 
is 2370bp) and it may have also been wise to have enriched the proportion of larger 
mRNA by size fractionation, either of mRNA (before reverse transcription) or of 
cDNA (before ligation into ^ZapII). Rather than carry on with time-consuming 
cloning work, it was decided that the original objectives to down-regulate expression 
in the murine system would be continued, but using full length human integrin p3 
cDNA obtained from other groups.
Human integrin p3 subunit (clone CD3A) cDNA, was obtained from Joseph 
Loftus (Scripps Institute, La Holla, CA., USA). Additionally, human av  cDNA (clone 
VnRa) and a mutant p3 clone CD3A D119A containing a point mutation in the ligand 
binding site and resulting in a single residue substitution at position 119 of the amino 
acid sequence, inactivating the integrin (detailed in Loftus et al., 1990) were also 
received (all are detailed in section 2.3, verification of this mutation is detailed in 
section 6.2).
The use of human cDNAs introduced interesting problems in that any antisense 
work carried out with human p3 vectors upon murine cell lines used cDNA which was 
not 100% homologous to murine p3 cDNA. Data presented here and by Cieutat et al. 
(1993) suggest a DNA homology of around 86% between human and murine p3
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integrins, and there are precedents for use of species variants in antisense experiments. 
Saelman et al. (1995) have successfully used a human a l  antisense construct, ligated 
into an integrating expression vector, to specifically reduce expression of canine a2 
integrin subunits. The homology between the latter two genes is not detailed, however 
Woolf et al. (1992) suggest that RNase H activity can be seen with oligonucleotides 
with as little as 6-10 concurrent base pairs of homology (section 1.5). Therefore, the 
likelihood of producing activity using antisense fragments of human (33 integrin 
against endogenous murine p3 is reasonable, however, the degree to which this 
inhibition would be specific is unknown. As a result of this incomplete homology, it 
was decided that antisense experiments would be carried out in parallel in the human 
melanoma cell line A375, and its more metastatic sub-population A375M.
Use of the mutant p3 clone (CD3A D119A) presents an immediate problem in 
that transfection of inactive human p3 clones into cells already expressing functional 
p3 subunits would make selective identification of the mutant subunit difficult without 
attaching a marker. Therefore it was decided to continue this work in the murine B16a 
cell line, by electroporation with the human mutant p3 clone. This strategy potentially 
allows identification of expressed human p3 using antibodies which do not bind to 
murine p3.
It should be possible to inhibit expression of native murine allbp3 by 
transfection of murine cells with mutated human p3 subunits, as long as CD3A 
D119A is capable of forming a heterodimer with murine allb. Examination of the 
sequences of different p integrin subunits indicates a high homology, both between
97
integrin subunits and between species (Hynes, 1992), suggesting that CD3A D119A is 
likely to form a heterodimer with murine allb.
An additional interesting experiment would be to transfect human av clones 
into murine B16a cells already expressing aDbp3, which may give an insight into 
changes in tumorigenicity and on competition between different a  subunits for p3 
integrins.
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Chapter 4: Characterisation of |33 integrin expression in 
murine and human melanoma cell lines.
Effective gene therapy techniques upon melanoma cells cannot be 
characterised unless a fairly detailed knowledge of P3 expression in cells studied has 
been undertaken. The role of p3 integrins (as allbp3) in the B16a murine melanoma 
cell line was examined through comparison of cell populations selected on the basis of 
p3 expression using fluorescence activated cell sorting (FACS). Further, more limited 
examination of avp3 expression in the human A375 melanoma cell line was also 
carried out, using FACS to ascertain expression of p3 integrins in cell lines isolated on 
the basis of metastatic potential.
4.1. Characterisation of p3 integrin subunit expression of B16a cells using FACS
Surface expression of p3 integrin subunits (expressed as the heterodimer 
allbp3) upon the surface of wild-type B16a cells was quantified using FACS as 
described in section 2.31. Characterisation of the interaction of murine P3 with 
hamster anti-mouse IgG, Hmp3 was necessary before this antibody could be used in 
assays. These studies included the effect of cell-detachment conditions upon detection 
of integrins by Hmp3, and the effect of integrin ligands upon antibody binding.
FACS was then subsequently used to generate control models for integrin 
allbp3 modulation by isolating two populations of B16a cells from a wild-type 
population on the basis of p3 expression. These sub-populations were further
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characterized for stability of p3 expression and a number of other in vitro techniques 
were used to investigate the effect of differential expression of p3 upon cellular 
phenotype.
4.1.1 FACS analysis o f B 16a cells using mAb Hm/33.
Initial FACS experiments using B 16a cells were designed to ascertain the level 
of p3 expression on the surfaces of wild-type cells and to characterise the nature of 
binding of antibodies specific for murine p3. FACS experiments were carried out 
using the labeling protocol described in section 2.31.2. All assays for the detection of 
murine p3 used the hamster anti-mouse IgG, HmP3 in dilutions of 1:50 as described. 
Secondary labeling of Hmp3 with fluorescent IgG was carried out using FTTC 
conjugated mouse anti-hamster IgG cocktail in dilutions of 1:50 as described.
The nature of this antibody binding is displayed by figures 4.1 and 4.2. The 
FL1 -height axis refers to the level of fluorescence emission measured from cells at 
wavelength 530 ± 15nm, while the events axis describes the relative number of cells at 
each flourescence intensity. Shaded regions indicate fluorescence of Hmp3 labeled 
cells while the unshaded region indicates non-specific IgG binding of the FITC 
conjugated anti-hamster IgG cocktail alone. Many of the FACS scans shown below 
have associated numerical values for the scan mean and peak channel. This represents 
the average surface fluorescence of the cell sample in the FL-1 wavelength and the 
associated fluorescence channel in which cells are maximally fluorescent.
Figure 4.1 overleaf, illustrates that detection of p3 expression with mAb Hmp3 














Fig 4.1 Effect of cell detachment method upon detection of murine (33 integrin surface expression by 
FACS using antibody FIm(33 against wild type B16a cells (I2). (A) Expression of (33 integrin subunit 
from B16a cells stripped from a 175cm2 flask by scraping. (B) Expression of (33 integrin subunit from 
B16a cells stripped from a 175cm2 flask with 1.5ml trypsin/EDTA. The non-shaded area represents 
non-specific binding of FITC conjugated anti-hamster IgG alone. These scans are representative of two 
experiments.
(A) (B)





Fig 4.2 FACS analysis of wild type B16a cells (I2) showing the extent of mAb Hm(33 binding in the 
presence of an excess of soluble ligand for allb(33. (A) Fluorescence of control wild type B16a cells 
treated with Hm(33 antibody and secondary FITC labeled anti-hamster IgG. (B) Fluorescence of B 16a 
cells labeled with Hm(33 antibody in the presence of 10|ig/ml fibronectin. The non-shaded area 
represents non-specific binding of FITC conjugated anti-hamster IgG alone. These scans are 
representative of two experiments.
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Subsequent FACS experiments were therefore carried out using cells detached with 
trypsin/EDTA treatment. Figure 4.2 shows the that presence of saturating 
concentrations of soluble fibronectin during the labeling procedure does not interfere 
with labeling efficiency (concentrations of fibronectin used were determined using 
information derived from static adhesion assays, detailed in section 4.2). This also 
indicates that antibody Hm(33 does not bind to the ligand binding site of allbp3 and 
will probably therefore not interfere with cell adhesion to ligand substrates.
Both figures indicate that wild type B16a cells are weakly positive for murine 
p3 integrin subunits, giving a small shift in FL1 fluorescence from control IgG-FITC 
treated cells. The intensity of this fluorescence was similar between cell samples (as 
illustrated by both figures), although unpredictable levels of fluorescence were often 
obtained from FACS of cells of higher passage number or from confluent density 
cultures. As a result, all FACS samples were generated from low passage (< Pio) cells 
recovered from semi-confluent flasks.
4.1.2. FACS o f B 16a cells using p3 expression as a selectable marker
FACS sorts were carried out as explained in section 2.31.2 under sterile 
conditions. Two populations of B 16a cells were isolated on the basis of p3 expression 
using a starting population of 5 x 106 wild type B16a cells (Pi). After treatment with 
HmP3 and FITC anti-hamster IgG, the fluorescent cell population was sorted into two 
tubes, isolating the top and bottom 5% of fluorescent cells. Samples from each tube 
were re-run through the FACS Vantage machine to check sorting efficiency (displayed 
by fig 4.3). Cells were subsequently seeded into 25cm2 tissue culture flasks and 
subcultured as usual for further analysis. Passaged cells from this sorting procedure 












Fig 4.3 FACS analysis of wild type B16a cells before and after fluorescence activated cell sorting of 
cells labeled with Hmp3 and anti-hamster FITC conjugated IgG. (A) Wild type B16a cell population 
used for cell sort. (B) Sample of cells isolated from the bottom 5% of fluorescent cells. (C) Sample of 
cells isolated from the top 5% of fluorescent cells. The shaded areas represents fluorescence of cells 
labeled with mAb HmP3 while the non-shaded areas represents non-specific binding of FITC 
conjugated anti-hamster IgG alone.
4.1.3. Stability of (13 expression from FACS isolated cells
The ability o f these sorted cell lines to retain a heterologous integrin 
expression profile was examined by FACS analysis of B16a cells using Hmp3 
antibody over a number of successive passages (figure 4.4). Each passage number 
represents a 3 day period where cells were trypsinised, counted, and two aliquots of
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5 x l0 5 cells were removed for FACS analysis. Remaining cells were split 1/10 into a 
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Fig 4.4 FACS analysis of B 16a cells using mAb Hm[33 for murine (33 expression, showing the effect of 
time in culture upon expression of (33 integrin subunits in the isolated B16a populations described. The 
shaded areas represent the fluorescence of cells labeled with hamster anti mouse Hm(33 and FITC 
conjugated anti-hamster IgG while the non-shaded areas represents non-specific binding of FITC 
conjugated anti-hamster IgG alone.
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Figure 4.4 illustrates that expression of murine (33 (detected using Hm(33) is 
fairly constant over the time period shown after isolation of HBE and LBE cell 
populations. Level of mean fluorescence does appear to settle down in the HBE cell 
line after sorting when compared to that of HBE cells immediately after cell sorting, 
although the degree of cell fluorescence still appears significantly higher than that of 
the LBE cell population.
4.1.4 Morphology o f FACS isolated cells
Morphology of HBE and LBE cell populations was examined by photography 
of typical cell populations using a M 40 inverted microscope under normal culture 
conditions, grown on tissue culture grade plastic. Fig 4.5 represents a typical semi­
confluent population of HBE and LBE cells two passages after sorting of cells by 
FACS.
(A) (B)
Fig 4.5 Typical morphology of isolated B 16a populations, grown on tissue culture plastic. Cells shown 
are magnified x300. (A) Low (33 expressing (LBE) population. (B) High (33 expressing (HBE) 
population. Unsorted cells have a characteristic mixed morphology of spread and rounded cells (not 
shown).
Figure 4.5 illustrates the differences observed between LBE and HBE cells 
clearly. LBE cells commonly have a much more rounded morphology and grow in 
much more concentrated colonies. No focal contact points are obvious with the
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culture surface and cells are poorly spread upon it. HBE cells typically appear to have 
a much more dendritic appearance and cells spread from colonies in a much more 
disperse manner. Contacts with the substratum appear to be concentrated at focal 
points.
4.2. Static adhesion assays using B16a cell populations
A primary function of integrin heterodimers is the mediation of adhesive 
contact formation with proteins of the ECM. Static adhesion assays were used to 
determine the binding of B 16a cells to matrices of ECM proteins. Assays were carried 
out using the [Cr51] labeling technique described in section 2.30, which was used to 
label live cells (Cr3+ is absorbed into cells through active uptake, Holden et al. 1973) 
using 96-well plates coated with known ligands for allbp3 (see table 1.3). The effect 
of surface expression of murine (33 integrins from B16a cells upon adhesion to these 
ECM proteins is shown below.
4.2.1. Calibration o f chromium-based cell detection protocol
The relationship between the number of cells, labeled using the standard [Cr51] 
treatment protocol and y  emission was examined by aliquotting known numbers of 
labeled cells into scintillation tubes, and measuring the mean y  emission of eight 
separate samples. Figure 4.6 illustrates the linear relationship between radiolabeled 
cell number and y  radiation emission of these cells. Due to the relatively short half- 
life of [Cr51] (27.7 days) and variation in the efficiency of uptake, the actual 
radioactive emission of cells was found to vary between labeling experiments. 
However, figure 4.6  shows that y  emission is directly proportional to the number of 
labeled cells counted. All subsequent static adhesion assays carried out were therefore
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expressed as a percentage of the mean counts per minute (CPM) of eight control 
sample aliquots of cells.
20000-1 Linear Regression for DATA1_B: 




R =0 .99823  
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Fig 4.6 Relationship between the number of viable Cr51 labeled B16a cells and y emission measured as 
mean counts per minute (CPM). Each point represents the mean y emission of samples ± standard 
deviation of samples (n=10). These data are representative of two replicated experiments.
4.2.2. Adhesion to surfaces coated with fibronectin
Fibronectin is a widely distributed glycoprotein, synthesised by most cells and 
present in high concentrations in most extracellular matrices and plasma (~300fig/ml). 
It is a known ligand for allbp3, which recognises fibronectin via an RGD ligand- 
binding motif (Pierschbacher and Ruoslahti, 1984). Experiments were carried out to 
study both the optimal coating concentration of fibronectin (fig 4.7) and the rate of 
adhesion to optimal concentrations of fibronectin, using both HBE and LBE cell lines 
(fig 4.8).
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Figure 4.7 indicates that the efficiency of adhesion of B16a HBE cells for 
fibronectin is high and cells saturate the surface of 96-well plates at fairly low 
concentrations of ligand. The surface area of a single well in a 96 well-plate is 
0.32cm2. Therefore, the HBE B16a cells shown in figure 4.7 are maximally bound to 
96-well plates coated with 1 jig/ml fibronectin. Experiments were carried out using a 
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Fig 4.7 Relative adhesion of HBE B16a (Ii0) cells to 96-well plates coated with various amounts of 
fibronectin. Emission of cells is standardised by comparison with emission of cells added to wells 
coated with 1% BSA alone. Adhesion is represented as the percentage of emission of total cells added 
to wells, adjusted by emission of cells adhered to BSA coated wells. Each point represents the mean y 
emmission of cells adhered to coated wells minus the mean y emission of cells adhered to BSA coated 
wells (n=4) divided by the mean y emission of total cells (n=8) ± standard deviation between samples of 
adhered and non-adhered cells. These data are representative of two replicated experiments.
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Figure 4.8 illustrates the rapid rate of B 16a cell adherence to substrates coated 
with fibronectin. Cells saturate fibronectin coated 96-well plates within 30 minutes 
and the majority of cells attaching within 15 minutes. Two repeats of this assay failed 
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Fig 4.8 Relative adhesion of sorted B16a populations to fibronectin coated wells (0.24|Lig/cm2) over 
time. Emission of cells is standardised by comparison with emission of cells added to wells coated with 
1% BSA alone. Adhesion is represented as the percentage of emission of total cells added to wells, 
adjusted by emission of cells adhered to BSA coated wells. Each point represents the mean y emission 
of cells adhered to coated wells minus the mean y emission of cells adhered to BSA coated wells (n=4) 
divided by the mean y emission of total cells (n=8) ± standard deviation between samples of adhered 
and non-adhered cells. These data are representative of two replicated experiments.
4.2.3. Adhesion to surfaces coated with fibrinogen
Fibrinogen is a soluble plasma protein, derived from hepatocytes and cleaved 
in the haemostatic pathway by thrombin from where it forms insoluble fibrin clots
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with platelets (Ginsberg et al, 1993). Integrin allbp3 represents the primary receptor 
for fibrinogen, recognised through a KQADGV ligand-binding motif and is 
responsible for the recognition of fibrinogen by platelets in the blood (D’ Souza et a l 
1991). Coating concentration and adhesion kinetics experiment were carried out in a 
similar fashion to 4.2.2.
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Fig 4.9 Relative adhesion of HBE and LBE B 16a cells to 96-well plates coated with various amounts of 
fibrinogen. Emission of cells is standardised by comparison with emission of cells added to wells 
coated with 1% BSA alone. Adhesion is represented as the percentage of emission of total cells added 
to wells, adjusted by emission of cells adhered to BSA coated wells. Each point represents the mean y 
emission of cells adhered to coated wells minus the mean y emission of cells adhered to BSA coated 
wells (n=4) divided by the mean y emission of total cells (n=8) ± standard deviation between samples of 
adhered and non-adhered cells.. These data are representative of two replicated experiments.
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Both LBE and HBE B16a cell populations have a similar adhesion efficiency 
to fibrinogen coated 96-well plates (Figure 4.9). A repeat of this experiment also 
failed to show any difference in cell binding between cell strains. The degree of this 
binding is much lower than that of cell adhesion to fibronectin and cells bind 
maximally at higher coating concentrations, of approximately 7.5jig/ml. Subsequent 
timed adhesion assays were carried out using surface concentration 10|ig/ml equating 
to a coating concentration of 1.56jig/cm2 (assuming fibrinogen coats wells with 100% 
efficiency).
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Fig 4.10 relative adhesion of sorted B16a populations to fibrinogen coated wells (1.56|ig/cm2) over 
time. Emission of cells is standardised by comparison with emission of cells added to wells coated with 
1% BSA alone. Adhesion is represented as the percentage of emission of total cells added to wells, 
adjusted by emission of cells adhered to BSA coated wells. Each point represents the mean y  emission 
of cells adhered to coated wells minus the mean y  emission of cells adhered to BSA coated wells (n=4) 
divided by the mean y  emission of total cells (n=8) ± standard deviation between samples of adhered 
and non-adhered cells. These data are representative of two replicated experiments.
I l l
The rate of cell attachment to fibrinogen coated surfaces are as rapid as that of 
attachment to fibronectin (Figure 4.10). Cells are maximally bound to 96-well plates 
after 20 minutes, with the majority of cells attaching within 10 minutes. However, 
adhesion of cells to fibrinogen is at a lower level than adhesion to fibronectin. 
Repeats of this experiment failed to produce any reproducible differences between 
HBE and LBE cell attachment.
4.2.4. Spreading ofB16a cells upon surfaces coated with fibronectin
Assays were carried using protocols described in section 2.30.3. Six well- 
plates were coated with 0.24pg/cm2 fibronectin and cell morphology studied over a 
120 minute time course. For clarity, only the first 30 minutes of the assay have been 
shown below, as cell morphology did not significantly change from 30-120 minutes in 
either cell population.
Figure 4.11 illustrates the differences in morphology between LBE and HBE 
cells when adhering to substrates coated with fibronectin over time. HBE cells show a 
considerably more spread morphology over time, with approximately 50% of cells 
flattening out and losing a well defined shape after 20 minutes. After 30 minutes, all 
HBE cells were seen to have attained a spread morphology upon the substrate. The 
majority of LBE cells did not spread considerably upon fibronectin over the time 
period studied. As indicated by the static assays described above, LBE cells adhere to 
fibronectin rapidly, however, the appearance of these cells once attached to substrate 
does not seem to significantly alter. The morphology of LBE cells was similar when 









Fig 4.11 Spreading of sorted B16a populations on tissue culture plastic coated with 0.24(ig/cm2 
fibronectin over a 30 minute time course. Cells are shown at x200 magnification. These photographs 
are representative of three replicate wells per time point.
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4.3. Proliferation of FACS isolated B16a cell populations
Examination of the proliferation rates of both HBE and LBE B16a cell-lines 
was carried out using standard tissue culture conditions and uncoated tissue culture 
plastic substrates. A standard MTT assay (as described in section 2.28) was used to 
ascertain this growth within 96-well plates, determining the total number of viable 
cells at controlled time points. The effect of cell density upon this proliferation was 
additionally observed by carrying out a number of parallel assays, seeding wells with 
different starting concentrations of cells ranging from lxlO3 up to 5xl04 cells per 96 
well-plate. Cells used for this study were both 2 passages from the original isolation 
of cells by FACS and harvested from semi-confluent flasks.
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Fig 4.13 MTT assay of B 16a sub-populations showing B16a cell proliferation from an initial seeding 
concentration of lxlO3 cells per well. Data points represent mean absorbance ± standard deviation of 
the mean (n=8). Difference in cell number is statistically significant to a level of p<0.001 (with 14 
degrees of freedom) at all points after day 1. These data are representative of six assays carried out at 
seeding densities of lxlO3 cells per well to 5xl04 cells per well.
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Figure 4.13 shows the rate of growth of LBE and HBE cells from a low initial 
number of cells. An apparent difference between cell lines was observed at all seeding 
concentrations, although saturation of the well plate occurred much more rapidly at 
higher concentrations. Using a low initial number of cells, LBE cells appear to exhibit 
a significant “lag period” before any increases in cell number. The overall saturating 
cell density at longer time periods also appeared to be lower with LBE cells.
4.4 Characterisation of (33 expression on the surface of human A375 melanoma 
cells using FACS.
Examination of B 16a cells under the influence of antisense (33 vectors lead to 
further experiments with these vectors in a human melanoma cell line, A375 (detailed 
in chapter 6). Due to time limitations, characterisation of (33 expression was limited to 
only brief FACS analysis of these cells using antibodies specific for human p3 and av. 
FACS analysis was carried out using a standard labeling protocol as described in 
section 2.31.
Previous reports have suggested that A375 cells express integrin avp3 and that 
this integrin is closely linked to a metastatic phenotype (Seftor et al, 1992). A375 
cells were obtained as a parental (“wild type”) cell line A375P cells and a highly 
metastatic sub-line of parental cells, A375MM cells. These were isolated by 
harvesting cells from secondary tumours, grown from injection of A375P cells into 
immunocompromised mice (carried out by Dr A Fabra, Cancer Research Institute, 
Hospital Duran I Reynals, Barcelona, Spain).
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Detection of surface av was carried out using a mouse anti-human av IgGl, 
P2W7 at dilutions of 1:100-1:500. Detection of surface (33 was carried out using a 
mouse anti-human p3 IgGl, Y2/51 at dilutions of 1:50. An R-phycoerythrin (RPE) 
conjugated F(ab’)2 fragment of goat anti-mouse IgG was used as a secondary labeling 
antibody for both P2W7 and Y2/51 in dilutions of 1:20. FACS profiles for these cells 
are displayed in a similar format to those shown in section 4.1, although PE labeled 
cells have a longer fluorescence emission waveband than FITC labeled cells. 
Fluorescence is therefore measured in the FL-2 emission range of 575 ± 13nm. The 
unshaded region of each profile indicates the degree of fluorescence of cells labeled 
with mouse IgGl negative control at the same dilution as primary antibodies, followed 
by labeling with a 1:20 dilution of RPE conjugated anti mouse F(ab’)2 fragment of 
IgGl.
Figure 4.14 overleaf, shows that A375MM cells appear to express more av  and 
P3 subunits than their parental cell line, A375P. Both cell lines appear to exhibit 
higher levels of cell fluorescence after FACS analysis than the level of fluorescence 
from B16a cells for the murine p3 subunit. Whether this is due to higher intensity of 
fluorescene from RPE labeled antigen, or due to a larger number of surface receptors 
is unclear.
Examination of the morphology of A375 cells reveals significant differences to 
that of B 16a cells. The metastatic A375MM cells can be seen to express higher levels 
of integrin avp3 than A375P cells, however, parental A375P cells are a highly 
adherent cell line while their metastatic counterpart are only weakly adherent in 
normal tissue culture conditions. This appears to be in direct contrast to the adhesive
116











Fig 4.14 FACS analysis of integrin av03 surface expression upon human melanoma A375P and 
A375MM cell lines (n=2). The shaded area represents the fluorescence of cells treated with either mAb 
P2W7 for a v  (dark shading) or Y2/51 for (33 (light shading). The unshaded area represents non­
specific fluorescence of cells treated with mouse IgGl negative control. (A) Scan of A375P cells for 
the av  integrin subunit. (B) Scan of A375P cells for the 03 integrin subunit.. (C) Scan of A375MM 
cells for the av  integrin subunit. (D) Scan of A375MM cells for the 03 integrin subunit. These data are 
representative of two replicated experiments.
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4.5 Discussion
FACS analysis appears to be an excellent system for the detection of p3 
integrin expression upon the surface of B 16a cells and selection of cells on this basis. 
Monoclonal antibody Hmp3 binding was not affected by the use of trypsin, or by the 
presence of soluble ligand, indicating that it is not an inhibitor of ligand binding, nor is 
it binding to a ligand induced binding site.
Sorting of wild type B16a cells on the basis of P3 expression generated stable 
(at least up to 6 passages) cell populations with distinctly different behavioural 
patterns. The specificity of selection of murine cell populations on the basis of p3 
expression, however, was difficult to establish without further FACS analysis of other 
murine a  and p integrin subunits and this must be taken into consideration when 
judging these results. Integrins known to be present on the surface of B16a cells 
include p i, a3 and a5 (Chen et al, 1992b; Qian et al, 1994) - all of which may have 
contributed to the adhesive and signaling profile of these cells.
Changes in p3 surface expression in B16a cells appeared to have dramatic 
effects upon cellular morphology and ability to spread upon fibronectin. The spread, 
dendritic appearance of HBE cells indicated the formation of focal contacts by the 
clustering of integrin receptors to ligand. LBE cells were much less willing to spread 
upon fibronectin and had a considerably more spherical appearance, suggesting 
adhesion of a less focal nature. These morphological differences were found to be 
independent of the nature of cell substratum used, be it a ligand for allbp3 or tissue 
culture plastic. However, adhesion of cells to tissue culture plastic in itself may
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increase cellular synthesis of ECM proteins and even expression of integrins (Streuli 
and Bissell, 1990; Delcommenne and Streuli, 1995). Therefore it is likely that 
observed interactions were occurring between ECM ligands and integrins even when 
they were examined “on plastic”.
In direct contrast to observed differences in cell spreading, the static adhesion 
of HBE and LBE cells to fibronectin or fibrinogen was not significantly changed. 
Although significant differences between HBE and LBE cells were observed at some 
individual points of timed assays (figures 4.8 and 4.10), repeats of these experiments 
failed to reproduce any significant differences. Assuming that HBE and LBE 
populations were specifically isolated on the basis of 03 expression, the high level of 
binding of cells to fibronectin was most likely due to the expression of other adhesion 
molecules. Both integrin a5p l and a3pl have an affinity for fibronectin (via the 
RGD motif). It is therefore possible that these (or other) integrins present in 
significant numbers on the surface of B 16a cells mediate adhesion to fibronectin. The 
spreading and morphological effects suggest that integrin allbp3 may have a 
significant role in the formation of focal adhesive contacts leading to ligand-induced 
cell spreading through signal transduction.
Both HBE and LBE cell lines bound with poor efficiency to fibrinogen. Since 
anb03 is reported to be the major receptor integrin for this ligand (Ginsberg et al., 
1983) it is not clear why no differences were observed between HBE and LBE cells. 
One possible explanation is that aDbp3 integrins expressed by HBE cells were not 
presented in a high affinity state. However, a counter-argument is that allbp3 has a 
high affinity for insoluble matrices (but not soluble ligand) of fibrinogen which is 
independent of activation state (Sims et al., 1991). Another consideration is that
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fibrinogen has a QAGDV motif which is specific for ocIIbp3, however, it also contains 
two RGD sequences in its a  chain and these can mediate adhesion through other 
integrins (Cheresh et al., 1989). Another possible explanation for the lack of 
difference in binding between HBE and LBE cells for either ligand could be that 
integrin allbp3 is not expressed in significant enough numbers on the surface of B 16a 
cells (even in the sorted HBE line) to influence primary binding to ligand.
Differences in static ECM adherence have been commonly reported using 
B16a cells (and other melanoma cell lines, such as A375, Seftor et a l, 1992) with 
highly metastatic and poorly metastatic potential (Chang et al., 1992; Honn et al, 
1992). Often, these changes in B 16a cells have been correlated with altered allbp3 
integrin expression. However these alterations in static adhesion are possibly the 
result of large-scale differences in the expression of a number of different adhesion 
molecules. The process of FACS selection for P3 expressing cell populations used 
here results in cell lines isolated on the basis of a single cell marker, not on the basis 
of in vivo tumorigenicity, and is possibly a more powerful tool for the specific 
characterisation of individual integrin function in tumour cells. This differences 
observed between cells isolated by different methods shall be discussed further in 
chapter 7.
Although allbp3 modulation does not appear to alter static adhesion profiles it 
does have a clear affect upon ligand-integrin associated signaling events such as focal 
adhesion formation and proliferation. LBE cells showed a reproducible reduction in 
the ability to proliferate on tissue-culture plastic, at all seeding densities, but 
particularly at low density. This may be an effect of integrin-related ECM matrix 
synthesis (Streuli and Bissel, 1990), or due to increased activation of specific signal
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transduction pathways in cells selected for high (33 expression. Rates of growth on 
ECM protein matrices were not determined, but could possibly have an effect upon 
these differences in proliferation rate.
Numerous reports in the literature have indicated that activity of allb|33 in 
B16a cells is a close parallel to that of av|33 integrin in a number of human melanoma 
cell lines (Chang et al. 1992, Honn et a l 1992). Characterisation in this study of 
A375 cells with different lung-colonising ability agreed with this pattern of expression 
in that A375MM cells expressed significantly more av(33 than their less metastatic 
counterpart. However, the A375MM cell had a much less adherent phenotype despite 
reports that they are significantly more invasive (Seftor et al., 1992). The data suggest 
that aDbp3 and ocvp3 may have similar roles in the progression of these two 
melanoma though they may function in a significantly different manner. Though 
integrins may have different mechanisms for their separate roles in malignancy, it is 
clear that p3 integrins have an important role in tumour progression. The data 
presented here additionally identifies a number of quantitative markers for the down- 
regulation of p3 expression in B 16a cells.
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Chapter 5: Treatment of melanoma cells with antisense 
mRNA against p3 integrins
The aim of this chapter is to ascertain the efficiency and efficacy of using 
antisense p3 constructs for the down-regulation of integrin p3 expression. Work 
carried out below details the generation of a number of antisense p3 fragments and 
ligation into mammalian expression vector pcDNA3. Transfection studies were 
subsequently carried out using B16a and A375 melanoma cells, and the transient 
effect of this treatment upon integrin expression was investigated using FACS 
analysis. Further studies have been carried out, using the antibiotic selection facility 
of pcDNA3 based vectors to select for stable polyclonal B16a transfectants using the 
neomycin analogue geneticin (G418). Further studies have been carried out using 
these polyclonal populations to study the effect of antisense p3 constructs upon total 
p3 expression and tumour cell proliferation.
5.1. Cloning of antisense p3 cDNA constructs into pcDNA3
The human integrin p3 cDNA clone, CD3A, obtained from Dr. Joseph Loftus 
is described in section 2.2. Samples of CD3A were obtained as lyophilized vector 
which was resuspended with 20jll1 of sterile water. A l|il aliquot of this solution was 
transformed into host strain E. coli MC1061/P3 as described in section 2.5 and vector 
isolated by miniprep before restrictional analysis with Bst XI and Xba I to verify 
presence of the p3 insert cDNA.
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5.1.1. Cloning o f an entire antisense p3 insert
The entire 3.9kb cDNA insert was cloned into pcDNA3 by endonuclease 
restriction o f CD3A with Xba I and isolation of the insert from a 1% horizontal gel 
band using Geneclean. This was ligated into pcDNA3, restricted with Xba I and 
dephosphorylated using calf intestinal alkaline phosphatase as described (section 
2.14). The ligation mix was transformed into host E. coli TOPI OF’ and transformed 
colonies isolated from LB amp/tet plates followed by minipreps from 10ml LB amp/tet 
cultures. Restrictional analysis of cloned plasmids identified two clones with 
opposing orientation, PC3A ((33 sense configuration) and PCa3A ((33 antisense 
configuration) (fig 5.1, fig 5.2).







Fig 5.1 1% horizontal TBE agarose gel stained with 0.5|ig/ml ethidium bromide showing restrictional 
analysis of PC3A (sense (33/pcDNA3) plasmid. From left, lanes 1&10 A Hind III/Eco RI, lane 2 uncut 
plasmid, lane 3 Bam HI, lane 4 Bgl II, lane 5 Eco RI, lane 6 Hind III, lane 7 Kpn I, lane 8 Not I, lane 9 
Xba I.
Figure 5.1 shows that restriction o f PC3A with Xba I linearised pcDNA3 
(5.4kb) and released the entire 3.9kb (33 insert. Restriction o f CD3A with Bgl II cut 
the plasmid once, showing that the entire plasmid construct was approximately 9.3kb. 
Sequence analysis of the human (33 integrin cDNA using the MAP program contained 
in the GCG Wisconsin package indicated internal Kpn I, Bam HI and Eco RI
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restriction sites at 505, 1500 and 2274bp respectively (chapter 2, figure 2.2). Both 
PC3A and PCa3A were restricted with these enzymes, giving information relating to 




Fig 5.2 1% horizontal TBE agarose gel stained with 0.5pg/ml ethidium bromide showing restrictional 
analysis of PCa3A (antisense |33/pcDNA3) plasmid. From left, lanes 1&7 X Hind III/Eco RI, lane 2 
uncut plasmid, lane 3 Bam HI, lane 4 Eco RI, lane 5 Kpn I, lane 6 Not I.
Figure 5.2 shows a restriction analysis profile for endonucleases known to cut 
both pcDNA3 and the p3 insert. Comparison with figure 5.1 shows that restriction of  
PC3A with Kpn I released three bands of ~600bp (faint), ~3300bp and ~5400bp, while 
Kpn I restriction o f PCa3A releases two visible bands of ~3300bp and ~5800bp. Since 
human p3 is known to have a Kpn I site at ~505bp, restriction o f correctly orientated 
p3 insert (CD3A) would be expected to release a band of approximately this size 
(figure 5.1). As three bands are produced on this gel, it can be deduced that another 
Kpn I site must be present at the 3 ’ end of the p3 cDN A insert. Endonuclease 
restriction with Bam HI and Eco RI also agreed with this pattern of insert orientation.
124
1.5.2. Cloning o f  pcDNA3 with partial antisense p3 inserts
To enable comparative studies for the relationship between antisense insert 
size and ability for these fragments to affect (33 expression, two smaller 5’ fragments 
of (33 were isolated and cloned in a reverse direction into pcDNA3 using the 
endonuclease map information gained above. Two P3 fragments were created using 
double endonuclease restriction digests of l|ig  of PC3A with either Kpn VXho I or 
Bam HITXho I. Subsequent isolation of the correctly sized fragment from a 1% TBE 
agarose gel was carried out using Geneclean. Approximately l|ig  of these p3 
fragments were then ligated into pcDNA3 as described, linearised with Kpn VXho I or 
Bam HI/Xho I and purified using Geneclean. Ligation mixes were transformed into 
host E. coli TOPI OF’ and amp/tet resistant clones isolated by miniprep. Restriction 
mapping of resulting vectors revealed the clones PCKpn3A and PCBam3A shown 
overleaf (fig 5.3).
Figure 5.3A shows that clone PCKpn3A is linearised when restricted with Xho 
I or Kpn I to reveal a single band of approximately 5800bp. Double restriction with 
Xho VKpn I released a ~5400bp pcDNA3 band and the ~500bp antisensed p3 
fragment. Figure 5.3B shows that clone PCBam3A is linearised when restricted with 
Xho I or Bam HI to reveal a single band of approximately ~6800bp. Double restriction 
with Xho UBam HI released a ~5400bp pcDNA3 band and the ~1500bp intermediate 
sized antisensed p3 fragment. Both clones PCKpn3A and PCBam3A were engineered 
to include antisensed portions of the 5’ end of p3, including the ATG start codon
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Fig 5.3 1% horizontal TBE agarose gel stained with 0.5p.g/ml ethidium bromde showing restrictional 
mapping of antisense (33 fragment clones. (A) Kpn I antisense plasmid, PCKpn3A: lanes 1 & 6 X Hind 
III/Eco RI markers, lane 2 uncut plasmid, lane 3 Kpn I, lane 4 Xho I, lane 5 double Kpn I/Xho I . (B) 
Bam HI antisense plasmid PCBam3A: lanes 1 & 6 A, Hind lll/EcoKl markers, lane 2 uncut plasmid, 
lane 3 Bam HI restriction, lane 4 Xho I restriction, lane 5 double Bam HI/Xho I restriction.
5.2. Characterisation of transient expression of antisense (33 vectors
Electroporation is an effective method for the generation of high levels of 
transient expression of transfected DNA in mammalian cells (see section 6.1). B16a 
and A375 cells were both used to ascertain the short-term effectiveness of the 
antisense vectors cloned above, using FACS to determine surface expression of 
integrins 24-72 hours after electroporation.
5.2.1. Transient expression using B16a cells
Transfection experiments were carried out by electroporation of 20pg of 
antisense or control pcDNA3 vectors in supercoiled form (using Qiagen Maxipreps) as 
described in section 2.29 and using the optimised electroporation settings detailed in 
section 6.1. Surface analysis of p3 expression was then compared using FACS, 
labeling with mAb HmP3 and FfTC labeled anti-hamster IgG. Expression of p3 was
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measured at 24, 48 and 72 hours. Figure 5.4 illustrates |33 expression of B 16a cells 48 
hours after electroporation (i.e. the peak of transient expression as ascertained by 























Fig 5.4 FACS analysis profiles showing surface expression of murine (33 integrin subunit from B16a 
cells 48 hours after transfection with antisense expression vectors, using Hm(33 mAb and FITC 
conjugated anti-hamster IgG (shaded area). (A) Control cells transfected with pcDNA3. (B) B16a cells 
transfected with PCKpn3A plasmid. (C) B16a cells transfected with PCBam3A plasmid. (D) B16a 
cells transfected with PCa3A plasmid. The non-shaded areas represents non-specific binding of FITC 
conjugated anti-hamster IgG alone. These scans are representative of three experiments.
Figure 5.4 shows a small decrease in the level o f B16a fluorescence by FITC 
labeled Hmp3 in cells transfected with antisense P3 constructs. However, all cells
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appeared to have reduced levels of murine p3 expression after electroporation. Levels 
of surface fluorescence of cells at 24 or 72 hour time points post electroporation also 
failed to show any additional decreases in surface expression of murine p3. Repeats 
of this assay failed to produce any more significant changes in p3 expression after 
transfection with antisense P3 constructs on a transient basis.
5.2.2. Transient expression using A375 cells
Transfection studies were carried out with both A375P and A375MM cell 
lines, examining expression of both human p3 (with mAb Y2/51) and human av (with 
mAb P2W7) integrin subunits using FACS. Both antibodies were labeled with a 
secondary RPE-conjugated goat anti-mouse immunoglobulins as described in section 
2.31. Optimisation experiments using electroporation were not carried out with A375 
cells. However, using the same optimised electroporation settings as B16a 
(250jllF/300V, see section 6.1) gave similar degrees of cell death (50-60%) which 
implied a similar level of electroporation efficiency.
Figure 5.5, overleaf shows that antisense DNA treatment of A375MM cells 
with the vectors constructed and using the electroporation protocol described failed to 
have a significant affect upon p3 or av  surface expression. Repeats of this experiment 
at 24 and 72 hours, or with A375P cells also failed to show any significant change in 
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Fig 5.5 FACS analysis profiles showing surface expression of human av  and (33 integrin subunits in 
A375MM cells 48 hours after transfection with antisense expression vectors. (A-D) (33 expression as 
measured by FACS using mAb Y2/51 and RPE conjugated anti-mouse IgGl (light shaded area). (I-IV) 
av  expression as measured using mAb P2W7 and RPE conjugated anti-mouse IgGl (dark shaded area). 
In order from top: PCDNA3 control transfected cells, PCKpn3A transfected cells, PCBam3A 
transfected cells, PCa3A transfected cells. The unshaded area represents non-specific fluorescence of 








5.3. Stable transformation of B16a cells with (33 antisense constructs
Transfection of HBE B16a cells and isolation of G418 resistant polyclonal 
populations was carried out as described in section 2.29 with optimised 
electroporation settings. The HBE B16a cell line was electroporated with 20p,g of 
plasmid linearised with Bgl n, and purified by phenol/chloroform precipitation of 
proteins (section 2.9). Transfected cells were treated with 1.5 mg/ml G418, added to 
MEM media 48 hours after electroporation. Resistant clones were ready for sub- 
culturing into 25cm2 flasks after a 2-3 week period. Polyclonal populations consisted 
of approximately 10-30 separate clones, with two populations generated per standard 
electroporation of lxlO7 cells. Polyclonal populations were subsequently grown in 1.5 
mg/ml G418 and these cells were not used for studies after more than 10 passages 
from the isolation of original G418 resistant colonies.
5.3.1. FACS analysis o f polyclonal stable transfectants
Standard FACS analysis was carried out as detailed, using murine (33 mAb 
Hmp3 and anti hamster FITC IgG to detect surface p3 expression. Surface expression 
was measured as soon as polyclonal populations could be transferred to 75cm tissue 
culture flasks. Cells were harvested from semi-confluent flasks, grown in the presence 
of 1.5 mg/ml G418.
Figure 5.6, overleaf indicates an apparent decrease in the mean fluorescence 
intensity of 44% to 49% of control pcDNA3 treated cell fluorescence. Repeats of 
these experiments with a second set of polyclonal populations showed a similar trend 
in downregulation, although the intensity of fluorescence from PCKpn3A cells often 
approached that of control pcDNA3 cells. The experiments detailed below aim to 
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Fig 5.6 FACS analysis profiles showing surface expression of murine 03 integrin subunit from G418 
stable polyclonal populations of B 16a cells, detected using antibody Hm(33 and FITC conjugated anti­
hamster IgG (shaded area). (A) Control cells transfected with pcDNA3. (B) B16a cells transfected 
with PCKpn3A plasmid. (C) B16a cells transfected with PCBam3A plasmid. (D) B16a cells 
transfected with PCa3A plasmid. The non-shaded area of each profile represents non-specific binding 
of FITC conjugated anti-hamster IgG alone. These scans are representative of three experiments.
5.3.2. Western blotting of total protein extracts from stable transfectants fo r  /33 
integrin
Total protein lysate preparations were extracted from G418 resistant B 16a cells 
and subsequent Western blotting was carried out as described in section 2.32. Semi­
dry transfer of proteins to nitrocellulose membranes was carried out, using diluted 
Ponceau S to verify equal loading of proteins across samples. After transfer,
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membranes were blocked with 10ml blocking buffer overnight before labeling murine 
p3 using 0.5(Lig/ml mAb Hmp3. Antibody was detected using cross-reaction of 
antibody with a 1/10 000 dilution of horseradish peroxidase conjugated mouse 
immunoglobulins. After high stringency washing, blots were developed in ECL for 1 
minute as described.
200 —  
116 —  
97 —
Sample Mean OD % Control pcDNA3 
transfected cells
pcDNA3 0.859 -
PCKpn3A transfected cells 0.813 94.6%
PCBam3A transfected cells 0.878 102.2%
PCa3A transfected cells 0.807 93.95%
Fig 5.7 Western blot of total cell proteins isolated from polyclonal populations of B 16a cells, probed 
for murine (33 protein using 0.5pg/ml Hm|33 and a 1:10000 dilution of horseradish peroxidase 
conjugated goat anti-mouse IgG under reducing conditions. From left, lane 1 pcDNA3 transfected 
B16a cells, lane 2 PCKpn3A transfected cells, lane 3 PCBam3A transfected cells, lane 4 PCa3A 
transfected cells. Densitometry of (33 bands was carried out using a Bio-Rad densitometer and 
Molecular Analyst software (Bio-Rad).
Human P3 integrin subunits are known to hybridise at 105-110 kDa under
reducing conditions. Figure 5.7 indicates that cross-reaction between Hmp3 and
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mouse immunoglobulins has isolated a band of approximately the correct size as the 
predicted murine p3 subunit. Densitometry of these bands revealed a potential 
decrease of up to 6.05% of band intensity in comparison to control pcDNA3 
transfected cells. This level of reduction is small and for PC3A transfected cells (lane 
4) could well be due to uneven edge effects of the SDS-PAGE gel. Accurate analysis 
of any statistics was not possible as this experiment was carried out once. The other 
bands shown on figure 5.7 are possibly non-specific hybridisation of detecting 
antibodies, or fragmented/polymerised P3 subunits.
5.3.3. Proliferation o f stable transfectants
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Fig 5.8 MTT assay of B16a cell number over time indicating the rates of proliferation of antisense 
treated polyclonal B16a populations in the presence of 1.5 mg/ml G418, seeded at a density of 2xl03 
cells per 96 well-plate. Data points represent mean absorbance ± standard deviation of the mean (n=8). 
Difference in cell number is statistically significant to a level of p<0.001 (with 14 degrees of freedom) 
for PCBam3A and PCa3A cells from day 2 onwards. PCKpn3A cells are significantly different from 
control to a level of p<0.05 from day 3 onwards Proliferation data shown is representative of six 
experiments, seeding cells at different densities between lxlO3 to lxlO4 cells per well.
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Sorting of B 16a cells using FACS on the basis of p3 expression produced cell 
lines with highly divergent spreading and proliferation rates (section 4.3, 4.4). 
Proliferation of polyclonal G418 resistant B16a cells was examined using a standard 
MTT proliferation assay (section 2.28). All cell lines were seeded from semi­
confluent flasks into 96 well-plates at a density of lxlO3 to lxlO4 cells per well. 
Assays were carried out over a 6 day period in the presence of 1.5mg/ml G418 (fig 
5.8).
Figure 5.8 indicates that transfection of B16a cells with larger antisense P3 
constructs (PCBam3A and PCa3A cells) did appear to have a significant effect upon 
cell proliferation rates. Parallel assays carried out with higher seeding densities of 
cells also showed a similar trend of growth. The data displayed above shows growth 
from a starting number of 2xl03 cells/well as this gave a good sigmoidal growth curve 
without premature confluency of wells. B16a polyclonal cells transfected with the 
larger antisense constructs (BamHI antisense, PCBam3A and total antisense, PCa3A 
fragments) appeared to not only proliferate at a slower rate than control cells, but also 
saturate the 96 well-plates at a lower density (much like LBE cells as shown in figure 
4.13).
5.4 Discussion
The data presented above describes the generation of a number of antisense p3 
expression vectors and their electroporation into human and murine melanoma cells. 
Analysis of the degree of inhibition of p3 synthesis and surface expression due to
134
these antisense vectors has lead to conflicting data of their efficacy and efficiency 
which are discussed below.
Transient expression studies using B16a cells (fig. 5.5), showed little sign of 
any significant antisense affect. Cells transfected in these studies showed a decrease 
in the expression of (33 subunits after electroporation, probably due to short-term 
recovery from the adverse effects of electroporation and introduction of high 
concentrations of exogenous DNA. B16a cells did not show high levels of surface (33 
expression (using FACS), even when sorted to produce the HBE cell line. Therefore, 
the identification of significant levels of integrin downregulation was difficult using a 
transient expression system.
Further studies using transient expression of antisense vectors were carried out 
using the A375 cell lines described in section 4.5. Fluorescence intensities 
corresponding to both av  and p3 integrin subunits were much higher in this system. 
Additionally, as A375 is a human melanoma cell line, (33 integrin expressed in these 
cells carries 100% homology to the antisense vectors constructed, eliminating the 
problem caused by incomplete antisense homology to murine (33.
Expression of the av  subunit by A375 cells was examined to identify potential 
secondary effects of antisense p3 on a  subunit expression. A number of reports have 
indicated that functional integrin heterodimer association occurs within the 
endoplasmic reticulum (ER) before secretion to the cell membrane. From studies of 
allbp3, absence of a complementary integrin subunit results in retention of monomers 
in the ER (O’Toole et al., 1989) and their eventual degradation (Kolodziej et al, 
1991). Therefore downregulation of complementary p3 integrin subunits (in the
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absence of an excess of other complementary p subunits) could possibly result in a 
simultaneous av downregulation.
In practice, no significant downregulation of either av  or p3 integrin subunit 
was observed at 24, 48 or 72 hours with either A375P or A375MM cell lines. Figure 
5.5 indicates a typical expression profile of antisense transfected A375MM cells after 
48 hours. This lack of significant effect in both A375 and B16a cells could possibly 
have been due to a time delay between antisense vector expression and observed 
changes in surface expression of integrins. The transient nature of gene expression in 
the majority of cells after electroporation results in cells being under an antisense 
influence for only limited periods. It is conceivable that a significant effect may have 
been present within another time window than the ones chosen. If for instance, the 
half-life of integrin receptors is longer than 72 hours, then little antisense reduction of 
P3 surface levels would be observed over the time course chosen. Some evidence 
against this theory was presented by Lallier and Bronner-Fraser, (1993) who used 
phosphorothioate oligonucleotides directed against a l  and pi integrins in neural crest 
cells. These antisense oligonucleotides were seen to exhibit a maximal antisense 
effect 4-6 hours after administration. If the half-life of integrins is beyond 72 hours, 
transient reduction of their expression would be difficult to observe using the 
constructs tested. This would be due to a reduction of transient vector expression after 
72 hours and eventual dilution of the plasmid-transfected cell population by daughter 
cells.
Another more likely explanation for the lack of antisense effect is that the level 
of transient expression of these antisense inserts was not large enough to have a 
discernible effect. Expression studies at optimum electroporation settings using the
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control marker plasmid, pRSV/acZ showed high levels of p-galactosidase activity in 
B16a cells (as studied in section 6.1). However, this should not be regarded as a 
guarantee of a high level of expression of a different insert, driven by a different 
promoter.
Studies of P3 expression were also carried out using B16a cells transfected 
with antisense vectors and then selected for integration of transfected DNA by 
treatment with G418. Results presented in figure 5.6 indicate that the polyclonal 
populations examined appeared to exhibit a downregulation of P3 expression, which 
was more effective with larger antisense fragments. It must be noted however, that the 
absolute degree of this reduction is difficult to ascertain using FACS due to variation 
in the level of surface expression observed when measuring cell fluorescence, and the 
small degree of differences in cell fluorescence between some samples. Additionally, 
data presented in section 4.4 suggests that downregulation of p3 decreased 
proliferation rate of pi6a cells in vitro. A possible consequence of this could be to 
decrease the proportion of cells expressing low levels of p3 in a polyclonal population, 
through rapid proliferation of unaffected cells. The studies conducted here using 
polyclonal populations were chosen to represent the effect of these antisense 
constructs upon a population of cells, simulating the activity that might be anticipated 
following treatment of a tumour in vivo. A potential method to more accurately 
ascertain antisense effects upon surface expression would be to study the effect of 
antisense constructs upon individual cells by isolation of colonies of cells after 
antibiotic selection using ring cloning. However, using this technique, care must be
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taken to separate antisense activity against p3 expression against natural variation 
between cells from a polyclonal population.
Data obtained from immunoblotting (Western blotting) of total cell proteins 
with HmP3 antibody supported the view that the level of downregulation in these cells 
was limited. Figure 5.8 clearly indicates a prominent band with a molecular weight of 
approximately 110 kDa for each sample loaded, in agreement with p3 bands identified 
in B 16a cells by Chen et al. (1992). No significant difference in the intensity of this 
band was identifiable in any of the immunoblots carried out for the different 
polyclonal populations generated. The significance of the other bands are not known, 
although are possibly due to non-specific hybridisation by Hmp3 or hybridisation to 
dimers or polymers of p3.
Contradictory data was obtained when the proliferation of polyclonal 
populations was examined. All B16a antisense cell-lines grew at a slower rate on 
tissue culture plastic in the presence of G418 antibiotic than cells transfected with 
expression vector alone. Antisense insert size appeared to be inversely correlated with 
proliferation rate of B 16a cells. This reduction in proliferation rate appears to mirror 
the observed proliferation data seen after sorting cells for a reduced p3 expression 
with FACS. The clear suggestion therefore is that in both experiments, reduction of 
(33 integrins in B 16a cells reduces their proliferation rate.
It is possible that this reduction in proliferation, and observed differences in 
surface p3 expression are a consequence of non-specific antisense events. These 
could be directed against other p integrins, due to the large areas of homology between 
P integrin subunits or other unpredictable non-specific events. The incidence of these
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non-specific events would be expected to increase with increasing antisense mRNA 
length. These arguments could be countered by performing further studies using these 
transfectants. Proliferation assays of transfected cells upon selected ECM matrices 
may help to deduce the specific nature of this downregulation. FACS analysis of the 
surface expression of other integrin subunits on transfected B16a cells may help to 
deduce non-specific inhibition of other endogenous integrin subunits. Also, using 
polyclonal cell populations transfected with other antisense integrin sequences with 
little homology to (33 as secondary controls, may give an insight into non-specific 
antisense effects. This type of experiment, however is potentially difficult to 
implement due to the high homology between integrin p subunits, and would be 
labour-intensive. These experiments were not conceivable within the timescale of this 
project, and given the low level of influence of the antisense p3 treatment on B16 and 
A375 cells, would be difficult to justify.
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Chapter 6: Competitive inhibition of P3 integrins by
transfection of cells with inactive p3 subunits
The aim of this chapter is to ascertain the efficiency and efficacy of using 
transfection of mutated (33 to competitively inhibit expression of functional (33 integrin 
heterodimers in melanoma cells. As discussed in section 3.5, failure to obtain an 
entire murine (33 cDNA has lead to an alternative plan of transfection of an inactive 
mutant of human p3 subunits into the B16a cell line.
This chapter includes transfection efficiency data to ascertain the effectiveness 
of the electroporation protocol used (section 2.29) in both B16a cells and the COS7 
cells described below. It also includes details for the verification of a functional 
mutation in the clone CD3A D119A by nucleotide sequencing and its cloning, as well 
as that of the av  clone, VnRa into the expression vector pcDNA3. Transfection 
experiments have been carried out in a control expression system using the COS7 cell 
line, an SV40 transformed simian cell line containing the large T antigen (Gluzman 
1981). This system replicates the vector and thereby amplifies the expression of any 
transfected gene when the vector includes the SV40 origin of replication. pcDNA3 
includes this sequence which should lead to a positive control for the activity of 
integrin expression constructs on a transient basis.
Other transfection assays with inactive p3 subunits were carried out using 
B16a cells, and FACS analysis was used to verify the specificity of antibodies for the 
human p3 and av subunits when expressed on the surface of murine B16a cells.
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Efficiency of this expression was ascertained on a transient basis, and by isolation of 
stable polyclonal B 16a populations using G418 as described.
6.1. Optimisation of electroporation of mammalian cells
Before any expression studies were carried out, a number of assays were 
studied in order to ascertain the efficiency of the transfection protocol used (as 
described in section 2.29). These assays included the use of FITC labeled dextran 
with FACS to quantify the degree of cell uptake of material after electroporation, the 
use of propidium iodide with FACS to ascertain the degree of cell death after 
electroporation and transfection of a reporter plasmid into cells to ascertain efficiency 
of gene expression after electroporation. Data obtained in this section also had direct 
implications upon the electroporation conditions used for antisense transfections, as 
detailed in chapter 5.
6.1.1. Determination o f B 16a cell uptake and viability after electroporation using 
FACS
B16a cells were electroporated with 0.5mg FTTC/dextran as described in 
section 2.29.1. Studies were carried out using a number of electroporation voltage 
settings, ranging from 100-400V, with an associated capacitance range of 125-250|iF. 
The extent of cell permeabilisation that these conditions caused was ascertained by 
measuring FTTC-dextran uptake by cells, as quantified by FACS analysis of cell 
fluorescence in the FL-1 emission range.
Figure 6.1 shows that the degree of cell fluorescence increases considerably 
when using the higher capacitance setting of 250|iF and higher voltage. Cell uptake of
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dextran at the lower capacitance setting (125|iF) was relatively small at all voltage 
settings.
500-1 —• — capacitance 125n F 
—A—  capacitance 250m. F
'Z  3 0 0 -
o  2 0 0 -
100-
100 200 250 300 350 400
Voltage
Fig 6.1 Graph showing mean FL-1 fluorescence obtained from FACS analysis after electroporation of 
lxlO6 B16a cells with of 0.5mg FITC labeled dextran as a function of electroporation settings. 
Fluorescence of cells was measured 4 hours post electroporation. This experiment was performed once.
Figure 6.2, overleaf, indicates that increased B16a uptake of FITC-dextran is 
closely mirrored by increased cell death, particularly at higher electroporation settings. 
Data shown in figure 6.2 does not give an entirely representative view of cell viability 
as propidium iodide does not identify cells fragmented by high voltage
electroporation. The longer-term viability of B16a cells after electroporation was
actually lower than the data above suggests, with approximately 20% B16a cells
surviving 24 hours after a 250jllF/400V electroporation. All subsequent
electroporation experiments with B16a cells (including those detailed in chapter 5)
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were carried out at 250|iF/300V, corresponding to a reasonable FITC dextran uptake 
(mean FL-1 height 206.88) and approximately 50-60% long-term viability.
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Fig 6.2 Graph showing viability of B16a cells obtained from FACS analysis after electroporation of 
lxlO6 B16a cells with of 0.5mg FITC labeled dextran as a function of electroporation settings. Degree 
of cell death was measured using FACS after addition of lOOng/ml propidium iodide and calculation of 
the proportion of the dead cells which had taken up PI, as measured by increased FL-2 fluorescence. 
This experiment was carried out once.
6.1.2. Determination o f COS7 cell uptake and viability after electroporation using 
FACS
Efficiency of COS7 cell electroporation was estimated by carrying out a 
similar FTTC-dextran electroporation procedure as described above. Figures 6.3 and
6.4 give an indication of cell uptake and cell viability at each electroporation setting.
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Fig 6.3 Graph showing mean FL-1 fluorescence obtained from FACS analysis after electroporation of 
lxlO6 COS7 cells with of 0.5mg FITC labeled dextran as a function of electroporation settings. 
Fluorescence of cells was measured 4 hours post electroporation. This experiment was carried out once
Figures 6.3 and 6.4 overleaf, show a similar picture of cell uptake and cell 
death using COS7 cells as seen with B 16a cells. However, the degree of FITC-dextran 
fluorescence using COS7 cells is considerably lower than the corresponding cell 
fluorescence of B 16a cells. Cell viability of COS7 cells after electroporation appears 
more erratic than B16a cells, although the trend of decreasing survival with increasing 
voltage and capacitance appear similar. The erratic nature of COS7 cell viability after 
transfection with FITC-dextran could possibly be due to poorly suspended cells in 
clumps protecting cells from electroporation. COS7 cells were seen to have a much 
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Fig 6.4 Graph showing viability of COS7 cells obtained from FACS analysis after electroporation of 
lxlO6 B16a cells with of 0.5mg FITC labeled dextran as a function of electroporation settings. Degree 
of cell death was measured using FACS after addition of lOOng/ml propidium iodide and calculation of 
the proportion of the dead cells which had taken up PI, as measured by increased FL-2 fluorescence. 
This experiment was carried out once.
6.1.3. determination o f electroporation efficiency using p galactosidase expression
A secondary method utilised to ascertain the efficiency of electroporation 
settings was transfection the reporter vector, pRSV/acZ expressing the P-galactosidase 
enzyme as described in section 2.29.3. Both B16a cells and control COS7 cells were 
used in this assay, with optimised electroporation settings obtained through FITC- 
dextran electroporation.
Figures 6.5 and 6.6 overleaf, show that the degree of P-galactosidase 
expression is roughly the same in both cell types. Maximal expression was seen at 48 
hours using either cell line, with maximal expression equating to approximately 50-
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60% blue cells. Few cells were seen to carry p-galactosidase activity 24 hours after 
electroporation, presumably due to the time delay between electroporation and cellular 
recovery. The intensity o f  colour seen after treatment o f  COS7 cells was notably 
greater than that seen with B16a cells.
(A) (B)
Fig 6.5 Photographs showing B16a cells, fixed and treated with X-Gal solution overnight after 
electroporation with 20pg pRSV/acZ at 250|o.F/300V. (A) 24 hours post-transfection. (B) 48 hours 
post transfection. Cells are shown at magnification x300. Cells positive for p-galactosidase activity 
appear blue after X-Gal treatment.
(A) (B)
Fig 6.6 Photographs showing COS7 cells, fixed and treated with X-Gal solution overnight after 
electroporation with 20pg pRSVlacZ at 250pF/400V. (A) 24 hours post-transfection. (B) 48 hours 
post transfection. Cells are shown at magnification x300. Cells positive for P-galactosidase activity 
appear blue after X-Gal treatment.
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6.2. Verification of mutation of CD3A D119A by nucleotide sequencing
Nucleotide sequencing of the ligand-binding domain (D109-E171, section
1.2.3.) o f human p3 clones CD3A and CD3A D119A was carried out using the 
dideoxy chain-termination method described in section 2.15. Double stranded 
templates were generated from minipreps of MC1061/P3 cells containing the plasmids 
o f interest, (section 2.15.2) and lp g  o f each template was used in an annealing 
reaction to an oligonucleotide primer designed for homology with a cDN A sequence 
downstream (3’) of the ligand binding domain:
LBS1- 5 ’ - A AGCC A ATCCGC AGGTT AC-3 ’
This 19-mer is homologous to the 3 ’ sense strand of human p3 at positions 
556-537 of the cDNA and has a GC content of approximately 50%.
CD3A CD3AD119A
Fig 6.7 Nucleotide sequencing of the ligand binding domain of human P3 cDNA clones CD3A and 
CD3A D119A. The arrow indicates the position of a T-» G mutation.
Figure 6.7 displays portions of the two sequencing gels obtained using the 
oligonucleotide primer described. The arrow at position 454 indicates a point 
mutation in the sequence of clone CD3A D119A from T—>G resulting in a codon
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change from alanine to aspartic acid at A119. Similar mutations of this position giving 
an A119—»Y119 substitution (Loftus et al, 1990) have been shown to result in a loss of 
ligand recognition. The replacement of a non-polar alanine with a highly charged 
acidic aspartic acid residue will therefore function by a similar mechanism to that 
described where substitution at this point is with a polar tyrosine group.
6.3. Cloning of integrin subunits into pcDNA3
Clone CD3A D119A was ligated into pcDNA3 in an identical manner to that 
used for clone CD3A described in section 5.1. Briefly, Xba I restriction of CD3A 
D119A released a ~3.9Kb cDNA insert which was cloned into pcDNA3 restricted 
with Xba I and dephosphorylated using alkaline phosphatase. Orientation of the 
subsequent pcDNA3 clone, PC3A D119A was verified by restriction mapping, 
identical to that carried out in section 5.1.
Clone VnRa contains a ~4kb cDNA fragment inserted into the Eco RI site of 
pBluescript SK. Lyophilised vector was reconstituted into 20|xl sterile water and a IjllI 
aliquot of this solution was transformed into host E. coli XLl-Blue MRF’ as described 
in section 2.5. Vectors were isolated by miniprep and orientation verified by 
restrictional analysis. The entire cDNA insert was directionally cloned into pcDNA3 
by double endonuclease restriction of ljLtg VnRa with Not I and Kpn I. This freed a 
~4kb cDNA insert which was removed from a 1% horizontal agarose gel using 
Geneclean and ligated into l|ig pcDNA3 restricted with Not I / Kpn I and similarly 
gel-purified with Geneclean. The ligated clone, PCVnRa was verified by restriction 
mapping.
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6.4. Transient expression of integrin subunits
Transient expression studies were carried out using both B16a and control 
COS7 cell lines at optimal electroporation settings as described in section 6.1. Initial 
expression studies were carried out using the COS7 cell line in order to verify activity 
of the pcDNA3 expression constructs cloned in sections 5.1 and 6.2. Control 
transfections were carried out using |33 integrin constructs PC3A and PC3A D119A 
and the effect of dual transfection with a complimentary av  subunit using PCVnRa 
was also studied.
6.4.1. Transient expression in COS7 cells
Transfections were carried out using 20|ig of supercoiled pcDNA3, PC3A, 
PC3A D119A or PCVnRa plasmids, obtained by maxiprep, in a standard transfection 
protocol under optimal electroporation conditions (see section 6.1). Each transfection 
was carried out using the contents of one semi-confluent 175cm2 tissue culture flask 
and cells were analysed by FACS 24-72 hours after transfection. Antibodies used for 
this analysis were the same as those used for detection of human subunits on A375 
cells (section 4.5). Therefore, p3 detection was carried out using mouse anti-human 
(33 IgGl, Y2/51 and RPE conjugated F(ab’)2 fragment of goat anti-mouse IgG. 
Detection of surface av was carried out using mouse anti-human av IgGl, P2W7 
with the same RPE secondary antibody. Fluorescence was measured in the FL-2 range 
of light emission.
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Fig 6.8 Surface expression of integrin subunits detected by FACS analysis of COS7 cells 48 hours post­
electroporation with integrin expression constructs, (i-v) Surface expression of human (33 detected 
using Y2/51 and RPE conjugated goat anti-mouse IgG (light shaded area), (i) pcDNA3 transfection, (ii) 
PC3A transfection, (iii) PC3A D119A transfection, (iv) dual PCVnRa/PC3A transfection, (v) dual 
PCVnRoc/PC3A D119A transfection. (A-D) Surface expression of human av  detected using P2W7 and 
PE conjugated goat anti-mouse IgG (dark shaded area). (A) pcDNA3 transfection, (B) PCVnRa 
transfection, (C) dual PCVnRa/PC3A transfection, (D) dual PCVnRa/PC3A D119A transfection. The 
unshaded area represents non-specific fluorescence of cells treated with mouse IgGl negative control. 
These scans are representative of three repeats.
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Figure 6.8 indicates an apparent reaction of both monoclonal antibodies with 
av  and p3 integrin subunits in control COS7 cells. As COS7 cells are derived from a 
primate cell-line, cross-reactivity with native integrin subunits would be expected, 
however, the large level of fluorescence obtained when using Y2/51 indicates the 
possibility of additional non specific surface-antibody interactions (although control 
IgGl does not cross-react). Despite this endogenous level of cell fluorescence, 
increases in integrin expression were still observed after transfection with all integrin 
constructs, as indicated by the percent of highly fluorescent cells (as denoted by % M l 
above). Use of the marker region Ml helps to illustrate the effect of dual transfection 
of a  and p integrin subunits. Although the proportion of highly fluorescent cells after 
these transfections was similar to that of single subunit electroporation (or even lower 
for p3 detection), the mean fluorescence of these positive cells is apparently greater. 
Expression in these studies was maximal 48-72 hours after electroporation, although 
only the data for expression at 48 hours is shown in figure 6.1. Data collected for 
expression at 24 and 72 hours after electroporation, and a repeat of this transfection all 
showed a similar pattern of integrin expression 
6.4.2. Transient expression in B16a cells
Electroporation of B16a cells was carried out in a similar fashion to that 
described above in section 6.3.1 using optimal transfection settings obtained in section
6.1. Cells were transfected using 20|ig of supercoiled vectors pcDNA3, PC3A, PC3A 
D119A or PCVnRa, generated by maxiprep. Electroporation was carried out using 
wild-type B16a cells from semi-confluent 175cm2 flasks. FACS analysis of cells was 
carried out using the standard analysis protocol at 24-72 hour time points with 
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Fig 6.9 FACS analysis of human integrin av(33 subunits expressed on the surface of B 16a cells 48 
hours after electroporation, (i-iii) FACS analysis of human (33 expression using Y2/51 and RPE 
conjugated goat anti-mouse IgG (light shaded area), (a-c) FACS analysis of human av  expression using 
P2W7 and RPE conjugated goat anti-mouse IgG (dark shaded area. (i)(a) Cells transfected with control 
pcDNA3, (ii) PC3A D119A transfection, (b) PCVnRa transfected cells, (iii)(c) dual PCVnRa/CD3A 
D119A transfection. The unshaded area represents non-specific fluorescence of cells treated with 
mouse IgGl negative control and RPE conjugated goat anti-mouse IgG. These scans are representative 
of three repeats.
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Figure 6.3 shows a typical FACS profile obtained from B16a cells transfected with 
mutant (33 integrin construct PC3A D119A 48 hours after electroporation.
Figure 6.9 illustrates that anti-human mAb Y2/51 and P2W7 did not cross- 
react with any surface antigens from murine B16a cells. Single subunit transfection 
gave an increase in cell fluorescence in approximately 5% of the cells analysed. Dual 
transfection with both subunits resulted in a more noticeable shift in cell fluorescence 
with approximately 20% of the cells analysed showing increased fluorescence (slightly 
more for av  scans). Very few cells in figure 6.3 could be seen to have large increases 
in cell fluorescence with only -1-4% of cells having a fluorescence greater than one 
log scale from mean cell fluorescence in single or dual transfections (as denoted by % 
M l). Unlike transfection of COS7 control cells, dual transfection of B 16a cells with 
av and (33 did cause a greater proportion of cells to react to both Y2/51 and P2W7, 
with a shift in intensity of the entire fluorescence profile.
Antibody P2W7 gave non-specific background fluorescence at dilutions less 
than 1:500 (<10jig/ml), although this was minimised at 1:500 dilution. Level of 
expression was not altered 72 hours after electroporation and repeats of this 
transfection showed a consistent pattern of cell fluorescence, as did expression when 
















Fig 6.10 FACS analysis of Polyclonal populations of B16a cells transfected with linearised plasmid 
constructs and isolated by treatment with 1.5mg/ml G418. Detection of integrin subunits is by mAb 
Y2/51 (for human [33, light shaded area) or P2W7 (for av, dark shaded area) and RPE conjugated goat 
anti-mouse IgG (i) human [33 expression in B16a cells transfected with control pcDNA3. (ii) human av  
expression in cells transfected with control pcDNA3. (A) human (33 expression in cells transfected 
with PC3A. (B) human (33 expression in cells transfected with PC3A D119A. (C) Human av
expression in cells transfected with PCVnRa. The unshaded area represents non-specific fluorescence 
of cells treated with mouse IgGl negative control and RPE conjugated goat anti-mouse IgG. These 
scans are representative of four repeats using separately transfected B16a samples.
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6.5. Stable expression of integrin subunits using B16a cells
B16a cells were electroporated with pcDNA3, PC3A, PC3A D119A or 
PCVnRa and subsequently treated with G418 to obtain resistant polyclonal 
populations as described in section 2.29.3. All plasmids for electroporation were 
linearised with restriction endonuclease Bgl n, except VnRa which was restricted with 
Pvu I as described. Cells were electroporated with 20jig linearised vector and 
transfected cells were treated with 1.5mg/ml G418 in MEM 48 hours after 
electroporation. Similarly to antisense vectors, clones were ready for subculturing into 
25cm2 flasks after a 2-3 week period. FACS analysis for human integrin subunits was 
carried out two passages from subculturing of clones, harvesting cells from semi­
confluent 75cm2 flasks. Standard FACS labeling assays were used with the anti­
human IgGl monoclonal antibodies described in section 2.31.1.
Figure 6.10 (previous page) indicates the degree of non-specific fluorescence 
given by antibody P2W7 when used in concentrations higher than 1:500. The assay 
shown in figure 6.4 was carried out with a labeling concentration of 1:100 P2W7 
(20|ig/ml). The degree of fluorescence of control pcDNA3 transfected cells was of the 
same intensity indicating its non-specific nature. A second set of independently 
isolated polyclonal populations also failed to react with Y2/51 or P2W7 antibodies 
using the same range of transfections as above.
6.5.1. Detection o f intracellular integrins using FACS
In order to check whether human integrin subunits transfected into B16a cells 
were being expressed at mRNA level and translated into active integrin subunits, but 
not transported to the surface of the murine cells, FACS analysis was carried out using 
permeabilised B16a transfectants as described in section 2.31.3. Polyclonal PC3A and
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PC3A D119A B16a cell lines were fixed with paraformaldehyde and made permeable 
with methanol as described, measuring fluorescence at each stage of the 
permeabilising process using mAb Y2/51 and RPE conjugated F(ab’ )2 fragment of 





Fig 6.11 Effect of cell permeabilisation with methanol upon FACS analysis of mutated human p3 
integrin subunit in PC3A D119A transfected, G418 stable polyclonal populations of B 16a cells using 
mAb Y2/51 and RPE conjugated F(ab’)2 fragment of goat anti-mouse IgG (shaded region). (A) Control 
PC3A D119A transfected B16a cells. (B) PC3A D119A transfected cells fixed with 0.25% 
paraformaldehyde before FACS analysis. (C) FACS analysis of paraformaldehyde fixed B16a cells 
permeabilised with 70% methanol for 60 minutes at 4°C. The unshaded area represents non-specific 
fluorescence of cells treated with mouse IgGl negative control and RPE conjugated goat anti-mouse 
IgG. These scans are representative of two repeats.
Figure 6.11 indicates that neither fixing or permeabilisation of the membranes 
of fixed cells gave any changes in the fluorescence o f PC3A D119A transfected cells. 
Further experiments carried out using this technique with other polyclonal 
populations transfected with PC3A also revealed that there were no sequestered (3
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integrin subunits in the antibiotic resistant cells isolated. No permeabilisation assays 
were carried out for PCVnRa transfected cells
6.6. Discussion
The data presented in section 6.1 clearly shows that electroporation is an 
efficient method for the introduction of DNA into mammalian cells. Expression of the 
reporter vector pRSV/acZ was visible in approximately 50-60% of B 16a or COS7 cell 
populations 48 hours after transfection. However, some conflicting data was obtained 
in that the intensity of FL-1 fluorescence measured after COS7 cell electroporation 
(figure 6.3) was considerably lower than that seen in B16a cells (fig 6.1). The degree 
of COS7 cell fluorescence also appeared to reach a maximum at higher electroporation 
settings. Therefore, it appears that COS7 cells are much more resistant to 
electroporation than B16a cells, having increased survival rates at higher 
electroporation settings, and lower degree of FTTC-dextran uptake. Studies with the 
reporter plasmid pRSV/acZ, however, indicated similar rates of transfection efficiency 
to B 16a cells. One possible explanation for this similarity is that the COS7 cells were 
amplifying expression of the gene by replicating the vector as a result of their 
transformation with the SV40 large T antigen, so that all cells which received vector 
tested positive. This also explained the higher intensity of colour in COS7 cells tested 
with X-Gal. COS7 cells, as expected produced a high level of expression and were 
therefore a useful control for expression of integrin sequences.
It can be clearly seen that the mutated sequence obtained from Dr J C Loftus 
did indeed contain an inactivating point mutation within the ligand binding region of 
CD3A at position A119. Additionally, the cloned human (33 and av  pcDNA3
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constructs were functional and expressed transiently in both control COS7 and B16a 
cells after electroporation. Evidence suggests that integrin subunits without a 
corresponding second subunit will not form a heterodimer and will not be secreted to 
the cell surface (O’Toole et al, 1989, Kolodziej et al, 1991) . Therefore, the 
detection of human av and P3 subunits on the surface of B 16a cells indicated that 
transfected subunits formed heterodimers with corresponding native integrin subunits. 
Increased expression of both integrin subunits was observed when cells were co­
transfected with both av and P3 integrin subunits simultaneously. This occurred in 
both B16a and COS7 cells, presumably as excess available complimentary subunits 
were available for heterodimer formation.
The drawback with the transfection data shown, with respect to practical gene 
therapy, was the level of transient surface expression. COS7 control cells showed a 
higher proportion of positive cells after electroporation, as would be expected due to 
their RSV transformed nature allowing replication of pcDNA3 and consequent 
enhancement of expression. However, the level of this expression was still low 
(discernible levels in only -10% of cells) and the efficiency of detection of positive 
cells, using either antibody (particularly mAb P2W7 for human av) was difficult to 
ascertain due to cross reaction and/or non-specificity between native COS7 integrins. 
B16a cells routinely expressed approximately 1-2% highly positive cells after 
electroporation with either a single, or both, a  and p integrin constructs. However, co­
transfection of both B16a and COS7 cells resulted in higher overall fluorescence after 
binding of specific antibodies for either subunit. However, co-transfection is not of 
practical value for gene therapy of melanoma where the strategy is concerned with 
competitive inhibition of functional p3 subunits.
158
The low numbers of positive cells which exhibited transient expression after 
electroporation may be due to a number of factors. Firstly, efficient transcription 
sometimes requires the presence of some 5’ untranslated intronic information. 
Sequencing of this region of the cDNA’s used was not carried out but restrictional 
analysis of both PCVnRa and PC3A plasmids suggests that some 5’ untranslated 
information was included (cDNA size of human p3 is 2366 bases while human av  is 
3146 bases). As yet there is no evidence for any such requirement of integrins for 
insertion of 5’ information before efficient transcription.
The resistance of cells to accept integrins by selection with an antibiotic 
marker suggests that cells are possibly reluctant to express further integrin subunits 
introduced by electroporation. The small degree of increase seen on dual transfection 
of cells with both a  and p subunits suggests that other inhibitory pathways may be in 
place other than simply a lack of available subunits for the formation of expressed 
heterodimers.
As suggested above, no B16a cells isolated by G418 treatment after 
transfection expressed human integrin subunits extracellularly or intracellularly. A 
number of conversations with other workers in the field of integrin transfection 
(primarily Dr John Marshall, ICRF, London) have indicated similar difficulties in 
obtaining clones by transfection of foreign integrin subunits and antibiotic selection. 
Some success has been obtained by the use of FACS to sort transiently expressing 
integrin populations during antibiotic selection for resistant cells (sorting cells every 
few days). This evidence suggests that unless treated cells are sorted frequently for 
transfected integrin expression during the antibiotic isolation process, positive cells 
are either diluted out or expression is lost. Time limitations prevented a repeat of
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transfection studies with the above protocol. Also of some significance to the low 
range of expression may be the type of expression vector used. Other vector systems 
are available that use different mechanisms for gene expression, such as viral based 
systems (integrating retrovirus-based or adenovirus-based) or episomal replicating 
mammalian expression vectors based on the Epstein Barr Virus (EBV). It would be 
particularly interesting to examine expression after retroviral transformation, and 
compare its efficiency with the plasmid transfections carried out here.
The initial aim of this chapter was to investigate the competitive inhibition of 
active (33 heterodimers by transfection with inactive (33 mutants. Using the expression 
vectors and electroporation conditions described above, it is clear that the amount of 
transfected integrin expressed on the surface of B 16a cells (and even COS7 cells) is 
insufficient to cause discernible differences in cell behaviour. Therefore, no further 
characterisation of cells was carried out in either transfection system.
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Chapter 7: Concluding Discussion
Characterisation of P3 integrin expression using B16a cells as a prospective 
model target for gene therapy of malignant melanoma unearthed a number of 
interesting observations. The integrin-specific sorting using FACS, which was used to 
isolate the cell lines LBE and HBE, resulted in populations of cells which were 
distinctly different from B16a cells isolated from solid tumours by centrifugal 
elutriation (Onada et al., 1988; Honn et al., 1992; Chang et al, 1992). Populations 
isolated on the this basis in these studies not only differed in expression of allbp3 but 
also exhibited notable differences in platelet aggregation, adhesion to substrates and in 
vivo tumorigenicity, the degree of which correlated with integrin expression.
Cells isolated by FACS in this study lacked these differences in static adhesion 
profiles while exhibiting significantly different proliferation and spreading rates. The 
papers cited above reported differences in the adhesion of sub-populations of B 16a 
cells to both murine pulmonary endothelial cells (CD3) and surfaces coated with 
fibronectin (~4.27|ig/cm2). Antibodies against allbp3 reduced this level of adhesion 
(but only in cells expressing high levels of receptor). Antibodies against the a5 
subunit failed to reduce adhesion to fibronectin, implying that they were not 
significant in the adhesion to fibronectin. No mention of differences in proliferation 
rates is made in any of the above papers and discussion with Prof Ken Honn (Wayne 
State University, Detroit) confirmed that no proliferation differences were noted in 
these subpopulations.
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In the assays described in section 4.2.2, B16a cells expressing different levels 
of p3 did not exhibit different adhesion profiles to either fibronectin or fibrinogen. 
This suggests that other adhesion molecules are involved in the mediation of 
adherence to these substrates. Further assays would be needed, however, using a 
wider range of ECM substrates and blocking antibodies against a 3 p l and a 5 p l before 
the similarity of adhesion seen here can be definitely assigned to other integrins.
Similar FACS based cell isolation studies have been carried out by Cheresh 
and Spiro (1987), using a human melanoma cell line, M21, and the integrin av subunit 
as a selection marker. Using an antibody specific for the human av  subunit, a sort of 
the top and bottom 0.05% of M21 cells was carried out. Bottom sorts of these cells 
were repeated four times until a cell line expressing no av subunit was obtained 
(termed M21-L cells). Cells isolated using this procedure had no difference in growth 
rates, or rates of protein synthesis, but did differ dramatically in their ability to bind to 
ECM proteins. FACS and immunoprecipitation studies additionally showed that the 
complementary P3 subunit was not detected on the surface of M21-L cells, but was 
translated and expressed intracellularly on a short term basis. This lack of p3 
expression in the absence of complementary a  subunits correlates with that seen for 
allbp3 heterodimer surface expression (O’Toole et al, 1989; Kolodziej et al, 1991).
The study by Cheresh and Spiro provides an interesting comparison with the 
work carried out here. B16a cell lines selected by FACS did not differ in their ability 
to attach to selected ECM substrates (expressing RGD or KQAGDV motifs), however, 
rates of growth and spreading were considerably altered. Studies by Cheresh and 
Spiro, using RGD affinity columns with M21-L cells showed that their ability to bind
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this motif was totally lost after cell sorting, suggesting that no other RGD integrins 
were present in the M21-L cell line. This would help to simplify characterisation of 
av(33 activity in this cell line and help to explain differences in static adhesion.
Further data has been reported by Wayner et al (1991), using two cell lines, 
M21 human melanoma (as described above) and H2981 lung carcinoma cells. Both 
cell lines were found to express ocvp3 and avp5 and required blocking of both 
receptors with specific antibodies before differences in static vitronectin adhesion 
could be observed. However, although both receptors recognised the same ligand, 
distribution studies revealed that only avp3 localised at sites of focal contact when 
plated on vitronectin. The presence of avp3 was therefore necessary for cell 
spreading upon vitronectin, even though both integrins contributed to cell affinity for 
this substrate. It could be possible that a similar system is at play in B 16a cells, where 
at least three integrins expressed on the B16a surface (allbp3, a 5 p i and a 3 p i)  can 
recognise the RGD motif, but only allbp3 will form focal adhesion sites and stimulate 
spreading on RGD substrates.
Changes in the proliferation of sorted B16a cells observed in the present study 
is not a phenomenon reported in similar studies carried out in human melanoma cell 
lines (A375 and M21) expressing integrin avP3. It is clear that allbp3, although 
mirroring avp3 activity in a number of tumour cell assays, has potentially different 
influences upon cellular signalling in the B16a system. The information described 
here, is indicative of the specific function of allbp3 on the surface of B16a cells, 
beyond its activity as an adhesion receptor. FACS analysis suggests that although the 
expression of this heterodimer is often low - particularly in wild-type cells, other
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assays carried out on sorted cells imply that its influence upon cell behaviour is 
considerable.
Another possible explanation for the changes observed in proliferation, other 
than the direct influence of ocIIp3 mediated signalling pathways is possible with 
reference to a number of papers concerning the “classic fibronectin receptor” a5p l. 
Elevated levels of a5p l have been associated with the suppression of a transformed 
phenotype in Chinese hamster ovary (CHO) cells (Giancotti and Ruoslahti 1990). 
Transfection of this receptor into transformed CHO cells resulted in an increase in 
fibronectin synthesis, and reduction in migration, growth in soft agar and saturation 
density. The transformed cells were also non-tumorigenic after subcutaneous injection 
into nude mice. Therefore, the presence of a5pl in these cells stabilises their 
phenotype. Another interesting report (Blystone et al, 1994) suggests that the avp3 
integrin may regulate the adhesive and phagocytic functions of a5p l when this 
receptor is transfected into human erythroleukaemia (K562) cells. Ligation of avp3 
was seen to inhibit a5p l mediated phagocytosis (of fibronectin coated beads) by an 
unknown signalling pathway. Taken together, these reports suggest that allbp3 and 
a5p l (or possibly a3p l) could be functioning in a non-independent fashion. 
Therefore, downregulation of aDbp3 may remove the influence of this integrin upon 
an a5 p i mediated phenotype similar to that suggested by Giancotti and Ruoslahti. It 
must be noted, however, that the a5p l integrin has also been associated with 
enhancing the proliferative response to fibronectin of serum starved human melanoma 
cell lines (Mortarini et al, 1992), which perhaps suggests that these combinatory
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relationships between integrins, and the effect of oc5pl upon proliferation are cell-type 
specific.
Down-regulation of p3 integrin heterodimers expressed on the surface of 
melanoma cell-lines proved to be a difficult objective to achieve reproducibly. Many 
studies have used antisense integrin constructs to reduce integrin expression by target 
cells, primarily using stable transfectants which were isolated using antibiotic 
resistance as individual cell clones, which were then examined for an antisense effect 
(Keely et al, 1995; Riikonen et al, 1995a, 1995b; Koivisto et al, 1994; described in 
section 1.5.2). A primary aim of this project was to investigate the effectiveness and 
efficiency of using antisense gene therapy against the expression of target p3 integrin 
heterodimers. Particular interest was focused upon reduction of P3 expression on a 
global, polyclonal basis. The basis for this aim is that use of any antisense integrin 
construct in vivo will not only need to be targeted to specific cells (such as melanoma 
cells), but also have a discernible effect on the majority of target cells. As the use of 
antibiotic markers is not possible in vivo, this vector based delivery system would need 
to express significant levels of antisense integrin message in the majority of cells on a 
transient basis. The studies conducted here did not result in an antisense effect upon 
p3 expression on a transient basis, using the transfection protocols described. Other 
techniques using different gene delivery strategies such retroviral or even replication 
competent viral delivery would carry the potential of an integration (or stable 
production) of antisense genes.
As a model for this potential, cells isolated using the G418 antibiotic resistance 
marker gave indications of an antisense affect when the cells were stably transfected. 
Melanoma cells appeared to exhibit downregulation of p3, particularly using FACS
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and proliferation assays, although these effects could also have been explained by non­
specific events as a result of the large size of antisense inserts. Conflicting data, 
primarily using Western blotting for total P3 expression also draws this phenomenon 
into doubt.
In conclusion, using the gene expression system detailed here, antisense 
therapy of (33 integrins does not give a reliably significant large-scale therapeutic 
reduction of integrin expression. However, it remains that P3 integrins are a valid 
target for gene and drug therapy and that antisense treatment of this target using 
alternative transfection and expression techniques may well provide more acceptable 
downregulation of expression. The use of ligand mimetics such as superfibronectin 
(Morla et al, 1994) are likely to produce a shorter term alternative for the treatment of 
integrin-related phenomena such as prevention of metastasis, angiogenesis (Brooks et 
al., 1994), haemostatic events (Smith et al., 1995) or bacterial endocytosis (Vannhieu 
et al., 1996).
Another potential field for rapidly growing clinical interest is the use of ligand 
mimetics to target cells for the delivery of genes or peptides. Recent work presented 
by Wickham et al. (1995) suggests a potential use for engineering of the adenovirus 
penton base to target gene delivery to specific integrins. Endocytosis mediated by 
these integrins may well provide a valuable tool for the targeting of drugs to specific 
tissues.
The validity of using inactive mutants of p3 integrins to competitively inhibit 
endogenous integrins of melanoma cells was not rigorously tested during this study 
due to problems involved with the efficiency of integrin transfection. Using a similar 
tactic, LaFlamme et a l (1994) have successfully used chimeras of integrin
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cytoplasmic domains to inhibit the spreading and migration of human fibroblasts. 
Rather than the use of complete integrin subunits they ligated integrin cytoplasmic 
domains to the extracellular and transmembrane domains of interleukin-2 (IL-2). This 
study indicated much higher levels of chimera expression after electroporation, and the 
authors postulated that the inhibition of endogenous integrin activity was dominant 
rather than competitive. This is due to the observation that (3 intracellular domains, 
expressed in the absence of a  intracellular domains bind to intracellular components 
with the same affinity as ligand-occupied integrins (LaFlamme et al., 1992), disrupting 
focal contact activity. Similar studies by Lukashev et al. (1994) have also noted 
similar trans-dominant inhibitory effects using pi cytoplasmic and extracellular 
domains ligated to a murine CD4 extracellular domain..
Using the system suggested in chapter 6, inhibition of integrins would be on a 
more competitive basis than that shown by LaFlamme et al., with inhibition arising 
from competition between endogenous and mutated P3 subunits for accompanying a  
subunits. This suggests that inhibition of integrins by transfection of inactive subunits 
will function as long as transfection efficiencies are sufficiently high. The use of 
integrin chimeras in this system would appear to be preferable as chimeras appear to 
carry integrin subunit specificity , but with a more efficient dominant-negative 
activity.
7.1. Further work
Initial studies using HBE and LBE B16a cells suggests an interesting role for 
allbp3 in the alteration of tumour cell proliferation. It may provide a valuable model 
for the examination of the signalling events associated with integrin-mediated
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stimulation of proliferation. Further studies in this area would be needed to dissect the 
individual roles of all B16a integrins, and the influence of substrate type upon this 
phenomenon. Experiments would therefore concentrate on proliferation of sorted and 
wild type B16a cells upon surfaces coated with various ECM ligands. Additionally, 
studies of the rate of protein synthesis in these studies (using [ H]leucine 
incorporation, as utilised by Cheresh and Spiro, 1987) will also elucidate 
complimentary information of cellular activity. Treatment of cells with blocking 
antibodies, inhibitory to integrin function (for allbp3, a3p l or a5p l) could be used. 
Such assays may reveal information concerning the significance of these individual 
integrins in proliferation, and their role in any potential feedback between integrins as 
mentioned above. For instance, treatment of LBE cells with anti a5p l antibodies will 
give information concerning its role in control of B16a growth and the observed 
phenotype of LBE cells.
Parallel studies in a cell line expressing the other p3 integrin, av|33 may help 
to differentiate between events mediated by each integrin. Therefore, similar studies 
could be carried out using the A375 cell line and sorting for populations on the basis 
of p3 expression. A375 cells isolated on the basis of in vivo metastatic ability (which 
exhibit higher avp3 expression) do not appear to exhibit differences in in vitro 
proliferation and it would be interesting to study whether this relationship holds for 
cells isolated purely on the basis of avp3 expression. Antibody treatment against 
other expressed integrins, and studies of proliferative response to ECM substrates 
would also mirror experiments carried out in B 16a cells.
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Alternatively, transfection of av subunits into LBE cells would be interesting 
as this would give clear information concerning homology between aDbp3 and avp3 
activities. A similar experiment along these lines would be possible with transfection 
of LBE A375 cells with allb subunits. Examination of the proliferation of other cell 
lines transfected with allbp3 may provide information as to whether this phenomenon 
is specific to this cell-line
Differences observed in B16a cell spreading upon fibronectin could be 
examined by labelling of B 16a cells with fluorescent antibodies to specific integrin 
subunits while attached to ECM substrates. Confocal microscopy of these samples 
would reveal cellular distribution patterns from which individual roles of integrins in 
focal adhesion formation will be revealed. It would be interesting to see if these 
integrin distribution patterns paralleled those seen by Wayner et al. (1991) as 
discussed above.
The inconsistency of downregulation of P3 integrins by the transfection 
protocol used may well be a product of the inefficiency of the delivery system used to 
express sufficient levels of antisense DNA (although transfection data gained from p- 
galactosidase expression would perhaps suggest otherwise). Alternatively, it may be a 
product of the type of expression vector selected for these studies. Parallel 
experiments using alternative gene delivery techniques would help to rule out these 
suggestions. Such studies could include transfection of HBE B16a cells with the 
pcDNA3 constructs using cationic liposomes such as DOTAP (Boehringer- 
Mannheim), known to give high levels of transient expression. Other experiments 
could concentrate upon the delivery of the antisense P3 inserts within alternative
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expression vectors, such as the episomal mammalian expression vectors based on the 
Epstein Barr virus, or adenoviral delivery and expression systems. Alternatively, use 
of retroviruses may be a valuable delivery technique for the generation of stable 
antisense transfectants.
Specificity of antisense downregulation would also be an interesting area for 
further work, to clarify the potential non-specific inhibition of integrin expression 
caused by the longer antisense p3 inserts. This could include examination of non­
specific integrin downregulation by measuring surface expression of a 5 p l and a 3 p l 
integrins in B16a cells before and after antisense transfection with P3 integrin 
constructs using specific antibodies and FACS. Antisense downregulation of B 16a 
proliferation will also need to be compared to that seen in LBE B16a cells more 
comprehensively in order to determine if specific p3 downregulation is the actual 
cause for this phenomenon. Studies could involve similar ECM and inhibitory 
antibody proliferation assays to those described above, with comparison to assays 
carried out on cells selected for low p3 expression.
The inhibition of integrins by the transfection of other subunits, or chimeras of 
other subunits still remains an interesting area for melanoma gene therapy. However, 
the use of chimeras of integrin subunits for dominant inhibition of integrin function, 
such as those described by La Flamme et a l (1994) may produce a more efficient 
inactivation of integrins. It may be possible to take this principle a step further by the 
use of peptides homologous to the functional groups of complementary 
transmembrane and cytoplasmic domains of integrins to produce a molecule capable 
of prevention of integrin heterodimer formation, specific to integrin subunit-type. 
Further elucidation of the mechanisms for integrin links with signalling pathways may
170
also uncover cytoplasmic interactions where homologous molecules may effectively 
block integrin mediated signal transduction.
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Appendix A: Amino acids.
Amino acid. Abbreviation. Code Letter. Mass. Properties (hydrophilicity).
Alanine Ala A 89.09 Neutral, (-0.5)
Arginine Arg R 174.2 Basic, (3.0)
Asparagine Asn N 132.1 Neutral, (0.2)
Aspartic acid Asp D 133.1 Acidic, (3.0)
Cysteine Cys C 121.12 Neutral, (-1.0)
Glutamic acid Glu E 147.13 Acidic, (3.0)
Glutamine Gin Q 146.15 Neutral, (0.2)
Glycine Gly G 75.07 Neutral, (0.0)
Histidine His H 155.16 Basic, (-0.5)
Isoleucine He I 131.17 Neutral, (-1.8)
Leucine Leu L 131.17 Neutral, (-1.8)
Lysine Lys K 146.19 Basic, (3.0)
Methionine Met M 149.21 Neutral, (-1.3)
Phenylalanine Phe F 165.19 Neutral, (-2.5)
Proline Pro P 115.13 Neutral, (0.0)
Serine Ser S 105.09 Neutral, (0.3)
Threonine Thr T 119.12 Neutral, (-0.4)
Tryptophan Trp W 204.22 Neutral, (-3.4)
Tyrosine Tyr Y 181.19 Neutral, (-2.3)
Valine Val V 117.15 Neutral, (-1.5)
Hydrophilicity value according to Hopp and Woods, (1981)
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Appendix B: Molecular Weight Markers.
For agarose gel electrophoresis, markers consisted of EcoRVHindJR-cut lambda DNA 
(Northumbria Biologicals). The digest consists of DNA fragments of the following 
sizes (Base pairs):
1: 21226 8: 1584
2: 5148 9: 1375
3: 4973 10: 947
4: 4268 11: 831
5: 3530 12: 564
6: 2027 13: 125
7: 1904
For PCR and small fragments, low weight electrophoresis markers were used 
(Promega). These consisted of DNA fragments of the following sizes (base pairs):
1: 1000 4: 300
2: 750 5: 150
3: 500 6: 50





Bovine serum albumin 79.5 kDa
Ovalbumin 49.5 kDa
Carbonic anhydrase 34.8 kDa
Soybean trypsin inhibitor 20.4 kDa
Aprotinin 7.2 kDa
196
Appendix C: Media and Solutions.
Where appropriate, media and solutions were sterilised by autoclaving for 20 minutes 
at 15 lbs/sq inch (121 °C) on a liquid cycle. Unless specified, all reagents were 
obtained from Sigma Biochemicals.
Chloroformiisoamyl alcohol: Chloroform mixed with isoamyl alcohol 24:1 
(Amresco).
Denaturing solution: 1.5M NaCl, 0.5M NaOH.
Denhardt’s solution (lOOx): 2% Bovine serum albumin (BSA), 2% Ficoll, 2%
polyvinylpyrrolidone (PVP).
DNA loading buffer: 0.5% SDS, 25% glycerol, 0.25% bromophenol blue, 0.05M 
EDTA.
Formaldehyde gel running buffer (5x): 0.1M MOPS (pH 7.0), 40mM sodium 
acetate, 5mM EDTA.
LB medium (Luria-Bertani Medium): (per litre) lOg Bacto tryptone (Difco), 5g Bacto 
yeast extract (Difco) and lOg NaCl, pH adjusted to 7.0 with NaOH. LB plates were 
made from 1 litre of LB medium plus 20g agar (Difco).
Neutralising solution: 1.5M NaCl, Tris HC1 pH 7.2, 0.001M EDTA.
NZY Broth: (per litre) 5g NaCl, 2g MgS04, 5g Bacto yeast extract (Difco) and iOg 
NZ amine (ICN) pH 7.5. NZY plates were made from 1 litre of NZY broth plus 20g 
agar (Difco).
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PBS: 15mM sodium phosphate, 150mM sodium chloride (pH 7.3).
Phenol/chloroform: Tris Phenol: Chloroform : Isoamyl alcohol 25:24:1 (Amresco).
SM (Phage dilution buffer): (per litre) 5.8g NaCl, 2g MgS04, 50ml 1M Tris pH 7.5 
and 5ml 2% gelatin.
SOC: 2% Bacto Tryptone (Difco), 0.5% Bacto yeast extract (Difco), lOmM NaCl, 
2.5mM KC1, lOmM Mgcl2, lOmM MgSC>4, 20mM glucose.
Solution I (minipreps): 50mM glucose, 25mJVl Tris, lOmM EDTA.
Solution II (minipreps): 0.2N NaOH, 1% SDS; freshly prepared asceptically from 
ION NaOH and 10% SDS stocks.
Solution III (minipreps): (per 100ml) 60ml 5M potassium acetate, 11.5ml glacial 
acetic acid, ddH20  28.5ml.
SDS-PAGE running buffer (lx): 25mM Tris base, 192mM glycine, 0.1% SDS.
SDS-PAGE blocking buffer: l%w/v ovalbumin, 0.05% sodium azide, in TBS.
SDS-PAGE loading buffer (5x): 5% SDS, 50% glycerol, 200mM Tris Hcl (pH 6.8), 
5% 2-mercaptoethanol, 2% bromophenol blue.
SDS-PAGE solubilisation buffer: 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% 
Nonidet P40, 10% glycerol, 5mM EDTA, ImM sodium vanadate, ImM sodium 
molybdate, lOmM sodium fluoride, 40jig/ml PMSF, 0.7|ig/ml pepstatin A, lOpg/ml 
aprotinin, lOjig/ml leupeptin, 10pg/ml soyabean trypsin inhibitor.
SSC (lx): 0.15M NaCl, 0.015M trisodium citrate pH 7.0
TBE (lx): (per litre) 10.8g Tris base, 5.5g boric acid, 0.93g Na2EDTA.H20, pH 8.3 
TBS: 150mM NaCl, 20mM Tris HC1, pH 7.5.
TBSN: 150mM NaCl, 20mM Tris HC1, pH 7.5, 0.05% NP-40
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TE: lOmM Tris-HCl, ImM EDTA pH 7.0
TE Glucose: 25% w/v glucose, lOOmM Tris, lOmM EDTA pH 7.0
TGS (Semi-dry transfer buffer): 39mM glycine, 48 mM Tris base, 0.0375% SDS, 
20%(v/v) methanol.
Tumour dispersion solution: (per 100ml) lOOmg collagenase type IE (Worthington 
Biochemicals), 7mg DNAse I (Sigma), lOmg soybean trypsin inhibitor (Worthington 
Biochemicals), lg  fatty acid free bovine albumin (Sigma).
X-Gal solution: 0.2% X-Gal (Melford laboratories), ImM MgCl2, 150mM NaCl, 
3.3mM K4Fe(CN)6, 3.3mM K3Fe(CN)6.
199
